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ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation or Term Definition 
6MET 6-minute steady-state exercise test 
6MWT 6-minute walk test 
ACE inhibitor angiotensin converting enzyme inhibitor 
AE adverse event 
ALAT Latin American Thoracic Association 
α, alpha Type I error rate 
ALT/SGPT alanine aminotransferase/serum glutamic pyruvate transaminase 
ANCOVA analysis of covariance 
AST/SGOT aspartate aminotransferase/serum glutamic oxaloacetic transaminase 
ATS American Thoracic Society 
BAL bronchoalveolar lavage 
bFGF basic fibroblast growth factor  
CFR Code of Federal Regulations 
CI confidence interval 
CK creatine kinase 
Cockcroft-Gault formula (140-age) * (weight in kg) * (0.85 if female) / (72 * serum creatinine 
in mg/dL) 
CRF case report form 
d day  
DLCO carbon monoxide diffusing capacity  
%DLCO  percent predicted carbon monoxide diffusing capacity  
DMC Data Monitoring Committee 
ECG electrocardiogram 
eCRF electronic case report form 
ERS European Respiratory Society 
FDA (United States) Food and Drug Administration 
FEV1 forced expiratory volume in one second 
FVC forced vital capacity 
%FVC percent predicted forced vital capacity 
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Abbreviation or Term Definition 
GGT gamma-glutamyl transferase 
GCP good clinical practice 
HIV human immunodeficiency virus 
HR hazard ratio 
HRCT high-resolution computed tomography 
IB Investigator’s Brochure 
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee 
IND Investigational New Drug 
IPF idiopathic pulmonary fibrosis 
IRB Institutional Review Board 
ITT intent-to-treat 
JRS Japanese Respiratory Society  
L liter 
LDH lactic dehydrogenase 
L/min liters per minute 
MedDRA Medical Dictionary for Regulatory Activities 
m meter 
MAC Mortality Assessment Committee 
mg milligram 
mg/d milligrams per day 
mL milliliter 
mmHg millimeters of mercury 
msec millisecond 
NIH National Institutes of Health 
PaO2 partial pressure of oxygen  
PAP pulmonary artery pressure 
PDGF platelet-derived growth factor 
PF pulmonary fibrosis 
PFS progression-free survival  
PFT pulmonary function test 
QT interval time between the start of the Q wave and the end of the T wave in the 
heart's electrical cycle 
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Abbreviation or Term Definition 
QTcB heart-rate–corrected QT interval using Bazett’s formula 
RV residual volume 
RVSP right ventricular systolic pressure 
SAE serious adverse event 
SLB surgical lung biopsy  
SP2 Shionogi Phase 2 study 
SP3 Shionogi Phase 3 study 
SPF sun protection factor 
SpO2 oxygen saturation by pulse oximetry 
SSD sum of squared deviations  
study treatment pirfenidone or placebo equivalent 
TGF-β transforming growth factor-beta 
TLCO carbon monoxide transfer capacity 
TID three times per day 
UCSD SOBQ University of California at San Diego Shortness-of-Breath 
Questionnaire 
UIP usual interstitial pneumonia 
ULN upper limit of normal 
US United States of America 
USP United States Pharmacopeia 
UV-A ultraviolet A (radiation) 
VATS video-assisted thoracoscopic surgery 
VC vital capacity 
wk week 
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Protocol Synopsis (continued) 
OBJECTIVES: • To confirm the treatment effect of pirfenidone 2403 mg/d 
compared with placebo on change in percent predicted forced 
vital capacity (%FVC) in patients with idiopathic pulmonary 
fibrosis (IPF) 
• To confirm the safety of treatment with pirfenidone 
2403 mg/d compared with placebo in patients with IPF 
STUDY DESIGN: This is a Phase 3, randomized, double-blind, placebo-controlled, 
efficacy and safety study of pirfenidone in patients with IPF. 
Approximately 500 patients will be randomized with equal 
probability to receive pirfenidone 2403 mg/d or placebo for 
52 weeks. The primary efficacy endpoint is change in %FVC from 
Baseline to Week 52, to be analyzed using a rank analysis of 
covariance (ANCOVA) model.  
Eligible patients aged 40–80 years (inclusive) must have a confident 
clinical and radiographic diagnosis of IPF according to pre-specified 
criteria. Patients will be required to have a %FVC ≥50% and ≤90% 
and percent predicted carbon monoxide diffusing capacity (%DLCO) 
≥30% and ≤90%.  
Eligible patients must discontinue all prohibited medications at least 
28 days before Screening during the Washout Period. Once patients 
complete the Washout Period, they will enter the Screening Period, 
which may last up to 56 days.  
Other than brief periods of corticosteroid use for acute IPF 
exacerbation, patients will not receive any other therapy for the 
treatment of IPF.  
The dose of study treatment will be titrated over 14 days. Patients 
will have a telephone assessment at Week 1 and an in-clinic 
assessment at Weeks 2, 4, 8, 13, 16, 20, 26, 39, and 52. Patients 
who, in the opinion of the investigator, are compliant with study 
treatment dosing (≥80%) will be permitted to enter the rollover 
study (during which all patients will receive pirfenidone 2403 mg/d) 
at the completion of their Week 52 visit. Patients who do not enter 
the rollover study will return for a Follow-up Visit 28 days after the 
last dose of treatment in this study. Patients should complete an 
adverse event (AE) and dosing compliance diary between all visits. 
If patients discontinue study treatment early for any reason, they 
should continue with all scheduled study procedures through 
Week 52.  
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Protocol Synopsis (continued) 
All deaths will be reviewed by a Mortality Assessment Committee 
(MAC). 
A Data Monitoring Committee (DMC) will monitor patient safety 
during the study.  
PATIENT 
POPULATION: 
Eligible patients must have a confident diagnosis of IPF based on 
clinical, radiologic, and pathologic data without evidence or 
suspicion of an alternative diagnosis that may contribute to their 
interstitial lung disease.  
Patients must fulfill all of the following criteria to be eligible for 
enrollment in the study: 
Diagnosis of IPF 
1. Clinical symptoms consistent with IPF of ≥12 months 
duration 
2. Diagnosis of IPF, defined as the first instance in which a 
patient was informed of having IPF, at least 6 months and 
no more than 48 months before randomization  
3. Age 40 through 80 years at randomization 
4. Diagnosis of UIP or IPF by HRCT and SLB as outlined in the 
following table (Note:  HRCT scan performed within 1 month 
of the start of Screening may be used if it meets image 
acquisition guidelines):  
 Surgical 
Lung Biopsy 
Not 
Available 
Pathology 
Panel:  
Definite UIP 
Pathology 
Panel:  
Probable UIP 
Pathology 
Panel: 
Possible UIP 
Pathology Panel: 
Inconsistent 
with UIP or Not 
Classifiable 
Radiology 
Panel: 
Definite UIP 
Eligible Eligible Eligible Eligible NOT Eligible 
Radiology 
Panel: 
Possible UIP 
NOT Eligible Eligible Eligible NOT Eligible NOT Eligible 
Radiology 
Panel: 
Inconsistent 
with IPF 
NOT Eligible NOT Eligible NOT Eligible NOT Eligible NOT Eligible 
 
 5. Extent of fibrotic changes (honeycombing, reticular changes) 
greater than the extent of emphysema on HRCT scan, 
confirmed by central review 
PIPF-016: protocol-or-amendment.pdf  --  Page 13 of 97
InterMune, Inc.  Protocol PIPF-016 
Phase 3 Study of Pirfenidone for IPF 16 March 2011
 
CONFIDENTIAL AND PROPRIETARY Page 14 
Protocol Synopsis (continued) 
 6. No features supporting an alternative diagnosis on 
transbronchial biopsy, bronchoalveolar lavage (BAL), or 
surgical lung biopsy, if performed 
IPF Disease Severity and Progression 
7. %FVC ≥50% and ≤90% at Screening, confirmed by central 
review.  
8. Change in pre- and post-bronchodilator FVC (measured in 
liters) between Screening and Day 1 must be a <10% relative 
difference, calculated as: 
Screen FVC (L) – Day 1 FVC (L)  × 100% 
Screen FVC (L)  
9. %DLCO ≥30% and ≤90% at Screening, confirmed by 
central review 
10. In the investigator’s opinion, no evidence of improvement 
in measures of IPF disease severity over the preceding year  
11. Able to walk ≥150 m during the 6-minute walk test 
(6MWT) at Screening   
Informed Consent and Protocol Adherence 
12. Able to understand and sign a written informed consent form 
13. Able to understand the importance of adherence to study 
treatment and the study protocol and willing to follow all 
study requirements, including the concomitant medication 
restrictions, throughout the study 
 Patients with any of the following will be excluded from the study: 
Disease-Related Exclusions 
1. Significant clinical worsening of IPF between Screening and 
Day 1, in the opinion of the investigator 
2. Not a suitable candidate for enrollment or unlikely to comply 
with the requirements of this study, in the opinion of the 
investigator 
3. Forced expiratory volume in one second (FEV1)/FVC ratio 
<0.8 after administration of bronchodilator at Screening, 
confirmed by central review 
4. Bronchodilator response, defined by an absolute increase 
of  ≥12% and an increase of 200 mL in FEV1 or FVC or 
both after bronchodilator use compared with the values 
before bronchodilator use at Screening, confirmed by 
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Protocol Synopsis (continued) 
central review 
5. Cigarette smoking within 3 months of Screening or 
unwilling to avoid tobacco products throughout the study 
6. History of clinically significant environmental exposure 
known to cause pulmonary fibrosis (PF), including but not 
limited to drugs (such as amiodarone), asbestos, beryllium, 
radiation, and domestic birds 
7. Known explanation for interstitial lung disease, including but 
not limited to radiation, drug toxicity, sarcoidosis, 
hypersensitivity pneumonitis, bronchiolitis obliterans 
organizing pneumonia, human immunodeficiency virus 
(HIV), viral hepatitis, and cancer 
8. Clinical diagnosis of any connective tissue disease, including 
but not limited to scleroderma, polymyositis/dermatomyositis, 
systemic lupus erythematosus, and rheumatoid arthritis 
9. History of asthma or chronic obstructive pulmonary disease  
10. Clinical evidence of active infection, including but not limited 
to bronchitis, pneumonia, sinusitis, urinary tract infection, or 
cellulitis  
11. Expected to receive a lung transplant within 1 year from 
randomization or, for patients at sites in the United States 
(US), on a lung transplant waiting list at randomization 
Medical Exclusions 
12. Any history of malignancy likely to result in significant 
disability or likely to require significant medical or surgical 
intervention within the next 2 years. This does not include 
minor surgical procedures for localized cancer (e.g., basal cell 
carcinoma) 
13. Any condition other than IPF that, in the opinion of the 
investigator, is likely to result in the death of the patient 
within the next 2 years 
14. History of severe hepatic impairment or end-stage liver 
disease  
15. History of end-stage renal disease requiring dialysis 
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Protocol Synopsis (continued) 
 16. History of unstable or deteriorating cardiac or pulmonary 
disease (other than IPF) within the previous 6 months, 
including but not limited to the following: 
a) Unstable angina pectoris or myocardial infarction  
b) Congestive heart failure requiring hospitalization 
c) Uncontrolled clinically significant arrhythmias 
17. Any condition that, in the opinion of the investigator, might 
be significantly exacerbated by the known side effects 
associated with the administration of pirfenidone 
18. Pregnancy or lactation. Women of childbearing capacity are 
required to have a negative serum pregnancy test before 
treatment and must agree to maintain highly effective 
contraception by practicing abstinence or by using at least two 
methods of birth control from the date of consent through the 
end of the study. If abstinence is not practiced, one of the two 
methods of birth control should be an oral contraceptive 
(e.g., oral contraceptive and a spermicide).   
19. History of alcohol or substance abuse in the past 2 years 
20. Family or personal history of long QT syndrome 
Laboratory Exclusions 
21. Any of the following liver function test criteria above 
specified limits:  total bilirubin above the upper limit of 
normal (ULN), excluding patients with Gilbert’s syndrome; 
aspartate or alanine aminotransferase (AST/SGOT or 
ALT/SGPT) >3 × ULN; alkaline phosphatase >2.5 × ULN 
22. Creatinine clearance (CrCl) <30 mL/min, calculated using the 
Cockcroft-Gault formula  
23. Electrocardiogram (ECG) with a QTcB interval >500 msec at 
Screening  
Medication Exclusions  
24. Prior use of pirfenidone or known hypersensitivity to any of 
the components of study treatment 
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 25. Use of any of the following therapies within 28 days before 
Screening:  
a) Investigational therapy, defined as any drug that has not 
been approved for marketing for any indication in the 
country of the participating site 
b) Any cytotoxic, immunosuppressive, cytokine-modulating, 
or receptor-antagonist agent, including but not limited to 
azathioprine, bosentan, ambrisentan, cyclophosphamide, 
cyclosporine, etanercept, iloprost, infliximab, leukotriene 
antagonists, methotrexate, mycophenolate mofetil, 
tacrolimus, montelukast, tetrathiomolybdate, TNF-α 
inhibitors, N-acetylcysteine (NAC), imatinib mesylate, 
Interferon gamma-1b (IFN-γ 1b), and tyrosine kinase 
inhibitors 
c) Medications that are specifically being used for the 
treatment of IPF, including but not limited to angiotensin 
converting enzyme (ACE)-inhibitors, colchicine, 
corticosteroids, heparin, warfarin, and HMG-CoA 
reductase inhibitors. These drugs may be used if given for 
a non-IPF indication if there is no clinically acceptable 
alternative therapy for the same indication. 
d) Fluvoxamine  
e) Sildenafil (daily use). Note: intermittent use for erectile 
dysfunction is allowed 
TREATMENTS: Study treatment is defined as either pirfenidone 2403 mg/d or 
placebo equivalent administered in divided doses three times per 
day (TID) with food. Study treatment will be titrated over 14 days to 
the full dose of 9 capsules per day (three 267-mg capsules taken 
orally TID with food). Patients will remain on a stable maintenance 
dose for the duration of the treatment period unless the dose is 
reduced to manage an AE or titrated again when restarting study 
treatment after a 28-day or greater lapse in treatment. 
RANDOMIZATION 
AND BLINDING: 
This is a double-blind study. Patients will be randomized in a 1:1 
ratio to receive either pirfenidone 2403 mg/d or placebo equivalent. 
The placebo will be visually equivalent to pirfenidone. 
OUTCOMES AND 
ASSESSMENTS: 
Primary Efficacy Outcome Variable: 
• Change from Baseline to Week 52 in %FVC  
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 Key Secondary Efficacy Outcome Variables: 
• Change from Baseline to Week 52 in 6MWT distance 
• Progression-free survival 
Other Secondary Efficacy Outcome Variables: 
• All-cause mortality 
• Treatment-emergent IPF-related mortality 
• Change from Baseline to Week 52 in dyspnea, as measured by 
the University of California at San Diego Shortness-of-Breath 
Questionnaire (UCSD SOBQ) score 
 Safety Outcome Measures: 
• Treatment-emergent AEs 
• Treatment-emergent serious adverse events (SAEs) 
• Treatment-emergent treatment-related AEs 
• Treatment-emergent treatment-related SAEs 
• AEs leading to early discontinuation of study treatment 
• Treatment-emergent deaths 
• Cause of death 
• Treatment-emergent changes in clinical laboratory findings 
and ECGs 
• Vital signs 
 Study Assessments: 
Patients will have a telephone assessment at Week 1 and in-clinic 
assessments at Weeks 2, 4, 8, 13, 16, 20, 26, 39, and 52. Patients 
who, in the opinion of the investigator, are compliant with study 
treatment dosing (≥80%) will be permitted to enter the rollover 
study at the completion of their Week 52 visit. Patients who do not 
enter the rollover study will return for a Follow-up Visit 28 days 
after their last dose of treatment in this study. Patients should 
complete an AE and dosing compliance diary between all visits.  
TRIAL 
MONITORING 
AND INTERIM 
ANALYSIS 
Throughout the study, individual SAE reports and laboratory 
toxicities will be reviewed on a continuous basis. In addition, safety 
data will be reviewed by an external DMC. The DMC will review 
data after 50% of enrollment is completed and approximately every 
6 to 9 months thereafter as specified in the DMC charter.  
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Protocol Synopsis (continued) 
STATISTICAL 
METHODS: 
The intent-to-treat (ITT) population, consisting of all patients who 
signed the informed consent form and were randomized, will be 
used as the primary population for efficacy analyses. The safety 
analysis population will include all patients who signed informed 
consent and received any amount of study drug. 
The primary efficacy analysis will compare change from Baseline to 
Week 52 in %FVC in the pirfenidone 2403 mg/d and placebo 
groups using a rank ANCOVA model, with a classification effect 
for treatment and Baseline FVC included as a covariate. Baseline 
%FVC will be defined as the average of the FVC measurements 
obtained at the Screening and Day 1 visits.  
The sample size and power calculations for this study are based on 
the primary endpoint, change in %FVC from Baseline to Week 52, 
and on a key secondary endpoint, change in 6MWT distance from 
Baseline to Week 52 (see Section 5.2). 
Adverse events, deaths, concomitant medications, vital signs, and 
laboratory data will be listed for each patient and summarized by 
treatment group. 
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1 BACKGROUND INFORMATION 
1.1 Idiopathic Pulmonary Fibrosis 
Idiopathic pulmonary fibrosis (IPF) is a debilitating disease of unknown etiology 
characterized by fibrosis of the lung interstitium, decrease in lung volume, and 
progressive pulmonary insufficiency typically leading to death (Lynch and Toews 1998).  
IPF is recognized by the American Thoracic Society (ATS) and European Respiratory 
Society (ERS) as a distinct form of interstitial lung disease that is defined by a 
constellation of clinical, histopathologic, and radiologic features, and is the most common 
of idiopathic interstitial pneumonias (ATS/ERS 2000; ATS/ERS 2002). Usual findings 
include slowly progressive dyspnea and a nonproductive cough with progressive loss of 
lung volumes (i.e., decreased forced vital capacity [FVC]) and decline in exercise 
tolerance. On high-resolution computed tomography (HRCT) scan, there are peripheral 
(subpleural), bibasilar, reticulonodular abnormalities with architectural distortion, 
honeycomb change, and traction bronchiectasis. The characteristic histopathologic 
pattern is that of usual interstitial pneumonia (UIP), with diffuse subepithelial 
fibroblastic foci. 
The diagnosis of IPF carries a bleak prognosis, with progressive disability due to 
respiratory insufficiency. Inexorable, slow progression tends to be interspersed with 
episodes of acute exacerbation that accelerate decline and may be fatal (Collard et al. 
2007). Thus, despite the fairly uniformly fatal outcome in affected patients over time, the 
course of the disease varies from patient to patient. There is no good evidence to suggest 
the efficacy of the therapies often administered to patients with IPF, such as 
corticosteroids and azathioprine (Walter et al. 2006). Worldwide, the only licensed 
treatment for IPF is pirfenidone, which is marketed as Pirespa® in Japan, Esbriet® in the 
European Union, and as Pirfenex in India. 
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1.2 Pirfenidone 
Pirfenidone is a small non-peptide molecule of low molecular weight (185.2 daltons). Its 
chemical name is 5-methyl-1-phenyl-2-(1H)-pyridone, and its empirical formula is 
C12H11NO.  
1.2.1 Nonclinical Overview Supporting Use in IPF 
The mechanism of action of pirfenidone in IPF is thought to be both anti-inflammatory 
and antifibrotic. Pirfenidone inhibits the synthesis and release of pro-inflammatory 
cytokines and reduces the accumulation of inflammatory cells in response to various 
stimuli (Pirfenidone Investigator’s Brochure, Edition 6, 2011). Pirfenidone also has been 
shown to attenuate fibroblast proliferation, production of fibrosis-associated proteins and 
cytokines, and the increased biosynthesis and accumulation of extracellular matrix in 
response to cytokine growth factors such as transforming growth factor-beta (TGF-β) and 
platelet-derived growth factor (PDGF). 
In rat, hamster, and mouse models of bleomycin-induced lung fibrosis, prophylactic 
administration of pirfenidone reduced pulmonary fibrosis assessed by both 
histopathologic analysis and quantitative determination of collagen content. Pirfenidone 
treatment also reduced pulmonary edema and pulmonary levels of TGF-β, basic 
fibroblast growth factor (bFGF), and various pro-inflammatory cytokines.  
Thus, both in vitro and in vivo nonclinical studies have provided evidence of 
reductions in fibroblast proliferation and collagen synthesis, decreased cellular and 
histologic markers of lung fibrosis, and reduced perturbations in lung function in 
animal models of fibrosis induction in association with pirfenidone. 
1.2.2 Summary of Findings from Human Clinical Studies 
A total of 15 controlled and uncontrolled clinical studies in healthy subjects and patients 
with IPF or pulmonary fibrosis (PF) have been conducted by Marnac (the original 
developer of pirfenidone), Shionogi, or InterMune. More than 1300 subjects and patients 
have received pirfenidone. Other smaller studies of pirfenidone in patients with IPF or PF 
conducted by independent investigators have been reported in the literature, with 
generally favorable results (Nagai et al. 2002; Raghu et al. 1999; Gahl et al. 2002). 
InterMune has conducted multiple Phase 1 studies to assess the clinical pharmacology 
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and safety of pirfenidone as well as two long-term, uncontrolled safety studies that are 
currently ongoing (PIPF-002 and PIPF-012). 
The double-blind, placebo-controlled Phase 2 study conducted by Shionogi in Japan 
(SP2) served as the initial proof-of-concept study suggesting a benefit of pirfenidone in 
patients with IPF. Three Phase 3 studies were subsequently executed independently to 
confirm these findings, one in Japan (Shionogi-sponsored Phase 3 study [SP3], initiated 
in July 2004) and two in North America, Europe, and Australia (InterMune-sponsored 
PIPF-004 and PIPF-006, initiated in July 2006 and April 2006, respectively). Results 
from SP3, which was ongoing at the start of PIPF-004 and PIPF-006, formed the basis for 
approval of pirfenidone (Pirespa®) in Japan in October 2008. Efficacy results from these 
four trials are summarized below. 
1.2.2.1 Shionogi Phase 2 Study (SP2) (Azuma et al. 2005)  
SP2 was a multicenter, randomized, double-blind, placebo-controlled trial of pirfenidone 
in patients with a confirmed diagnosis of IPF conducted from 09 November 2000 to 
30 September 2002 (Azuma et al. 2005). A total of 109 patients in Japan were 
randomized in a 2:1 ratio to receive oral pirfenidone (1800 mg/d) or placebo for 
52 weeks. Based on a planned interim analysis at 24 weeks, the Efficacy and Safety 
Assessment Committee recommended stopping the study due to a significantly lower 
incidence of acute exacerbations, favoring pirfenidone.  
In the final analysis at 36 weeks, there was a trend toward a pirfenidone benefit in the 
primary efficacy outcome variable (mean area-above-the-curve for oxygen saturation by 
pulse oximetry [SpO2] during the 6-minute steady state exercise test [6MET], 8.12 vs. 
8.23; p = 0.093). In secondary analyses, patients receiving pirfenidone had a reduced 
mean decline from Baseline in vital capacity (VC) (-0.03 L vs. -0.13 L; p = 0.037) and a 
lower rate of acute exacerbations of IPF (1.4% vs. 14.3%; p = 0.014).  
1.2.2.2 Shionogi Phase 3 Study (SP3) (Taniguchi et al. 2010)  
SP3 was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study 
conducted in Japan between 13 July 2004 and 30 August 2006 (Taniguchi et al. 2010).  
A total of 275 IPF patients from 73 sites were randomized 2:2:1 to receive pirfenidone 
1800 mg/d, placebo, or pirfenidone 1200 mg/d for 52 weeks. Sixty-six percent of patients 
completed the study.  
PIPF-016: protocol-or-amendment.pdf  --  Page 22 of 97
InterMune, Inc.  Protocol PIPF-016 
Phase 3 Study of Pirfenidone for IPF 16 March 2011
 
CONFIDENTIAL AND PROPRIETARY Page 23 
SP3 demonstrated a significant benefit of pirfenidone 1800 mg/d compared with placebo 
on the primary outcome variable of change from Baseline in VC at Week 52 (-90 mL vs. 
-160 mL; absolute difference 70 mL; relative difference 43.8%; p = 0.042, analysis of 
covariance [ANCOVA]). There was also a reduced mean decline in %VC at Week 52 in 
the pirfenidone 1800 mg/d group (-2.91% vs. -5.13%; p = 0.044, ANCOVA). 
Progression-free survival (PFS), one of two key prespecified secondary endpoints, was 
prolonged in pirfenidone 1800 mg/d-treated patients relative to placebo (hazard ratio 
[HR] 0.45; 95% confidence interval [CI] 0.11–0.79; p = 0.028, log-rank test). In the 
pirfenidone 1200 mg/d treatment group, there was a reduced mean decline in VC 
compared with placebo (-80 mL vs. -160 mL; p = 0.039, ANCOVA), without evidence of 
a dose response compared with pirfenidone 1800 mg/d. 
1.2.2.3 InterMune PIPF-004  
In PIPF-004, a multinational, Phase 3, double-blind, placebo-controlled study, 
435 patients with IPF were randomized 2:2:1 to receive pirfenidone 2403 mg/d (n = 174), 
placebo (n = 174), or pirfenidone 1197 mg/d (n = 87). Study treatment lasted from 
randomization until approximately 72 weeks after the last patient had been randomized in 
the study. Most patients (84%) completed the study.  
In the primary efficacy analysis, treatment with pirfenidone 2403 mg/d resulted in a 
statistically significant reduction in the mean decline from Baseline in percent predicted 
forced vital capacity (%FVC) at Week 72 compared with placebo (-8.0% vs. -12.4%; 
absolute difference 4.4%; relative difference 35.3%; p = 0.001, rank ANCOVA), as well 
as across all study time points using a repeated measures analysis (p < 0.001). In an 
analysis of PFS, there was a 36% reduced risk of death or disease progression with 
pirfenidone 2403 mg/d treatment at Week 72 relative to placebo (HR 0.64; 95% CI 0.44–
0.95; p = 0.023, log-rank test), and a much lower proportion of patients with a decline of 
≥10% in %FVC at Week 72 in the pirfenidone 2403 mg/d group (20.1% vs. 34.5%). 
There was no discernible effect of pirfenidone on other secondary efficacy endpoints.  
There was a 39% relative reduction in the risk of death in the pirfenidone 2403 mg/d 
group compared with placebo (HR 0.61; 95% CI 0.28–1.29; p = 0.191). In the analyses of 
on-treatment mortality, both the incidence of on-treatment all-cause deaths (i.e., deaths 
occurring between time of randomization and 28 days after last dose of study treatment) 
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and that of IPF-related deaths was lower in the pirfenidone 2403 mg/d group than in the 
placebo group (10 vs. 14 deaths and 5 vs. 11 deaths, respectively).  
Evidence of a dose response was observed with pirfenidone 1197 mg/d relative to 
pirfenidone 2403 mg/d in the analysis of the primary efficacy outcome and several 
secondary outcome variables. 
1.2.2.4 InterMune PIPF-006  
PIPF-004 and PIPF-006 studies were identical in almost all major design features; 
however, PIPF-006 included two rather than three treatment groups. A total of 
344 patients were randomized to receive pirfenidone 2403 mg/d (171 patients) or placebo 
(173 patients). Most patients (83%) completed the study.  
The primary efficacy analysis did not reach statistical significance (mean change from 
Baseline in %FVC at Week 72, -9.0% vs. -9.6%; p = 0.501, rank ANCOVA); however, 
there was evidence of a treatment effect of pirfenidone 2403 mg/d at multiple earlier time 
points (p < 0.001 at Week 24, p = 0.011 at Week 36, and p = 0.005 at Week 48). In 
addition, a repeated measures analysis with averaging across all study time points showed 
a reduced decline from Baseline in %FVC in pirfenidone 2403 mg/d patients overall 
(p = 0.007). Also, there was evidence of an effect of pirfenidone 2403 mg/d compared 
with placebo in the change from Baseline in 6-minute walk test (6MWT) distance at 
Week 24 (p = 0.038), Week 36 (p = 0.044), Week 48 (p = 0.023), Week 60 (p = 0.014), 
and Week 72 (p < 0.001, rank ANCOVA). There was no discernable treatment effect of 
pirfenidone compared with placebo for the endpoint of PFS (HR 0.84; 95% CI 0.58–1.22; 
p = 0.355) or in other secondary efficacy endpoints. There was no protective effect on 
overall survival (HR 0.95; 95% CI 0.48–1.87; p = 0.872). A total of 16 (9.4%) and 17 
(9.8%) patients in the pirfenidone 2403 mg/d and placebo groups, respectively, died. 
However, in the analyses of on-treatment mortality, the incidence of both all-cause deaths 
and of IPF-related deaths was lower in the pirfenidone 2403 mg/d group than in the 
placebo group (9 vs. 15 deaths and 7 vs. 14 deaths, respectively).  
1.2.2.5 Efficacy Results Across Trials 
PIPF-004 and PIPF-006 
PIPF-004 and PIPF-006 were essentially identical trials by design, and pooling of their 
data was prespecified to provide a single, robust estimate of treatment effect. There was a 
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marked reduction in the mean decline from Baseline in %FVC in patients receiving 
pirfenidone 2403 mg/d compared with placebo at Week 72 (p = 0.005, rank ANCOVA), 
with the positive treatment effect of pirfenidone beginning at Week 12 (p = 0.003) and 
sustained throughout every subsequent study time point:  Week 24 (p < 0.001), Week 36 
(p < 0.001), Week 48 (p < 0.001), and Week 60 (p < 0.001). A repeated-measures 
analysis of the overall pirfenidone treatment effect on change in %FVC across all study 
time points also showed a strong benefit compared with placebo (p < 0.001). The 
proportion of patients with a decrement of ≥10% from Baseline in %FVC at Week 72, a 
threshold repeatedly found to predict mortality (Collard et al. 2003, Flaherty et al. 2003, 
King et al. 2005) was 30% lower in patients receiving pirfenidone 2403 mg/d than in 
patients receiving placebo (21.5% vs. 30.5%).  
In addition, treatment with pirfenidone 2403 mg/d resulted in a 26% reduction in the risk 
of death or progression of disease relative to placebo (HR 0.74; 95% CI 0.57–0.96; 
p = 0.025), as well as a reduced mean decline from Baseline in 6MWT distance at 
Week 72 (-52.8 m vs. -76.8 m; absolute difference of 24 m; p < 0.001) and at all earlier 
study time points after Week 12. Despite the lack of adequate power for the outcome of 
survival, the risk of death in the pirfenidone 2403 mg/d group relative to placebo was 
reduced by 23% (HR 0.77; 95% CI 0.47–1.28; p = 0.315), with 7.8% and 9.8% of 
patients in the two groups dying. In the  analyses of on-treatment mortality, the incidence 
of all-cause death was 35% lower in the pirfenidone 2403 mg/d group than in the placebo 
group (19 vs. 29 deaths), and the incidence of IPF-related deaths was 52% lower in the 
pirfenidone 2403 mg/d group than in the placebo group (12 vs. 25 deaths). 
PIPF-004, PIPF-006, SP3, and SP2 
Standardized estimates of the magnitude of the treatment effect on FVC/VC were derived 
from PIPF-004, PIPF-006, SP3, and SP2 to facilitate a direct comparison of study results 
(Figure 1-1). PIPF-004 and PIPF-006 analyzed change from Baseline in %FVC at time 
points that included Weeks 24, 36, 48, and 72, whereas SP3 and SP2 assessed the change 
from Baseline in VC at time points that included Weeks 28 and 36. SP3 also included an 
assessment at Week 52. The results show a high level of consistency in these results 
across time points (with the exception of Week 72) and across these studies. In addition, 
all of the meta-analysis estimates favor pirfenidone and clearly exclude no effect. At the 
Week 48/52 time point, point estimates of effect are remarkably similar in the three 
Phase 3 studies, and the confidence intervals in all 3 studies exclude the null effect.  
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A similar consistency in the hazard ratios for PFS was found for the 3 studies that 
included this endpoint (i.e., PIPF-004, PIPF-006, and SP3): a recent independent meta-
analysis by the Cochrane Review (Spagnolo 2010) of these three Phase 3 trials 
(N = 1046) demonstrated significant improvement in PFS, with an overall 30% reduction 
in the risk of death or disease progression (HR 0.70; 95% CI 0.56, 0.88; p = 0.002).  
 
PIPF-016: protocol-or-amendment.pdf  --  Page 26 of 97
InterMune, Inc.   Protocol PIPF-016 
Phase 3 Study of Pirfenidone for IPF 16 March 2011  
 
CONFIDENTIAL AND PROPRIETARY    Page 27 
 
Figure 1-1 Individual Study and Meta-analysis Estimates of the Pirfenidone Treatment Effect on VC/FVC Across Time 
Points 
Line represents standardized treatment effect of pirfenidone vs. placebo and 95% confidence interval.  
The dose of pirfenidone was 2403 mg/d in PIPF-004 and PIPF-006 and was 1800 mg/d in SP3 and SP2. 
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1.2.2.6 InterMune Pooled Phase 3 Safety Data 
Safety results from the pooled PIPF-004 and PIPF-006 pirfenidone 2403 mg/d study 
population were similar to those in previous studies. Common treatment-emergent 
adverse events (AE) that occurred more frequently in the pirfenidone group than the 
placebo group included gastrointestinal disorders (nausea, diarrhea, dyspepsia, vomiting, 
and stomach discomfort), skin disorders (rash and photosensitivity reaction), anorexia, 
decreased appetite, fatigue, and dizziness. Although more pirfenidone 2403 mg/d than 
placebo patients had at least 1 dose reduction for at least 1 day, dose reductions tended to 
be short-lived, related to transient gastrointestinal events or skin disorders, and 
implemented in accordance with the protocol-specified guidelines. The rate of treatment 
discontinuation due to an AE in the pirfenidone 2403 mg/d group was only 6% higher 
than in the placebo group. Mild or moderate serum transaminase elevations (serum ALT 
or AST >3 × upper limit of normal [ULN]) occurred more frequently in patients treated 
with pirfenidone 2403 mg/d than placebo, but they were most often effectively managed 
with dose modification and not associated with untoward clinical consequences. More 
extreme elevations in serum ALT or AST (>10 × ULN) were rare in both treatment 
groups, and no instances of liver function abnormality meeting the criteria for Hy’s law 
occurred. 
1.3 Potential Benefits and Risks to Human Subjects 
The collective data from InterMune-sponsored PIPF-004 and PIPF-006, as well as 
Shionogi-sponsored SP3 and SP2, provide evidence that pirfenidone provides a 
clinically meaningful benefit to patients with IPF as measured by lung function, 
exercise tolerance, and progression-free survival. 
The safety of pirfenidone has been characterized in 15 studies involving 
1345 subjects and patients; 770 patients have received pirfenidone at a dose of 
2403 mg/d or greater. Analyses of these data suggest that the side effects of 
pirfenidone are readily monitored, typically reversible, and related to tolerability 
rather than morbidity. Escalation of dose over the first 2 weeks, dosing with food, 
use of protection against sun exposure, prompt symptomatic management of 
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intolerance, and monitoring of liver function tests during dosing are recommended to 
maximize tolerability.   
1.4 Study Rationale 
IPF is a life-threatening and severely debilitating disease characterized by poor survival 
and a current lack of efficacious therapeutic options outside of the regions where 
pirfenidone is approved. Results from four controlled trials, as described above, suggest 
that pirfenidone treatment is safe and well tolerated and results in clinically meaningful 
benefits in a variety of domains, including lung volume (%FVC/VC), exercise tolerance 
(change in 6MWT distance), and progression-free survival time in patients with IPF. 
Given the primacy of loss of lung volumes over time in patients with IPF, this protocol is 
intended to confirm that pirfenidone 2403 mg/d reduces decline in FVC over 52 weeks, 
as observed in the previous studies, compared with placebo in patients with IPF. 
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2 STUDY OBJECTIVES 
The objectives of this study of pirfenidone in patients with IPF are as follows: 
• To confirm the treatment effect of pirfenidone 2403 mg/d compared with 
placebo on change in percent predicted FVC (%FVC) in patients with 
idiopathic pulmonary fibrosis (IPF) 
• To confirm the safety of treatment with pirfenidone 2403 mg/d compared with 
placebo in patients with IPF 
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3 INVESTIGATIONAL PLAN 
3.1 Study Design 
This is a Phase 3, randomized, double-blind, placebo-controlled, efficacy and safety 
study of pirfenidone in patients with IPF. Approximately 500 patients will be randomized 
with equal probability to receive pirfenidone 2403 mg/d or placebo. The primary efficacy 
endpoint is the change from Baseline in %FVC. Patients will receive blinded study 
treatment from the time of randomization until the Week 52 Visit.  
Eligible patients aged 40–80 years must have a confident clinical and radiographic 
diagnosis of IPF. Patients will be required to have a %FVC ≥50% and ≤90% and percent 
predicted carbon monoxide diffusing capacity (%DLCO) ≥30% and ≤90% at Screening, as 
well as 6MWT distance ≥150 meters at Screening. Any patient identified for the study 
must discontinue all prohibited therapies including therapy targeted to treat IPF for at 
least 28 days before the start of Screening. Other than brief periods of corticosteroid use 
for acute IPF exacerbation, patients will not receive any other therapy for the treatment of 
IPF (see Section 3.7.1). Once patients complete the Washout Period, they will enter the 
Screening Period, which may last up to 56 days.  
The dose of study treatment will be titrated over 14 days. Patients will receive a 
telephone assessment at Week 1 and visit the clinic at Weeks 2, 4, 8, 13, 16, 20, 26, 39, 
and 52. Patients who, in the opinion of the investigator, are compliant with study 
treatment dosing (≥80%) will be permitted to enter the rollover study at the completion of 
their Week 52 visit. Patients who do not choose to enter the rollover study will return for 
a Follow-up Visit 28 days after the last dose of study treatment. Patients should complete 
an adverse event (AE) and dosing compliance diary between visits. 
If patients discontinue study treatment for any reason before the end of the study, they 
should continue with all scheduled study procedures through Week 52.   
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3.2 Rationale for Study Design 
Protocol PIPF-016 is a randomized, double-blind, placebo-controlled trial designed to 
confirm the effect of pirfenidone on reducing the decline in lung function observed in the 
four previously conducted randomized controlled trials of pirfenidone in patients with 
IPF (SP2, SP3, PIPF-004, and PIPF-006).  
The protocol eligibility criteria, including a confident diagnosis of IPF in patients with 
%FVC ≥50% and ≤90% and %DLCO ≥30% and ≤90%, will ensure that an appropriate 
population is studied to confirm the findings in previously completed studies. Based on 
results from the previous studies, the eligibility criteria have been modified to enroll 
patients with a greater likelihood of disease progression over the ensuing year. This 
includes criteria designed to exclude patients with obstructive lung disease who are less 
likely to experience FVC progression than patients with pure restrictive disease.  
The primary endpoint of the study, change in %FVC from Baseline to Week 52, represents a 
clinically meaningful outcome measure that has been demonstrated to be reliable, valid, and 
predictive of changes in other important clinical endpoints in patients with IPF (du Bois 
2009). Multiple previous authors have reported that a decrement in %FVC over 6 months, 
particularly if ≥10% in magnitude, is both clinically significant and highly predictive of 
mortality (Collard et al. 2003; Flaherty et al. 2003; Zappala et al. 2010). We have chosen to 
assess the change in %FVC over the more prolonged duration of 12 months (52 weeks), 
which is twice the 6-month duration used in many of the studies assessing the performance 
characteristics of FVC. Decrements in %FVC at 12 months have also been robustly 
associated with mortality (Collard et al. 2003; Latsi 2003; King et al. 2005). There is 
significant precedent for the conduct of trials of 1-year duration to assess the impact of 
interventions on lung function in IPF patients, including both government- and industry- 
sponsored studies.  
The design features of PIPF-016 support the study objectives of confirming prior 
pirfenidone trial results while also providing new insights in this modified study population. 
This design will also enable direct comparisons and meta-analyses with previous 
pirfenidone trials, as well as comparisons with the results of studies with other interventions 
designed to assess effects on lung function endpoints. 
PIPF-016: protocol-or-amendment.pdf  --  Page 32 of 97
InterMune, Inc.  Protocol PIPF-016 
Phase 3 Study of Pirfenidone for IPF 16 March 2011
 
CONFIDENTIAL AND PROPRIETARY Page 33 
3.3 Dose Rationale 
Pirfenidone 2403 mg/d was the dose evaluated in PIPF-004 and PIPF-006, which 
demonstrated favorable efficacy and safety results compared with placebo. 
3.4 Selection of Study Population 
The study population consists of male and female IPF patients aged 40–80 years who 
meet the inclusion and exclusion criteria outlined below. 
3.4.1 Inclusion Criteria 
Eligible patients must have a confident diagnosis of IPF based on clinical, radiologic, 
and/or pathologic data without evidence or suspicion of an alternative diagnosis that may 
contribute to their interstitial lung disease. In addition, patients must fulfill all of the 
following criteria to be eligible for enrollment into the study: 
Diagnosis of IPF: 
1. Clinical symptoms consistent with IPF of ≥12 months duration 
2. Diagnosis of IPF, defined as the first instance in which a patient was informed of 
having IPF, at least 6 months and no more than 48 months before randomization  
3. Age 40 through 80 years, inclusive, at randomization 
4. Diagnosis of UIP or IPF by HRCT and SLB as outlined in Table 3-1 (Note:  
HRCT scan performed within 1 month of the start of Screening may be used if it 
meets image acquisition guidelines): 
Table 3-1 Summary of Select Criteria for Diagnosis of IPF 
 Surgical 
Lung Biopsy 
Not Available 
Pathology 
Panel:  
Definite UIP 
Pathology 
Panel:  
Probable UIP 
Pathology 
Panel: 
Possible UIP 
Pathology Panel: 
Inconsistent with 
UIP or Not 
Classifiable 
Radiology 
Panel: 
Definite UIP 
Eligible Eligible Eligible Eligible NOT Eligible 
Radiology 
Panel: 
Possible UIP 
NOT Eligible Eligible Eligible NOT Eligible NOT Eligible 
Radiology 
Panel: 
Inconsistent 
with IPF 
NOT Eligible NOT Eligible NOT Eligible NOT Eligible NOT Eligible 
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5. Extent of fibrotic changes (honeycombing, reticular changes) greater than the 
extent of emphysema on HRCT scan, as determined by central review 
6. No features supporting an alternative diagnosis on transbronchial biopsy, 
bronchoalveolar lavage (BAL), or SLB, if performed 
IPF Disease Severity and Progression:  
7. %FVC ≥50% and ≤90% at Screening, confirmed by central review 
8. Change in pre- and post-bronchodilator FVC (measured in liters) between 
Screening and Day 1 must be a <10% relative difference, calculated as shown 
below: 
Screen FVC (L) – Day 1 FVC (L)  × 100% 
Screen FVC (L) 
9. %DLCO ≥30% and ≤90% at Screening, confirmed by central review 
10. In the investigator’s opinion, no evidence of improvement in measures of IPF 
disease severity over the preceding year 
11. Able to walk ≥150 m during the 6-minute walk test (6MWT) at Screening 
Informed Consent and Protocol Adherence: 
12. Able to understand and sign a written informed consent form 
13. Able to understand the importance of adherence to study treatment and the study 
protocol and willing to follow all study requirements, including the concomitant 
medication restrictions, throughout the study 
3.4.2 Exclusion Criteria 
Patients with any of the following will be excluded from the study: 
Disease-Related Exclusions: 
1. Significant clinical worsening of IPF between Screening and Day 1, in the 
opinion of the investigator  
2. Not a suitable candidate for enrollment or unlikely to comply with the 
requirements of this study, in the opinion of the investigator 
3. Forced expiratory volume in one second (FEV1)/FVC ratio <0.8 after 
administration of bronchodilator at Screening, confirmed by central review 
4. Bronchodilator response, defined by an absolute increase of  ≥12% and an 
increase of 200 mL in the predicted FEV1 or FVC or both after bronchodilator 
use compared with the values seen before bronchodilator use at Screening, 
confirmed by central review  
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5. Cigarette smoking within 3 months of Screening or unwilling to avoid tobacco 
products throughout the study 
6. History of clinically significant environmental exposure known to cause PF, 
including but not limited to drugs (such as amiodarone), asbestos, beryllium, 
radiation, and domestic birds 
7. Known explanation for interstitial lung disease, including but not limited to 
radiation, drug toxicity, sarcoidosis, hypersensitivity pneumonitis, bronchiolitis 
obliterans organizing pneumonia, human immunodeficiency virus (HIV), viral 
hepatitis, and cancer 
8. Clinical diagnosis of any connective tissue disease, including but not limited to 
scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus, and 
rheumatoid arthritis 
9. History of asthma or chronic obstructive pulmonary disease  
10. Clinical evidence of active infection, including but not limited to bronchitis, 
pneumonia, sinusitis, urinary tract infection, or cellulitis  
11. Expected to receive a lung transplant within 1 year from randomization or, for 
patients at sites in the United States (US), on a lung transplant waiting list at 
randomization  
Medical Exclusions: 
12. Unable to perform 6MWT or to undergo pulmonary function test (PFT) 
13. Any history of malignancy likely to result in significant disability or likely to 
require significant medical or surgical intervention within the next 2 years. This 
does not include minor surgical procedures for localized cancer (e.g., basal cell 
carcinoma) 
14. Any condition other than IPF that, in the opinion of the investigator, is likely to 
result in the death of the patient within the next 2 years 
15. History of severe hepatic impairment or end-stage liver disease 
16. History of end-stage renal disease requiring dialysis 
17. History of unstable or deteriorating cardiac or pulmonary disease (other than 
IPF) within the previous 6 months, including but not limited to the following:  
a. Unstable angina pectoris or myocardial infarction  
b. Congestive heart failure requiring hospitalization 
c. Uncontrolled clinically significant arrhythmias 
18. Any condition that, in the opinion of the investigator, might be significantly 
exacerbated by the known side effects associated with the administration of 
pirfenidone 
19. Pregnancy or lactation. Women of childbearing capacity are required to have a 
negative serum pregnancy test before treatment and must agree to maintain 
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highly effective contraception by practicing abstinence or by using at least two 
methods of birth control from the date of consent through the end of the study. If 
abstinence is not practiced, one of the two methods of birth control should be an 
oral contraceptive (e.g., oral contraceptive and a spermicide).   
20. History of alcohol or substance abuse in the past 2 years 
21. Family or personal history of long QT Syndrome 
Laboratory Exclusions: 
22. Any of the following liver function test criteria above specified limits:   
total bilirubin above the upper limit of normal (ULN), excluding patients with 
Gilbert’s syndrome; aspartate or alanine aminotransferase (AST/SGOT or 
ALT/SGPT) >3 × ULN; alkaline phosphatase >2.5 × ULN 
23. Creatinine clearance (CrCl <30) mL/min, calculated using the Cockcroft-Gault 
formula 
24. Electrocardiogram (ECG) with a QTcB interval >500 msec at Screening 
Medication Exclusions: 
25. Prior use of pirfenidone or known hypersensitivity to any of the components of 
study treatment 
26. Use of any of the following therapies within 28 days before Screening:  
a. Investigational therapy, defined as any drug that has not been approved for 
marketing for any indication in the country of the participating site 
b. Any cytotoxic, immunosuppressive, cytokine modulating, or receptor 
antagonist agent including but not limited to azathioprine, bosentan, 
ambrisentan, cyclophosphamide, cyclosporine, etanercept, iloprost, 
infliximab, leukotriene antagonists, methotrexate, mycophenolate mofetil, 
tacrolimus, montelukast, tetrathiomolybdate, TNF-α inhibitors, 
N-acetylcysteine (NAC), imatinib mesylate, Interferon gamma-1b (IFN γ 1b), 
and tyrosine kinase inhibitors 
c. Medications that are specifically used for the treatment of IPF including but 
not limited to angiotensin converting enzyme (ACE) inhibitors, colchicine, 
corticosteroids, heparin, warfarin, and HMG-CoA reductase inhibitors. These 
drugs may be used if given for a non-IPF indication if there is no clinically 
acceptable alternative therapy for the same indication 
d. Fluvoxamine  
e. Sildenafil (daily use). Note: intermittent use for erectile dysfunction is 
allowed 
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3.5 Study Treatment 
3.5.1 Initial Dosing and Study Treatment Administration 
Study treatment is defined as either pirfenidone 2403 mg/d or placebo equivalent 
administered in divided doses three times per day (TID) with food. Study treatment 
should be titrated over 14 days, as tolerated, to the full dose of 9 capsules per day (three 
capsules TID), as follows: 
• Days 1–7:  one capsule TID 
• Days 8–14:  two capsules TID 
• Day 15 and continuing:  three capsules TID (maximum of 9 capsules daily) 
Each dose should be taken with food, at the same times each day. Patients will remain on 
a stable maintenance dose for the duration of the study period unless the dose is reduced 
to manage an AE (see Section 3.6).  
Doses of more than 9 capsules per day are not recommended for any patient.  
3.5.2 Missed Doses 
If patients miss a scheduled dose, that dose should be skipped. Regular dosing should 
resume with the next scheduled dose. Patients should not take any extra doses to make 
up for missed doses.  
3.5.3 Interruption in Study Treatment 
Any patient with an actual or anticipated interruption of study treatment for a period of  
≥28 consecutive days will be reported by telephone to InterMune’s medical monitor or 
designee to discuss the circumstances of the case. Once the patient restarts study 
treatment, the dose must be re-titrated over 14 days as described in Section 3.5.1. 
Pre-Restart and a series of Restart Visits are required, as described in Section 4.3.7.   
3.5.4 Study Treatment Supply 
InterMune will supply all study treatment. There will be 270 capsules per bottle, which 
will be labeled for investigational use only. Pirfenidone 267-mg and placebo will be 
supplied in opaque, hard, white gelatin capsules that are visually indistinguishable.  
The contents of the pirfenidone 267-mg capsules are as follows:  
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• Pirfenidone 82.15% 
• Croscarmellose sodium 8.15% 
• Microcrystalline cellulose 7.39% 
• Povidone, USP, EP 1.85% 
• Magnesium stearate 0.46% 
The contents of the placebo capsules are as follows:  
• Microcrystalline cellulose 79.99% 
• Pre-gel starch 19.5% 
• Magnesium stearate 0.5% 
• Bitrex 0.01% 
Study treatment will be shipped to the investigational sites at room temperature and 
should be stored between 15 and 30° C. DO NOT FREEZE OR REFRIGERATE. Do not 
use beyond the expiration date.  
3.5.5 Randomization and Blinding 
This is a randomized, double-blind, placebo-controlled study. Neither site personnel nor 
the patients will know which study treatment the patient is receiving. Pirfenidone and 
placebo will both be supplied in capsules that are visually indistinguishable. Pirfenidone 
and placebo packaging and labeling will be identical.  
Patients will be randomized at the Day 1 Visit (see Section 4.3.4.1) in a 1:1 ratio to 
receive either pirfenidone 2403 mg/d or placebo equivalent using an automated system. 
All randomization codes will be generated by a statistician independent of the trial 
conduct.  
No personnel involved in conducting pulmonary function tests (PFTs) or administering 
the 6MWT should be involved in the assessment of AEs and pulmonary symptoms.  
3.5.6 Unblinding 
Individual patient treatment assignments will not be unblinded during the study unless 
there is a regulatory obligation or a patient safety issue arises in which unblinding is 
necessary to ensure optimal patient management. While the study is ongoing, individual 
patient unblinding not related to regulatory requirements will only occur after approval 
from the InterMune medical monitor or designee. The PI and the medical monitor will 
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use the process outlined in the Study Reference Guide. Once the study is complete, the 
database has been locked, and the final analysis completed, treatment assignments will be 
unblinded for all patients. 
3.5.7 Study Treatment Accountability 
The monitoring of the inventory of study treatment supplies may be delegated to the 
responsible pharmacist; however, the Investigator is ultimately responsible for 
monitoring of study treatment inventory. Study treatment may not be used for any 
purpose other than that described in the protocol. All study treatment must be stored in a 
secure place with access restricted to authorized personnel.   
Patients should return all used and unused bottles of study treatment at every 13-week 
visit. After drug accountability has been assessed and drug return has been authorized by 
the monitor, sites will return all used and unused study treatment bottles to the 
distribution center or in accordance with site-specific standard operating procedures. 
All bottles of study treatment will be recorded in a Drug Accountability Log. The 
Investigator or designee will account for all study treatment received at the site, 
dispensed to the patients, returned by the patients, not used, and sent for destruction. All 
documentation of study treatment shipments must be retained. 
3.5.8 Dispensing of Study Treatment 
Study treatment will be dispensed to the patient every 13 weeks, but may be dispensed at 
other visits, as needed. Patients will be instructed to store study treatment at room 
temperature. Patients will be instructed to use study treatments in the order in which they 
are dispensed and that they must return all used and unused study treatment bottles. 
3.6 Dosing Guidelines and Dose Modifications 
3.6.1 Precautionary Measures  
Exposure to sunlight (including sunlamps and tanning beds) should be avoided or 
minimized during study treatment due to the possibility of photosensitivity reactions or 
rash. Patients should be instructed to use sunscreens that have a sun protection factor 
(SPF) of 50 or higher as well as protection against ultraviolet A (UV-A) radiation, and 
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also to wear clothing that protects against sun exposure and avoid concomitant 
medications known to cause photosensitivity reactions, if possible.   
All doses of study treatment are to be taken with food to reduce the likelihood of 
gastrointestinal symptoms. The dose titration period of 14 days at the initiation of study 
treatment is designed to maximize tolerability. 
3.6.2 Dose Modifications 
It is the responsibility of the investigator to monitor patients as frequently as clinically 
indicated for toxicities and consistent with the instructions of the package inserts for any 
medication used to treat a study patient. Refer to Section 1.2.2.6 for safety data from 
InterMune’s Phase 3 clinical studies of pirfenidone. 
If a patient experiences significant side effects, treatment of symptoms and/or temporary 
dose reductions, interruptions, or discontinuation of study treatment should be 
considered. Any such dosing modifications should be recorded in the patient diary. The 
InterMune medical monitor or designee will be available to discuss the management of 
AEs and dose modification, as needed. 
In the event of elevated liver aminotransferase tests, the recommendations in Table 3-2 
should be followed. The InterMune medical monitor or designee may be contacted for 
further discussion, as needed. 
Table 3-2 Recommended Procedures for Patients with Elevated Liver 
Aminotransferase Test Results 
Magnitude of Elevation in 
ALT or AST 
Recommendation 
3 to 5 × ULN Confounding medications should be discontinued, other 
causes excluded, and the patient monitored closely. The dose 
of study treatment may be reduced or interrupted if clinically 
appropriate, with subsequent titration to full dose, as 
tolerated. 
≤5 × ULN accompanied 
by symptoms or 
hyperbilirubinemia 
(>2 × ULN) 
Study treatment should be permanently discontinued. 
>5 × ULN Study treatment should be permanently discontinued.  
 
ALT = alanine aminotransferase; AST = aspartate aminotransferase;  
ULN = upper limit of normal.  
 
PIPF-016: protocol-or-amendment.pdf  --  Page 40 of 97
InterMune, Inc.  Protocol PIPF-016 
Phase 3 Study of Pirfenidone for IPF 16 March 2011
 
CONFIDENTIAL AND PROPRIETARY Page 41 
In the event of a QTcB >500 msec, refer to Section 4.3.2.10 for instructions. 
With the exceptions noted above, study treatment may be restarted at the discretion of the 
investigator. For treatment interruptions of ≥28 days, a Pre-Restart Visit and a series of 
Restart Visits are required, as outlined in Section 4.3.7, in addition to study treatment 
titration.  
In patients requiring hospitalization for an acute pulmonary process of unclear 
etiology, the investigator should consider continuing study treatment, if appropriate. If 
the patient is hospitalized at an institution other than the study site, the treating 
physician should be encouraged to discuss the patient’s management with the 
investigator at the earliest possible time. All records pertaining to the hospitalization 
should be obtained. 
The Modified Common Terminology Criteria for Adverse Events (Appendix D) will be 
used to define toxicity. All toxicities will be followed according to procedures in 
Section 6.  
The ultimate decision regarding study treatment interruption, restart, and dose 
modification is the responsibility of the investigator. For example, it is the investigator's 
responsibility to determine whether study treatment should be restarted in the setting of 
changing toxicity grades. Investigators are encouraged to contact the InterMune medical 
monitor or designee to discuss patient safety and dose-modification issues. 
3.7 Concomitant Medications 
All of the following are considered concomitant medications, and data regarding their use 
must be collected and recorded:  
• Prescription drugs 
• Over-the-counter drugs, including vitamins, antacids, herbal and dietary 
supplements 
• Permitted IPF therapies (see Section 3.7.1) 
• Excluded therapies (see Section 3.7.2) 
Information on all concomitant medications will be collected until 28 days after the last 
dose of study treatment; thereafter, for patients who discontinue study treatment early, 
only concomitant medications used for pulmonary indications will be collected. 
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Collection of concomitant medication data ceases if a patient enters the rollover study. A 
list of concomitant medications used for pulmonary indications will be provided in the 
Study Reference Guide. 
3.7.1 Treatment for Acute IPF Exacerbations  
Corticosteroids may be used at the discretion of the investigator, without dose restriction, 
for a period of up to 21 days in patients experiencing an episode of acute IPF 
exacerbation. The study drug should be continued during this time, if possible. If study 
treatment interruption/discontinuation is being considered, it must be immediately 
reported by telephone to InterMune’s medical monitor or designee to discuss the 
circumstances of the case.  
The following guidelines are offered as a definition of an acute IPF exacerbation 
(Ley et al. 2011). The definition specifies that a patient develop evidence of all of the 
following criteria within a 4-week period: 
• Decline of ≥5% in resting SpO2 on room air or decline of ≥8 mmHg from the 
last recorded level in resting PaO2 on room air  
• Clinically significant worsening of dyspnea or cough, triggering unscheduled 
medical care (e.g., clinic visit, hospitalization) 
• New, superimposed ground-glass opacities or consolidation on CT scan or 
new alveolar opacities on chest x-ray 
• No clinical or microbiologic evidence of infection (i.e., absence of grossly 
purulent sputum, fever >39° C orally) 
• All other causes excluded (e.g., pneumothorax, cardiac event, infection, or 
thromboembolism)  
3.7.2 Excluded Therapies 
The therapies listed below are not permitted during the study:  
• Investigational therapy, defined as any drug that has not been approved for 
marketing for any indication in the country of the participating site 
• Corticosteroids when used for the treatment of IPF (except for durations of up 
to 21 days for acute IPF exacerbation, see Section 3.7.1). No restrictions apply 
to corticosteroids used for reasons other than IPF therapy (e.g., allergic 
reactions, sepsis); however, the specific reason for use must be recorded 
• Any cytotoxic, immunosuppressive, cytokine-modulating, or receptor-
antagonist agent including but not limited to azathioprine, bosentan, 
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ambrisentan, cyclophosphamide, cyclosporine, etanercept, iloprost, 
infliximab, leukotriene antagonists, methotrexate, mycophenolate mofetil, 
tacrolimus, montelukast, tetrathiomolybdate, TNF-α inhibitors, N-
acetylcysteine (NAC), imatinib mesylate, Interferon gamma-1b (IFN-γ 1b), 
and tyrosine kinase inhibitors 
• Concomitant medications being used for the treatment of IPF including but 
not limited to ACE inhibitors, colchicine, warfarin, heparin, and HMG-CoA 
reductase inhibitors. These drugs may be used if given for a non-IPF 
indication if there is no clinically acceptable alternative therapy for the same 
indication; however, the specific reason for use must be recorded 
• Fluvoxamine 
• Sildenafil (daily use). Note: intermittent use for erectile dysfunction is 
allowed 
3.8 Early Discontinuation of Study Treatment and Early Withdrawal from Study 
Procedures 
3.8.1 Early Discontinuation of Study Treatment 
Study treatment will be discontinued for any of the following reasons: 
• Unacceptable toxicity (this may include serious adverse events [SAEs] related 
to study treatment) 
• Patient request or withdrawal of consent 
• Pregnancy 
• Protocol deviation (at InterMune’s discretion) 
• Investigator discretion 
• Termination of study by InterMune  
• Lung transplantation 
If early discontinuation of study treatment is being considered, it must be immediately 
reported by telephone to the InterMune medical monitor or designee to discuss the 
circumstances of the case.  
If study treatment is discontinued, patients will complete a Follow-up Visit 28 days after 
the last dose of study treatment (Section 4.3.5). Patients who discontinue study treatment 
should complete all scheduled study assessments and procedures through Week 52.    
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3.8.2 Early Withdrawal from Study Procedures 
It is critical to the integrity of this study that patients adhere to the visit schedule outlined 
in the protocol. As such, every reasonable effort should be made to convey the 
importance of remaining on study to the patients. Any patient withdrawing from study 
procedures must be reported immediately by telephone to the InterMune medical monitor 
or designee to discuss the circumstances of the case in an effort to ensure patient safety 
and appropriate documentation of events. Patients who wish to withdraw from study 
procedures will continue Vital Status Assessments until death or through Week 52 (see 
Section 4.3.6). 
3.8.3 Lung Transplantation 
Patients may have clinically appropriate testing in preparation for lung transplantation 
while on the study. Patients who receive a lung transplant during the study will 
discontinue study treatment and withdraw from study procedures. Patients will complete 
a Follow-up Visit 28 days after the last dose of study treatment (Section 4.3.5). Patients 
who undergo lung transplantation will continue Vital Status Assessments until death or 
through Week 52 (see Section 4.3.6). 
3.9 Sponsor Study Termination 
InterMune has the right to terminate this study at any time. Reasons for terminating the 
study may include, but are not limited to, the following: 
• The incidence or severity of adverse drug reactions in this or other studies 
involving pirfenidone indicates a potential health hazard to patients 
• Patient enrollment is unsatisfactory 
• Administrative reasons 
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4 OUTCOMES AND ASSESSMENTS 
4.1 Efficacy Outcome Variables 
4.1.1 Primary Efficacy Outcome Variable 
The primary efficacy outcome variable is change from Baseline to Week 52 in %FVC.  
4.1.2 Secondary Efficacy Outcome Variables 
The key secondary efficacy outcome variables are as follows: 
• Change from Baseline to Week 52 in 6MWT distance 
• Progression-free survival 
Other secondary efficacy outcome variables are: 
• All-cause mortality 
• Treatment-emergent IPF-related mortality 
• Change from Baseline to Week 52 in dyspnea as measured by the University 
of California at San Diego Shortness-of-Breath Questionnaire (UCSD SOBQ) 
score 
4.2 Safety Outcome Measures 
Safety outcome measures will include the following: 
• Treatment-emergent AEs 
• Treatment-emergent SAEs 
• Treatment-emergent treatment-related AEs 
• Treatment-emergent treatment-related SAEs 
• AEs leading to early discontinuation of study treatment 
• Treatment-emergent deaths 
• Cause of death 
• Treatment-emergent changes in clinical laboratory findings and ECGs 
• Vital signs 
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4.3 Description of Study Assessments 
Informed consent must be obtained prior to the Washout Period and Screening and 
before any study-mandated procedures take place. Study procedures are defined as 
laboratory tests, spirometry, DLCO/TLCO (carbon monoxide transfer capacity), 6MWT, 
Borg Scale, ECG, HRCT scan, directed history, physical examination, vital signs, 
height, weight, and any changes to existing treatment regimens. During the study, 
procedures and observations will be monitored to confirm that study requirements are 
being followed as outlined in the Appendix A. Patients will be followed through the 
Follow-Up Visit or until entry into the rollover study, whichever occurs earlier. Patients 
who undergo lung transplantation or who chose to withdraw from study procedures 
early will be followed for vital status until Week 52.  
If any study procedure is deemed not acceptable for quality issues, the procedure should 
be repeated.  
4.3.1 Laboratory Assessments 
4.3.1.1 Routine Clinical Laboratory Tests 
The following assessments will be performed at a central laboratory according to 
Appendix A, as summarized below:   
• Hematology (complete blood count with platelet count and automated 
differential) 
• Serum chemistry profile (albumin, alkaline phosphatase, ALT/SGPT, 
AST/SGOT, direct bilirubin, total bilirubin, calcium, cholesterol, creatine 
kinase [CK], creatinine, triglycerides, gamma-glutamyl transferase [GGT], 
glucose, lactic dehydrogenase [LDH], magnesium, phosphorus, potassium, 
sodium, urea nitrogen, uric acid and amylase)  
• Pregnancy test for women of childbearing capacity  
Additional laboratory assessments that will be performed by the central laboratory during 
Screening include serologic tests (rheumatoid factor, anticyclic citrullinated peptide and 
antinuclear antibody titer and pattern). 
It is the investigator’s responsibility to perform clinical laboratory assessments more 
frequently, if clinically indicated.  
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4.3.1.2 Biomarkers in Blood 
Certain biomarkers may be differentially expressed in IPF and may change as a 
result of pirfenidone treatment (e.g., possibly cytokines, chemokines, microRNA 
expression, and other cellular and molecular markers of fibrosis). The blood 
samples that are being obtained for this study may help identify these biomarkers 
and may be used to assess their response to pirfenidone therapy.   
4.3.1.3 Genetic Polymorphisms (Assessed at Select Sites) 
Genetic polymorphisms have been demonstrated to alter the development and clinical 
course of a number of different diseases. The purpose of assessing genetic 
polymorphisms in this study is to understand their potential role in the pathogenesis of 
IPF and in clinical outcomes. 
It is understood that some countries, municipalities, institutions, or local 
Institutional Review Boards/Independent Ethics Committees (IRBs/IECs) do not 
allow the study of genetic polymorphisms. Therefore, the assessment of genetic 
polymorphisms will only be conducted at institutions in which such research is in 
accordance with country and local law and institutional regulations. Patient 
participation for this assessment is voluntary and declining participation will in no 
way influence eligibility for this study. Patients agreeing to participate will sign a 
separate informed consent form. 
4.3.2 Pulmonary Function and Clinical Assessments 
4.3.2.1 HRCT Scans and Surgical Lung Biopsies 
HRCT Scans 
HRCT scans obtained before the Screening period as part of the standard of care for a 
patient may be used to confirm eligibility, provided they meet all of the image acquisition 
and quality criteria required by the central expert readers and were obtained within 
1 month before the start of the Screening Period (see Appendix B). All HRCT digital 
images are to be stored on a dedicated disk or tape at each study center. The images will 
be transferred electronically to the vendor tasked with interpretation and archiving of the 
images.  
PIPF-016: protocol-or-amendment.pdf  --  Page 47 of 97
InterMune, Inc.  Protocol PIPF-016 
Phase 3 Study of Pirfenidone for IPF 16 March 2011
 
CONFIDENTIAL AND PROPRIETARY Page 48 
The HRCT scans will be reviewed by two central readers who are radiologists with 
expertise in IPF. If the two central readers do not agree, a third expert reader will 
adjudicate. Data regarding the HRCT interpretation will be entered electronically into the 
vendor’s database and incorporated into the clinical database. 
Pathology 
Surgical lung biopsy (SLB), if performed, may be obtained up to 4 years before 
randomization. Histopathologic criteria for UIP are outlined in Appendix C. The slides 
will be submitted and reviewed by two central readers who are pathologists with 
expertise in IPF. If the two central readers disagree, a third expert central reader will 
adjudicate. Data regarding the pathology findings will be entered directly into the 
electronic case report form (eCRF).  
The observations of the central readers in radiology and pathology will be stored in the 
clinical database. Based on the algorithm detailed in Table 3-1, patient eligibility will be 
communicated to the study site by the Sponsor’s designated vendor. 
4.3.2.2 Spirometry and DLCO (or TLCO) Measurements 
All equipment, procedures, and personnel qualifications for the assessment of lung 
function are based on the recommendations of the American Thoracic Society (ATS 
2005):  
• Spirometry measurements will include FVC and FEV1 before and after 
administration of albuterol (or salbutamol) from a metered dose inhaler  
• DLCO or TLCO will be measured by determining the diffusing/transfer capacity 
of the lung for carbon monoxide. DLCO or TLCO measurement should be 
performed before or at least 30 min after the last bronchodilator puff  
Spirometry and DLCO (or TLCO) measurements should be performed as specified in the 
Study Reference Guide. Both DLCO and TLCO measurements are acceptable; however, 
TLCO measurements must be converted to DLCO at Screening to determine eligibility. All 
FVC and DLCO data collected throughout the study will be evaluated by a central reader 
blinded to treatment assignment. Data for FVC, DLCO/TLCO will be entered electronically 
into the vendor’s database and incorporated into the clinical database. 
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4.3.2.3 Screening Oxygen Titration Procedure 
During Screening, resting room air SpO2 will be assessed, and the amount of 
supplemental oxygen (if any) needed to maintain SpO2 at ≥90% will be determined. This 
level of supplemental oxygen will be used during 6MWTs throughout the study. Details 
of how to perform this procedure will be provided in the Study Reference Guide. 
4.3.2.4 6-Minute Walk Test (6MWT) and Borg Scale 
The 6MWT measures the distance that a patient can walk at his/her own pace on a 
measured, flat hard surface in a period of 6 min. The 6MWT assesses the global and 
integrated responses of all body systems involved during walking. The 6MWT has been 
established as the walk test of choice in cardiorespiratory diseases and has shown 
correlations with physiologic measurements and severity of disease classifications 
(American Association for Respiratory Care 1992; Solway et al. 2001; du Bois et al. 
2010; Swigris et al. 2009; Lederer et al. 2006; Eaton et al. 2005). The 6MWT based on 
ATS recommendations (ATS 2002) will be performed as outlined in the Study Reference 
Guide. 
The Borg Scale is an instrument to be self-administered by the patient as part of the 
6MWT procedure (Borg 1982; see Appendix E). Study staff will enter the 6MWT data 
into the eCRF. 
4.3.2.5 UCSD SOBQ 
The UCSD SOBQ is a symptom-specific, 24-item, patient-self-administered 
questionnaire that assesses shortness of breath while doing a variety of activities of daily 
living (see Appendix F). Study staff will enter the SOBQ data into the eCRF. 
4.3.2.6 Physical Exam and Vital Signs 
A complete physical examination should be performed, including all body systems 
pertinent to the patient. If clinically significant abnormalities are observed before Day 1, 
they should be reported in the patient’s medical history. If clinically significant 
abnormalities are observed after Day 1, the investigator should decide if they are new 
adverse events.  
Vital signs for this study protocol include heart rate and blood pressure. 
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4.3.2.7 Directed History During the Study 
The following will be assessed as directed history: 
• AEs/SAEs 
• Concomitant medications 
• Dosing and compliance 
• Supplemental oxygen use 
• Hospitalizations 
4.3.2.8 Vital Status Assessments 
Vital status must be assessed at protocol-specified time points until the Follow-Up Visit 
or entry into the rollover study (whichever occurs earlier), even if the patient cannot 
physically be present for the visit. Patients who undergo lung transplantation or who 
chose to withdraw from study procedures early will be followed for vital status until 
Week 52. This assessment may be accomplished remotely if necessary (i.e., via telephone 
or electronically), provided these communications are well documented. Vital status 
procedures are as follows: 
1. If the patient is not available, an authorized family member or representative 
will be contacted 
2. In the case of lung transplant, the date of the transplant, details of the 
transplant, dates of hospitalization, and the current vital status will be obtained 
3. In the case of patient death, the date, details, and cause of death will be 
requested from the patient’s representative or family member 
4. If a patient is lost to follow-up, vital status will be ascertained through the use 
of Death Registries, where approved and available (see Section 4.3.9) 
4.3.2.9 Mortality Assessment Committee 
A Mortality Assessment Committee (MAC) will closely examine the details and review 
the relationship to IPF for each death. Documentation regarding deaths must be requested 
and should include (but is not limited to) discharge summaries, death certificates, and 
autopsy reports. 
4.3.2.10 Electrocardiograms (ECGs) 
All ECGs for this study will be 12-lead ECGs that will be evaluated by a central reviewer 
blinded to treatment assignment. ECGs should be performed before bronchodilator 
administration or on a separate day. Unique triplicate ECGs are required at Screening.  
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During the study, if the QTcB interval is >550 msec, confirmed by a repeat ECG within 
24 h, and verified by a study site or local cardiologist, study drug should be interrupted 
until the reading is confirmed by the ECG central reader. If the reading is confirmed, the 
patient should be discontinued from study treatment. If the QTcB interval is between 
500 and 550 msec, confirmed by a repeat ECG within 24 hours, and verified by a study 
site or local cardiologist and the ECG central reader, study treatment should be 
interrupted. If an alternative explanation is identified (e.g., electrolyte abnormality or 
concomitant medication), re-initiation of study treatment may be considered by the 
investigator in consultation with the medical monitor or designee. ECG data will be 
entered directly into the vendor’s database and incorporated into the clinical database. 
4.3.3 Washout and Screening Periods  
Written informed consent must be obtained before initiating any study-associated 
procedures or changes to a pre-existing treatment regimen for purposes of this study. 
Procedures conducted during Screening will be used to determine the eligibility of each 
patient for study inclusion before randomization and to establish patient Baseline status. 
If patients fail Screening due to a condition that subsequently resolves (e.g., infection), 
they may be considered for rescreening; however, these patients must be discussed with 
the InterMune medical monitor or designee before rescreening.  
Washout Period (28 Days) 
Before entering a patient in the Washout Period, all relevant medical history, diagnostic 
findings, and measures of disease severity should be reviewed to evaluate the patient’s 
suitability for the study. Any patient identified for the study must discontinue all 
prohibited medications at least 28 days before Screening. This is the Washout Period. If a 
medication must be tapered, tapering must start early enough that the patient has 
discontinued the drug 28 days before the start of Screening.  
Written informed consent must be obtained before withdrawing or tapering the patient off 
prohibited therapies. The investigator must explain to the patient that entry into the study 
is not guaranteed.  
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Screening Period (Day -56 to Day -2) 
The Screening period is defined as the time between the date of the first Screening 
procedure and Day -2 and may last up to 56 days. Screening procedures may be 
conducted on different days within the Screening period if convenient.  
The following procedures will be performed during Screening:   
1. Written informed consent, if not already obtained during the Washout Period 
2. Complete medical history, review of systems, and review of concomitant 
medications  
3. Physical examination, vital signs, weight, and height  
4. Clinical laboratory assessments, including hematology, serum chemistries, 
serologic tests, and pregnancy test for women of childbearing capacity 
5. Unique triplicate ECGs (obtained before bronchodilator administration or on a 
separate day) 
6. Resting Oxygen Titration Procedure 
7. A 6MWT and Borg Scale (see Appendix E) must be performed within the 
2 weeks before Day 1 
8. UCSD SOBQ 
9. Transfer of all surgical lung biopsies, if available, to the InterMune-designated 
vendor for evaluation by the central readers  
10. Review of transbronchial biopsy and/or BAL, if available, to assess eligibility 
11. HRCT scan to assess eligibility (see Appendix B). HRCT scans performed 
within 1 month of the Screening period may be used to confirm eligibility (see 
Section 4.3.2.1) 
12. Spirometry (FVC, FEV1) before and after bronchodilator administration 
13. DLCO or TLCO (obtained before or 30 min after bronchodilator administration) 
4.3.4 Assessments During Treatment 
4.3.4.1 Eligibility and Randomization (Day 1) 
All Day 1 procedures must be performed before randomization and before administration 
of study treatment. This study has no Day 0. 
Randomization (Day 1) will occur no more than 56 days after the start of the Screening 
period, and study treatment should begin on the day of randomization. All results of the 
Screening assessments and eligibility documentation will be submitted to InterMune or 
designee for approval at least 2 working days before the targeted randomization day. 
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Once a patient’s documentation is received and the patient is confirmed to be eligible for 
randomization, the site will be instructed to randomize the patient at the end of Day 1.  
The following procedures will be performed on Day 1: 
Before Randomization  
1. Directed history (including review of AEs/SAEs, concomitant medications, 
oxygen use, and hospitalizations) 
2. Physical examination, vital signs, and weight 
3. Clinical laboratory assessments, including hematology, serum chemistries, 
pregnancy test for women of childbearing capacity, and biomarkers  
4. Genetic polymorphisms at select sites 
5. Spirometry (FVC, FEV1) before and after bronchodilator administration  
6. 6MWT and Borg Scale  
7. UCSD SOBQ 
8. Confirmation of patient eligibility for study participation  
Randomization: 
9. Randomize patient using an automated system  
After Randomization: 
10. Instruct the patient on how to titrate the dose of study treatment 
11. Dispense 13-week supply of study treatment. Dosing should start on the day of 
randomization 
12. Dispense patient diary and instruct patients on how to properly record 
information using the diary 
4.3.4.2 Week 1 Telephone Assessment (± 2 days) 
A telephone interview will be conducted to determine vital status and to assess 
tolerability of study treatment, patient compliance with dosing, and titration of study 
treatment.  
4.3.4.3 Weeks 2, 4, and 8 (± 1 week)  
The following procedures will be performed at Weeks 2, 4, and 8: 
1. Directed history (including review of AEs/SAEs, concomitant medications, 
oxygen use, hospitalizations, dosing, and diary) 
2. Physical examination, vital signs, and weight 
3. ECG (at Weeks 4 and 8 only) 
PIPF-016: protocol-or-amendment.pdf  --  Page 53 of 97
InterMune, Inc.  Protocol PIPF-016 
Phase 3 Study of Pirfenidone for IPF 16 March 2011
 
CONFIDENTIAL AND PROPRIETARY Page 54 
4. Clinical laboratory assessments, including hematology, serum chemistries, and 
pregnancy test for women of childbearing capacity 
5. Vital Status Assessment  
4.3.4.4 Weeks 13, 26, and 39 (± 2 weeks)   
The following will be performed at Weeks 13, 26, and 39: 
1. Directed history (including review of AEs/SAEs, concomitant medications, 
oxygen use, hospitalizations, dosing, and diary) 
2. Physical examination, vital signs, and weight 
3. ECG (obtained before bronchodilator administration or on a separate day) 
4. Spirometry (FVC, FEV1) before and after bronchodilator administration.  
5. Clinical laboratory assessments, including hematology, serum chemistries, 
pregnancy test for women of childbearing capacity, and biomarkers  
6. 6MWT and Borg Scale 
7. UCSD SOBQ 
8. Collection of any unused study treatment, review compliance and dispensing of 
13-week supply of study treatment 
9. Dispense new diary, if required. 
10. Vital Status Assessment 
4.3.4.5 Weeks 16 and 20 (± 1 week) 
The following will be performed at Weeks 16 and 20: 
1. Liver function testing (AST, ALT, bilirubin, and alkaline phosphatase) 
2. Vital Status Assessment 
4.3.4.6 Week 52A Visit (± 1 week) 
At the Week 52A Visit, the following procedures will be performed:  
1. Spirometry (FVC, FEV1 before and after bronchodilator administration)  
2. 6MWT and Borg Scale  
3. UCSD SOBQ  
Patients will return within 3 days for a Week 52B Visit 
4.3.4.7 Week 52B Visit (1–3 Days after Week 52A Visit) 
Patients will return within 3 days after the Week 52A Visit for the Week 52B Visit. Study 
treatment will stop for all patients upon completion of all procedures for the Week 52B 
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Visit. Patients must return all used and unused study treatment bottles from this study to 
the study center. 
The following procedures will be performed at the Week 52B Visit:  
1. Directed medical history (including review of AEs/SAEs, concomitant 
medications, oxygen use, hospitalizations, dosing, and diary) 
2. Physical examination, vital signs, and weight 
3. ECG (obtained before bronchodilator administration) 
4. Clinical laboratory assessments, including hematology, serum chemistries, 
and pregnancy test for women of childbearing capacity, and biomarkers 
5. Spirometry (FVC, FEV1 before and after bronchodilator administration)   
6. 6MWT and Borg Scale 
7. UCSD SOBQ 
8. Collection of all used and unused bottles of study treatment  
9. Dispensing of a new diary, if required.  
10. Vital Status Assessment 
 
After completion of the Week 52B procedures, eligible patients may enter the rollover 
study. 
4.3.4.8 Follow-up Visit (+ 7 days) 
Patients who do not enter the rollover study or who discontinue study treatment early will 
be required to return for a Follow-up Visit, 28 to 35 days after their last dose of study 
treatment in this study. The following procedures will be performed at the Follow-up 
Visit: 
1. Directed medical history (including review of AEs/SAEs, concomitant 
medications, oxygen use, hospitalizations, dosing, and diary) 
2. Physical examination, vital signs, and weight 
3. Clinical laboratory assessments, including hematology, serum chemistries, 
pregnancy test for women of childbearing capacity, and biomarkers   
4. Collection of diary  
5. Vital Status Assessment 
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4.3.5 Early Discontinuation of Study Treatment 
Patients who discontinue study treatment before Week 52 will complete a Follow-up 
Visit (see Section 4.3.4.8). In addition to the procedures listed above for the Follow-up 
Visit, patients who discontinue study treatment before Week 52 must return all used and 
unused study treatment. Patients who discontinue study treatment will continue to 
complete all scheduled study assessments and procedures through Week 52.  
4.3.6 Early Withdrawal from Study Procedures 
Patients who withdraw from study procedures early for reasons other than withdrawal of 
consent will cease study procedures but should be reminded that they gave permission for 
Vital Status Assessments when they consented to participate in the study. Consent for 
Vital Status Assessments remains intact when a patient withdraws from study procedures. 
Such patients will continue to complete Vital Status Assessments through Week 52.  
Patients who withdraw consent in writing will cease all study procedures including vital 
status assessments. 
4.3.7 Study Treatment Pre-Restart and Restart Visits 
Patients should be encouraged to restart study treatment whenever possible and 
appropriate. If the patient has interrupted study treatment for ≥28 days, Restart Visits are 
required. The Pre-Restart Visit will be conducted on the day study treatment is resumed, 
followed by Restart Visits at Weeks 1, 2, 4, and 8 to be scheduled based on the date of 
study treatment restart.  
The following procedures will be performed at the Pre-Restart Visit: 
1. Directed history (including review of AEs/SAEs, concomitant medications, 
oxygen use, and hospitalizations ) 
2. Physical examination, vital signs, and weight 
3. Clinical laboratory assessments, including hematology, serum chemistries, and 
pregnancy test for women of childbearing capacity   
4. Instruction on how to re-titrate the dose of study treatment 
5. Dispensing of study treatment, as necessary  
6. Dispensing of patient diary, as necessary   
Visit requirements and visit windows for Restart Week 1 and Restart Weeks 2, 4, and 8 
are the same as those described in Section 4.3.4.2 and Section 4.3.4.3, respectively. 
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Patients who restart study treatment will resume the visit schedule based on their date of 
randomization. If a regularly scheduled visit (Weeks 13, 26, 39, etc.) coincides with one 
of the Restart Visits (Restart Weeks 2, 4, or 8), then all of the elements of the regularly 
scheduled visit should be performed in lieu of the Restart Visit. 
4.3.8 Unscheduled Visits 
Any follow-up that is performed to monitor patient safety should be collected as an 
Unscheduled Visit. The investigator is responsible for monitoring patient AEs or 
toxicities. The elements of the visit are up to the discretion of the investigator. Additional 
clinical laboratory assessments as outlined in Section 4.3.1.1 should be obtained through 
the central laboratory. 
4.3.9 Patients Lost to Follow-Up 
If a patient has missed a visit and is not responding to telephone calls from the site (all 
attempts to contact the patient should be documented), the site will need to take more 
aggressive action in locating the patient. The site should make at least two attempts to 
contact the patient by telephone and two additional attempts to contact the patient’s 
emergency contact. If these attempts are not successful, a registered letter should be sent 
to the last known address of the patient. If this is not successful, as a last resort, the site 
should check the national death registries, where approved by regulatory authorities and 
available. If this is unsuccessful, the patient will be considered lost to follow-up.  
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5 STATISTICAL METHODS 
The objectives of the study are to confirm the efficacy and safety of pirfenidone 
2403 mg/d compared with placebo in the treatment of patients with IPF.  
5.1 Randomization and Treatment Assignment 
In this double-blind study, patients will be randomized to receive either pirfenidone 
2403 mg/d or placebo in a 1:1 ratio using block randomization. 
5.2 Sample Size and Power Considerations 
The sample size and power calculations for this study are based on the primary endpoint, 
change in %FVC from Baseline to Week 52, and on a key secondary endpoint, change in 
6MWT distance from Baseline to Week 52. Estimates are based on the results from 
pooled data (ITT population) of studies PIPF-004 and PIPF-006.  
Approximately 500 patients will be randomized in a 1:1 ratio of pirfenidone 2403 mg/d 
or placebo.  
For the primary efficacy comparison of change in %FVC between the 2403 mg/d and 
placebo groups, 250 patients per group will provide at least 90% power to detect a 
difference in normalized ranks of 0.08 with a standard deviation of 0.27. For change in 
6MWT distance, 250 patients per group will provide approximately 75% power to detect 
a difference in normalized ranks of 0.068 with a standard deviation of 0. 285. 
In this study of pirfenidone to reduce decline in lung function, mortality is included as a 
secondary endpoint to provide supportive evidence of benefit, but the study has not been 
powered to show a significant mortality benefit. A sample size of 250 patients per group 
provides only 10% power with an alpha of 0.05 to detect a hazard ratio of 0.77 in all-
cause mortality, the effect size observed in the pooled analyses of PIPF-004 and 
PIPF-006. Furthermore, pooling data from this study with those from the two previous 
studies, PIPF-004 and PIPF-006, provides less than 20% power to detect a hazard ratio of 
0.77 at an alpha of 0.05. 
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5.3 Analysis Populations 
The primary population for efficacy analyses will be the intent-to-treat (ITT) population, 
consisting of all patients who signed informed consent and were randomized to study 
treatment. The safety analysis population will include all patients who signed informed 
consent and received any amount of study drug. 
5.4 Statistical Analyses 
5.4.1 Demographic and Baseline Data 
Descriptive statistics will be used to summarize demographic and Baseline patient 
characteristics. Continuous-scaled variables (e.g., age) will be summarized with means, 
medians, standard deviations, quartiles, and minimum and maximum values. Categorical 
variables (e.g., sex) will be summarized using patient counts and percentages. 
Baseline medical histories and pre-existing conditions will be summarized by treatment 
group based on mapping to system organ classes and preferred terms in the Medical 
Dictionary for Regulatory Activities (MedDRA). 
Medications taken after informed consent is signed and before randomization will be 
summarized by treatment group, based on mapping to drug classes and generic terms in 
the WHO Drug Dictionary. 
5.4.2 Efficacy Analyses 
5.4.2.1 Primary Efficacy Outcome Variable and Analysis 
The primary efficacy outcome variable is the absolute change in %FVC from Baseline to 
Week 52. Baseline FVC will be the average of the highest FVC measurement recorded at 
the Screening and Day 1 visits. The FVC at Week 52 will be the average of the highest 
FVC measurement recorded on two separate days at Week 52. Data will be analyzed 
using a rank ANCOVA model with the average standardized rank change in %FVC at 
Week 52 as the outcome variable and standardized rank Baseline %FVC as a covariate. 
The treatment effect will be tested using the Mantel-Haenszel mean score chi-square test 
as described by Stokes, Davis, and Koch (Stokes et al. 2000). The primary efficacy 
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analysis will be tested at an alpha level of 0.0498; adjusting for the two anticipated 
interim mortality analyses. 
Missing data due to reasons other than death will be replaced with imputed values based 
on the average measurements for “similar” patients at that time point. Similar patients are 
those whose data have the smallest sum of squared deviations (SSD) from that patient for 
all visits prior to the one with the missing data. Missing data due to lung transplant will 
be imputed using the SSD method even if the patient dies after lung transplant. 
Patients with missing assessments due to death will be ranked worse than those who 
remain alive. Patients who die will be ranked according to the time until death, with the 
shortest time until death as the worst rank. 
The magnitude of the treatment effect of pirfenidone will be presented as the distribution 
(number and percentage) of patients across two categories of change from Baseline: 
• Decline of ≥10% or death before Week 52 
• Improvement of ≥0% 
Missing data due to reasons other than death will be imputed using the SSD method. 
Missing data due to lung transplant will be imputed using the SSD method even if the 
patient dies after lung transplant. 
Supportive analyses of the primary efficacy outcome will include the following: 
• Landmark analyses of change from Baseline in %FVC to Weeks 13, 26, 
and 39 
• Change from Baseline to Week 52 in FVC volume (in mL) 
• Change from Baseline in %FVC across all study time points using a repeated 
measures mixed linear model 
5.4.2.2 Key Secondary Efficacy Outcome Variables and Analyses 
Two key secondary endpoints are change in 6MWT distance from Baseline to Week 52 
and progression-free survival. Multiplicity will be controlled as follows:  If the primary 
endpoint is significant at p = 0.0498, then the two key secondary endpoints will be 
analyzed using Hochberg’s procedure for two tests of significance (Hochberg 1988). 
5.4.2.2.1 Distance Walked During 6-Minute Walk Test 
Change in 6MWT distance from Baseline to Week 52 is a key secondary endpoint. 
Baseline 6MWT distance will be the average of the measurements recorded at the 
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Screening and Day 1 visits. The 6MWT distance at Week 52 will be defined as the 
average of the 6MWT distance recorded on two separate days at Week 52. Data will be 
analyzed using a rank ANCOVA model similar to that outlined in Section 5.4.2.1. 
The magnitude of the treatment effect of pirfenidone will be presented as the distribution 
(number and percentage) of patients across two categories of change from Baseline: 
• Decline of ≥50 m or death before Week 52 
• Improvement of ≥0 m 
5.4.2.2.2 Progression-free Survival 
Progression-free survival is a key secondary endpoint and is defined as the time to the 
first occurrence of any of the following: 
• Death 
• Confirmed ≥10% absolute decline from Baseline in %FVC  
• Confirmed ≥50-meter decline from Baseline in 6MWT distance  
Progression-free survival will be compared between the pirfenidone 2403 mg/d and 
placebo groups using the log-rank test. A proportional hazards model will be used to 
estimate the hazard ratio. 
5.4.2.3 Additional Secondary Efficacy Outcome Variables and Analyses 
Dyspnea and mortality are additional secondary endpoints. 
5.4.2.3.1 Dyspnea (UCSD SOBQ Score) 
Change in dyspnea, as measured by UCSD SOBQ score, from Baseline to Week 52 is a 
secondary endpoint and will be analyzed using the same methods described in 
Section 5.4.2.1. Baseline UCSD SOBQ score will be the average of the measurements 
recorded at the Screening and Day 1 visits. The UCSD SOBQ score at Week 52 will be 
defined as the average of the UCSD SOBQ score recorded on two separate days at 
Week 52. 
The magnitude of the treatment effect of pirfenidone will be presented as the distribution 
(number and percentage) of patients across two categories of change from Baseline: 
• Increase of ≥25 or death before Week 52 
• Decrease of ≥0 
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5.4.2.3.2 Mortality 
The two mortality endpoints are all-cause mortality and treatment-emergent IPF-related 
mortality. Mortality data from this study will be analyzed alone, and also will be pooled 
with the data from Studies PIPF-004 and PIPF-006. Supportive endpoints are IPF-related 
mortality and treatment-emergent all-cause mortality. Treatment-emergent mortality is 
defined as deaths that occur between randomization and 28 days (inclusive) after the last 
dose of blinded study treatment. Relationship of cause of death to IPF will be assessed by 
the MAC. 
Mortality will be compared between the pirfenidone 2403 mg/d and placebo groups using 
the log-rank test. A proportional hazards model will be used to estimate the hazard ratio. 
5.4.3 Safety Analyses 
Safety endpoints are: 
• Treatment-emergent AEs 
• Treatment-emergent SAEs 
• Treatment-emergent treatment-related AEs 
• Treatment-emergent treatment-related SAEs 
• AEs leading to early discontinuation of study treatment 
• Treatment-emergent deaths 
• Cause of death 
• Treatment-emergent changes in clinical laboratory findings and ECGs 
• Vital signs 
AEs will be mapped to system organ classes and preferred terms in MedDRA. Treatment-
emergent events are defined as those that start or worsen after the start of study treatment 
and up to 28 days after the last dose of study treatment. AEs will be summarized by 
treatment group, system organ class, and preferred term, and also by event severity and 
by the event’s relationship to study treatment. At each level of summation, patients will 
be counted only once, under the greatest severity and strongest study-drug relationship 
(as reported by the investigator).  
Clinical laboratory data will be summarized for each treatment group at each 
measurement time point and for each patient’s final post-Baseline measurement in the 
following ways: (1) with descriptive statistics (mean, standard deviation, median, and 
range) for each measurement time point; (2) with descriptive statistics for the change 
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from Baseline in the measurements at each post-Baseline time point; and (3) with shift 
tables summarizing the frequencies of patients below, within, and above the normal 
ranges at each time point as compared with Baseline. All clinical laboratory values 
collected during the study will be listed, with values outside the normal ranges flagged 
for clinical evaluation. Grade 3 and 4 laboratory results will be listed and summarized. 
Vital signs will be summarized by treatment group and listed for each patient.  
Concomitant medications will be summarized by treatment group based on mapping to 
drug classes and generic terms in the WHO Drug Dictionary. 
5.5 Trial Monitoring and Interim Analysis 
Throughout the study, an external Data Monitoring Committee (DMC) will review 
individual SAE reports and laboratory toxicities. In addition, the DMC will review all 
safety data after 50% of enrollment is completed and approximately every 6 to 9 months 
thereafter as specified in the DMC charter. The DMC will review unblinded data. 
The DMC may recommend stopping the study for safety concerns that are set forth in the 
DMC Charter. The DMC also may recommend stopping the studies based on favorable 
efficacy results if an analysis of survival time is statistically significant using nominal 
alpha for all-cause mortality of 0.0001 (two-sided). Formal survival analyses will be 
performed at regularly scheduled DMC meetings after all patients have been enrolled in 
the study. Based on expected enrollment rates, only two formal survival analyses are 
anticipated. 
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6 ADVERSE EVENTS 
6.1 Investigator’s Responsibilities 
Investigators are responsible for monitoring the safety of patients who have entered this 
study and for providing appropriate medical care. In addition, the investigators are 
responsible for alerting InterMune or its designee to any event that seems unusual, even if 
the event may be considered an unanticipated benefit to the patient. An SAE should be 
reported to InterMune or its designee within 24 hours after becoming aware of its 
occurrence. Investigators must report all SAEs to their governing IRB/IEC as required by 
local regulations and guidelines. 
By exercising appropriate health-care options, the investigator remains responsible for 
managing AEs that are serious or that cause the patients to withdraw before completing 
the study. Frequency of follow-up beyond that mandated in the protocol is left to the 
discretion of the investigator. Duration of follow-up and requirements for immediate SAE 
reporting (within 24 hours of the event) are described below. 
6.2 Adverse Events (AEs) 
6.2.1 Definition of AE 
An AE is any unfavorable, harmful, or pathologic change in a research subject 
administered a pharmaceutical study treatment as indicated by physical signs, symptoms, 
and/or clinically significant laboratory abnormalities that occur in a study patient during 
treatment or post-treatment periods regardless of suspected cause. This definition 
includes the following:  
• Any pre-existing condition that increases in severity or changes in nature 
during or as a consequence of the study treatment administration 
• Complications resulting from protocol-mandated procedures 
• AEs occurring as a result of product withdrawal, abuse, or overdose; and a 
change in a laboratory variable if considered by the investigator to be 
clinically significant or if it caused (or should have caused) the investigator to 
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reduce or discontinue the use of the product or initiate a non-protocol therapy 
or procedure 
It does not include the following: 
• Elective surgery or procedures for pre-existing conditions that are stable and 
have not worsened 
• Medical conditions or laboratory test abnormality before the consent form was 
signed and not related to any protocol-mandated procedure 
 
6.2.2 Adverse Event Collection Period 
6.2.2.1 Start of AE Collection 
If a patient experiences an AE after the informed consent document is signed but 
before the first dose of study treatment is administered, the event will be considered 
medical history. If the patient experiences an SAE after signing consent and before the 
first dose of study treatment is administered, it should be reported as an SAE only if 
the investigator believes that the event may have been caused by a protocol-required 
procedure, including Screening procedures. Note that the InterMune standards for 
reporting AEs are to be followed, regardless of other applicable regulatory 
requirements that may be less stringent. 
6.2.2.2 Ongoing AE Collection During the Study 
The investigator will instruct the patients before the first dose of study treatment to report 
any changes or new symptoms they notice during the study. AEs should be elicited with 
minimal connotations. For example:  “Have you had any health problems since your last 
visit?” 
Before administration of the first dose of study treatment, site personnel will note the 
occurrence and severity of each medical condition for the patient. During the study, site 
personnel will note any change in the severity of Baseline medical condition(s) and the 
occurrence and nature of any AEs. Whenever possible, a diagnosis should be given for 
AE signs and symptoms of a common pathology. When recording AEs/SAEs, describe 
the event using commonly accepted medical terminology, if possible. 
The study staff should review the patient diary with the patient during visits to determine 
if there are any new AEs or changes to ongoing AEs. The diary is considered to be a tool 
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and the information contained in the diaries requires a thorough medical interpretation. 
The details of each event should be discussed with the patient. If the event is serious, it 
must be reported to InterMune or its designee within 24 hours of learning of the event.  
6.2.2.3 End of AE Collection 
AEs will be collected and reported until 28 days after last dose of study treatment. For 
patients who enter the rollover study, collection of AE data will cease when they enter the 
rollover study or no later than 28 days after last dose of study treatment. 
6.3 Serious Adverse Events (SAEs) 
6.3.1 Definition of Serious Adverse Event (SAE) 
An AE is considered a serious adverse event if it:  
• Results in death 
• Is life-threatening 
Note:  The term “life-threatening” in the definition of serious refers to an 
event in which the subject was at immediate risk of death at the time of the 
event; it does not refer to an event that hypothetically might have caused death 
had the event been more severe. 
• Requires inpatient hospitalization (at least 24 hours or overnight) or prolongs 
existing hospitalization 
Exceptions that will not be reported as SAEs and will not be recorded as AEs 
include: 
– Elective surgical procedures requiring hospitalizations that are scheduled 
for stable conditions  
– Hospitalizations not associated with a precipitating event or not indicated 
for a medical reason (Examples: study treatment administration, “social” 
reasons) 
• Results in a persistent or significant disability or incapacity 
That is, the event severely or permanently disrupts the subject’s ability to 
perform normal life functions or daily activities 
• Results in a congenital anomaly or birth defect 
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• Is an important medical event 
Important medical events that may not result in death, be immediately life-
threatening, or require hospitalization may be considered an SAE when, based 
on appropriate medical judgment, they may jeopardize the patient and may 
require intervention to prevent one of the other outcomes listed above. 
Examples of such events are intensive treatment in an emergency room or at 
home for allergic bronchospasm, blood dyscrasias, or convulsions that do not 
result in hospitalization; or development of drug dependency or drug abuse. 
 
6.3.2 Serious Adverse Event Reporting Requirements  
Information on SAEs must be collected and reported starting from the time of informed 
consent until the end of the AE collection period (see Section 6.2.2). 
Regardless of whether the SAE is deemed related to use of the study treatment, the data 
for the SAE must be reported with the appropriate information to InterMune or its 
designee within 24 hours of learning of the event. The InterMune medical monitor or 
designee may be contacted at any time for immediate discussion regarding such an event.  
Investigators must report all SAEs to their governing IRB/IEC, as required by local 
regulations and guidelines. 
Deaths in patients who withdraw from study procedures early and continue with Vital 
Status Assessments will not be considered SAEs if the death occurs more than 28 days 
after last dose of study treatment. 
6.3.3 Follow-Up of SAEs 
New follow-up data must be reported within 24 hours of receipt. All SAEs will be 
followed as clinically indicated until resolution or, if non-resolving, until considered 
stable or until the end of the AE collection period (see Section 6.2.2), whichever comes 
first.   
PIPF-016: protocol-or-amendment.pdf  --  Page 67 of 97
InterMune, Inc.  Protocol PIPF-016 
Phase 3 Study of Pirfenidone for IPF 16 March 2011
 
CONFIDENTIAL AND PROPRIETARY Page 68 
6.4 AE and SAE Severity Grades and Relationship to Study Treatment 
The seriousness of an AE should not be confused with its severity. The severity of AEs is 
to be graded according to the Modified Common Terminology Criteria for Adverse 
Events, which are included in Appendix D. For events not listed in Appendix D, the 
following guidelines should be used to evaluate the grade of severity for the AE:  
Grade 1–Mild  Transient or mild discomfort; no limitation in 
activity; no medical intervention/ therapy required 
Grade 2–Moderate Mild to moderate limitation in activity; some 
assistance may be needed; no or minimal medical 
intervention/ therapy required 
Grade 3–Severe  Marked limitation in activity; some assistance 
usually required; medical intervention/ therapy 
required, hospitalization possible 
Grade 4–Life 
Threatening  
Extreme limitation in activity; significant assistance 
required; significant medical intervention/therapy 
required, hospitalization or hospice care probable 
 
The relationship of study treatment to the AE will be determined by the investigator 
based on the following definitions: 
Not Related: Another cause of the event is most plausible; and/or 
clinically plausible temporal sequence is 
inconsistent with the onset of the event and the 
study treatment administration; and/or a causal 
relationship is considered biologically implausible. 
Possibly Related: An event that follows a reasonable temporal 
sequence from administration of the study 
treatment, or follows a known or expected response 
pattern to the suspected drug, but that could readily 
have been produced by a number of other factors. 
Probably Related: An event that follows a reasonable temporal 
sequence from administration of the study 
treatment, and there is a biologically plausible 
mechanism for study treatment causing or 
contributing to the AE and the event could not be 
reasonably explained by the known characteristics 
of the patient’s clinical state. In addition, the 
relationship may be confirmed by improvement of 
the event on stopping study treatment and 
reappearance of the event on repeated exposure to 
study treatment. 
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6.4.1 Pregnancy 
Pregnancies should be reported from the time the patient signs the informed consent form 
until the final study visit. Study treatment must be immediately discontinued if a patient 
becomes pregnant. Although pregnancy is not considered an SAE, all pregnancies should 
be reported as SAEs to InterMune. Pregnancies must be followed until termination of 
pregnancy or for a minimum of 6 months after the birth of the child. 
6.4.2 Overdose  
Data from InterMune study PIPF-008 suggest that a dose of pirfenidone 4005 mg/d 
(administered as 5 capsules TID) is tolerated in the short term (2 days) without clinically 
concerning safety signals in a healthy, older population. Based on these data, for the 
purposes of this study, an overdose is >15 capsules/day or >5 capsules per dose.   
If an overdose results in an SAE, it must be reported to InterMune as an SAE. The 
narrative for the SAE should explain that the event was associated with an overdose. All 
available clinical information relevant to overdose, including dates, data, signs and/or 
symptoms, laboratory findings, and therapeutic measures and/or treatments and 
antidotes (if available), should be summarized and discussed.  
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7 DATA QUALITY ASSURANCE 
The study will be monitored by clinical study monitors to assess adherence to good 
clinical practice (GCP) and to this clinical study protocol according to a Clinical 
Monitoring Plan. 
The study may be audited by InterMune’s clinical quality assurance group to assess 
compliance with GCP (including but not limited to US Food and Drug Administration 
(FDA) regulations, International Conference on Harmonisation (ICH) GCP guidelines, 
and other applicable regulations). Regulatory authorities, the IRB/IEC, and/or 
InterMune’s clinical quality assurance group may request access to all source documents, 
eCRFs, and other study documentation for on-site audits or inspections. Direct access to 
these documents must be guaranteed by the Investigator, who must provide support at all 
times for these activities. 
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8 ETHICAL AND LEGAL ASPECTS 
8.1 Good Clinical Practice 
This study will be conducted in compliance with GCP as described in FDA regulations 
(21 CFR parts 50, 54, 56, and 312) and the ICH document “Guideline for Good Clinical 
Practice, E6 (R1),” dated 10 June 1996. These practices are consistent with the principles 
stated in the Declaration of Helsinki (version as currently endorsed by the European 
Medicines Evaluation Agency and the US FDA). The study will also be carried out in 
keeping with local legal and regulatory requirements.  
8.2 Independent Ethics Committee/Institutional Review Board 
The protocol and informed consent forms that will be used must be approved by the 
investigator’s IRB/IEC before the study is initiated; documentation of this approval 
(i.e., a copy of the document showing IEC/IRB approval including the chairperson’s 
signature and the date of approval) must be provided to InterMune or its designee and 
made available during an inspection by the US FDA or other regulatory agency 
inspectors.  
Other investigator responsibilities regarding IEC/IRB requirements include 
the following: 
• Submit to the IEC/IRB and to InterMune or its designee for review any 
advertisements that will be used to recruit patients 
• During the conduct of the study, submit progress reports to the IEC/IRB, if 
required, and request re-review of the study at least once a year 
• Report, in writing, to the IEC/IRB any SAEs that occur during the study or 
SAEs reported in other studies using study treatment, per local IEC/IRB 
regulations 
• Inform the IEC/IRB of any changes in the protocol and obtain documented 
IEC/IRB approval of the changes 
• Provide the IEC/IRB with any other information it requests before or during 
the conduct of the study 
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• Maintain a file of study-related information, including all correspondence with 
the IEC/IRB 
• Provide the IEC/IRB with a final report on the study within a time period 
consistent with local requirements 
8.3 Informed Consent 
The investigator or designee is responsible for the content of the informed consent form, 
but the content must be approved by the IEC/IRB and InterMune or designee. The 
content of the informed consent must comply with FDA regulations (21 CFR 50.25) and 
the ICH document “Guideline for Good Clinical Practice, E6 (R1),” dated 10 June 1996. 
It should also include any additional information required by local laws relating to 
institutional review.  
The investigator is responsible for obtaining informed consent from each patient 
participating in the study. If there are any amendments to the informed consent, patients 
should be consented properly in a timely fashion. All pertinent aspects of the study must 
be explained to the patient before he or she signs the informed consent form. Informed 
consent must be obtained from the patient before any Screening activity or treatment is 
undertaken that is not part of routine care. This includes, but is not limited to, the 
performance of diagnostic or therapeutic procedures and the administration of the first 
dose of the study treatment. Before a patient’s participation in the study, the written 
informed consent form must be signed and personally dated by the patient or by the 
patient’s legally acceptable representative, and by the person who conducted the 
informed consent discussion. The investigator is responsible for keeping this document in 
a secure place. This document should not be displayed or made accessible to any third 
party except InterMune or designee or regulatory agency representatives. 
If a patient permanently revokes informed consent and declines further observation and 
Vital Status Assessments, then recording of study data will stop.  
8.4 Delegation of Principal Investigator Responsibilities 
The investigator should ensure that all persons involved in the conduct of the study  
are informed about the protocol, protocol amendments, study procedures, and any  
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study-related duties. The investigator is responsible for assuring that study site staff are 
properly trained and credentialed to perform any delegated tasks. 
8.5 Coordinating Investigator 
The coordinating investigator will be one of the principal investigators on the study. The 
coordinating investigator will be responsible for signing the final clinical study report and 
assuring that the study has been executed according to the protocol. 
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9 OTHER STUDY SUPPLIES 
9.1 Investigator Brochure 
The investigator will review the current version of the Investigator Brochure (IB). It is 
obligatory that the investigator be familiar with all sections of the brochure before 
initiation of the study. The brochure will be submitted to the IEC/IRB. 
9.2 Case Report Forms 
Each center will be instructed by InterMune or its designee regarding how to record and 
complete electronic case report forms (eCRFs). Data should be recorded via eCRF as 
soon as possible after collection.  
Spirometry, DLCO, ECG, and central laboratory data should be reviewed, initialed, and 
dated by the principal investigator or designee within 24 hours of receipt. Completed 
eCRFs are to be reviewed by the investigator to ensure accuracy, completeness, and 
legibility within 2 weeks of last patient contact unless the forms are incomplete because 
of laboratory data or medical event follow-up that is not yet available.  
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10 STUDY DOCUMENTATION 
10.1 Study Records 
The study-related records that must be maintained include the following: 
1. Copies of the protocol and all amendments 
2. Signed Principal Investigator Page for the protocol and all amendments 
3. Signed Statement of Principal Investigator Form (Form FDA 1572), which will 
be updated with changes in site staff 
4. Approval letter(s) from and all other correspondence to and from the IEC/IRB 
5. Curricula vitae and medical licenses for the Principal Investigator and any 
subinvestigators 
6. Documentation of study treatment shipments from InterMune or designee 
7. Completed and signed dispensing records for study treatment 
8. Documentation of study treatment returned to InterMune or designee  
9. Signed list of all study personnel including delegation of authority for all study 
personnel 
10. Copies of all versions of the Investigator Brochure 
11. The original signed informed consent forms for each patient screened. Originals 
of all signed consent forms must be retained for all consent amendments for 
each randomized patient 
12. Copies of eCRFs or electronic data capture data sets for each randomized 
patient   
13. Copies of results of all laboratory tests and other original data from which eCRF 
information was obtained as well as laboratory normal ranges and certifications, 
when indicated 
14. Master Patient Log 
15. Copies of all correspondence relating to this investigation 
16. Copies of financial disclosure documents at the start of the study, during or at 
the end of the study, and up to 1 year after the close-out visit if any of the 
financial disclosure documents change 
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10.2 Retention of Data 
The Principal Investigator must ensure that study data are accessible to InterMune or its 
representatives and to FDA or other regulatory agency inspectors. All study-related 
records (e.g., research charts, eCRFs, and other study records) must be retained until 
disposal is authorized by InterMune, which will be no sooner than 2 years after approval 
of the study agent for marketing in an ICH region (United States, Europe) and until there 
are no pending or contemplated marketing applications in an ICH region or 2 years have 
elapsed since the formal discontinuation of clinical development of the investigational 
product. These documents may need to be retained for longer periods in some countries 
due to local regulatory requirements. 
10.3 Publication/Presentation Policy 
InterMune personnel will share authorship with investigators and their designees in any 
publications resulting from this study. Investigational plans, protocols, and data related to 
this study will be treated as confidential information. Before submission, InterMune must 
review publication or presentation of data or information derived from this study. 
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Appendix A Schedule of Study Assessments & Procedures 
 
Screening and Day 1 
Study Assessments 
Washout 
(Day -85 to 
Day -57) 
Screening 
(Day -56 to 
Day -2) Day 1 
Informed Consenta X X  
Complete Medical History (review of systems, 
concomitant medications) b 
X X  
Directed History (including review of AEs/SAEs, 
concomitant medications, oxygen use, and 
hospitalizations) 
  X 
Physical Examination, Vital Signs  X X 
Height  X  
Weight  X X 
ECGc,d  X  
Review Lung Biopsy/Transbronchial Biopsy/BAL X Xe  
HRCTf  X   
Spirometry (FVC, FEV1) before and after 
bronchodilator use 
 X X 
DLCO or TLCO
g  X  
6MWT and Borg Scale  X X 
UCSD SOBQ  X X 
Laboratory:  Hematology, Serum Chemistries, 
Pregnancy Test 
 X X 
Serologic Tests   X  
Biomarkers    X 
Genetic Polymorphismsh   X 
Confirm Eligibility/Randomizei   X 
Patient Instruction on Dose Titration /Dispense 
13-Week Supply of Study Treatment  
  X 
Dispense Patient Diary   X 
a Written informed consent must be obtained prior to any study-associated procedure, including 
discontinuing any prohibited medications. 
b If Complete Medical History was performed during the Washout Period, then during Screening, update 
the list of concomitant medications and medical history to include any events that occurred since the 
patient signed the informed consent form for the study. 
c Before bronchodilator administration or on a separate day.  
d Perform unique triplicate ECGs 
e If assessed during the Washout Period and acceptable, do not repeat during Screening. 
f HRCT scan performed within 1 month of the start of Screening may be used if it meets image acquisition 
guidelines. 
g Before or 30 min after bronchodilator administration  
h Performed at select sites only. 
i Submit eligibility documents to InterMune at least 2 working days before randomization. 
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Appendix A Schedule of Study Assessments & Procedures (continued) 
Week 1 through Follow-up Visit 
Study Assessments Week 1 Week 2 
Weeks 4 
and 8 Week 13 
Weeks 16 
and 20 Week 26 Week 39 
Weeks 52A 
and 52B Follow-up Visit 
Visit Windows ± 2 d ± 1 wk ± 2 wks ± 1 wk ± 2 wks ± 2 wks ± 2 wks 28–35 d after last dose 
Phone Call Assessment X         
Directed History (including review of AEs/SAEs, 
concomitant medications, oxygen use, 
hospitalizations, dosing, and diary) 
 X X X 
 
X X X X 
Physical Examination, Vital Signs, Weight  X X X  X X X X 
ECGa   X X  X X X  
Spirometry (FVC, FEV1) before and after 
bronchodilators 
   X  X X 52A and 
52Bb 
 
6MWT and Borg Scale    X  X X 52A and 
52Bb 
 
UCSD SOBQ    X  X X 52A and 
52Bb 
 
Laboratory:  Hematology, Serum Chemistries,  
Pregnancy Test 
 X X X Xc X X X X 
Biomarkers     X  X X X X 
Dispense/Collect Unused Study Treatment, Review 
Compliance 
   X  X X Xd   
Review/Dispense Patient Diary X X X X  X X X Xe 
Vital Status Assessment X X X X X X X X X 
a Before bronchodilator administration or on a separate day. 
b Obtain at both Week 52A and Week 52B Visits. 
c LFTs only (AST, ALT, bilirubin, and alkaline phosphatase). 
d Study treatment should be collected after the second assessment day is completed. 
e Collect only. 
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Appendix B High-Resolution Computed Tomography Criteria for UIP 
Pattern 
UIP Pattern 
(All 4 Features) 
Possible UIP Pattern 
(All 3 Features) 
Inconsistent with UIP Pattern 
(Any of the 7 Features ) 
• Subpleural, basal 
predominance 
• Reticular abnormality 
• Honeycombing with or 
without traction 
bronchiectasis 
• Absence of features 
listed as inconsistent 
with UIP pattern (see 
third column) 
• Subpleural, basal 
predominance 
• Reticular abnormality 
• Absence of features 
listed as inconsistent 
with UIP pattern (see 
third column) 
• Upper or mid-lung 
predominance 
• Peribronchovascular 
predominance 
• Extensive ground-glass 
abnormality (extent 
greater than reticular 
abnormality) 
• Profuse micronodules 
(bilateral, predominantly 
upper lobes) 
• Discrete cysts (multiple, 
bilateral, away from areas 
of honeycombing) 
• Diffuse mosaic 
attenuation/air-trapping 
(bilateral, in 3 or more 
lobes) 
• Consolidation in 
bronchopulmonary 
segment(s)/lobe(s) 
 
UIP = usual interstitial pneumonia 
Reference 
American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/ Latin American 
Thoracic Association. 2011. An official ATS/ERS/ JRS/ALAT statement:  idiopathic pulmonary fibrosis:  
evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:1–38 
[In press]. 
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Appendix C Histopathologic Criteria for UIP Pattern 
UIP Pattern 
(All 4 Criteria) 
Probable UIP Pattern Possible UIP Pattern 
(All 3 Criteria) 
Not UIP Pattern 
(Any of the 6 Criteria ) 
• Evidence of 
marked fibrosis/ 
architectural 
distortion, ± 
honeycombing in 
a predominantly 
subpleural/ 
paraseptal 
distribution 
• Presence of 
patchy 
involvement of 
lung parenchyma 
by fibrosis 
• Presence of 
fibroblast foci 
• Absence of 
features against a 
diagnosis of UIP 
suggesting an 
alternate 
diagnosis (see 
fourth column) 
• Evidence of 
marked fibrosis/ 
architectural 
distortion, ± 
honeycombing 
• Absence of either 
patchy 
involvement or 
fibroblastic foci 
• Absence of 
features against a 
diagnosis of UIP 
suggesting an 
alternate 
diagnosis (see 
fourth column) 
 
OR 
 
• Honeycomb 
changes onlyc  
 
• Patchy or diffuse 
involvement of 
lung parenchyma 
by fibrosis, with 
or without 
interstitial 
inflammation 
• Absence of other 
criteria for UIP 
(see UIP Pattern 
column) 
• Absence of 
features against a 
diagnosis of UIP 
suggesting an 
alternate 
diagnosis (see 
fourth column) 
• Hyaline 
membranesa  
• Organizing 
pneumoniaa,b 
• Granulomasb 
• Marked 
interstitial 
inflammatory cell 
infiltrate away 
from 
honeycombing 
• Predominant 
airway centered 
changes 
• Other features 
suggestive of an 
alternate 
diagnosis 
a Can be associated with acute exacerbation of idiopathic pulmonary fibrosis. 
b An isolated or occasional granuloma and/or a mild component of organizing pneumonia pattern may 
rarely be coexisting in lung biopsies with an otherwise UIP pattern.  
c This scenario usually represents end-stage fibrotic lung disease where honeycombed segments have been 
sampled but where a UIP pattern might be present in other areas. Such areas are usually represented by 
overt honeycombing on HRCT and can be avoided by pre-operative targeting of biopsy sites away from 
these areas using HRCT. 
HRCT = high-resolution computed tomography; UIP = usual interstitial pneumonia 
 Reference 
American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/ Latin American 
Thoracic Association. 2011. An official ATS/ERS/ JRS/ALAT statement:  idiopathic pulmonary fibrosis:  
evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:1–38 
[In press]. 
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Appendix D Modified Common Terminology Criteria for Adverse Events 
 
 Grade 
Toxicity 0 1 2 3 4 
LABORATORY FINDINGS 
(WNL = within normal limits; LLN = lower limit of normal; ULN = upper limit of normal) 
Leukocytes (total 
WBC) 
WNL <LLN–3.0 × 109/L 
<LLN–3000/mm3 
≥2.0–<3.0 × 109/L 
≥ 2000–<3000/mm3 
≥1.0–<2.0 × 109/L 
≥1000–<2000/mm3 
<1.0 × 109/L 
<1000/mm3 
Platelets WNL <LLN–75.0 × 109/L 
<LLN–75,000/mm3 
≥50.0–<75.0 × 109/L
≥50,000 
<75,000/mm3 
≥25.0–<50.0 × 109/L 
≥25,000 <50,000/mm3 
<25.0 × 109/L 
<25,000/mm3 
Hemoglobin (Hb) WNL <LLN–10.0 g/dL 8–<10.0 g/dL 6.5–<8.0 g/dL <6.5 g/dL 
Neutrophils/Granulocy
tes 
(ANC/AGC) 
WNL ≥1.5–<2.0 × 109/L 
≥1500-<2000/mm3 
≥1.0–<1.5 × 109/L 
≥1000–<1500/mm3 
≥0.5–<1.0 × 109/L 
≥500–<1000/mm3 
<0.5 × 109/L 
<500/mm3 
Lymphopenia WNL <LLN–1.0 × 109/L 
<LLN–1000/mm3 
≥0.5–<1.0 × 109/L 
≥500–<1000/mm3 
<0.5 × 109/L 
<500–200/mm3 
<0.2 × 109/L  
<200/mm3 
Bilirubin WNL >ULN–1.5 × ULN >1.5–3.0 × ULN  >3.0–10.0 × ULN >10.0 × ULN 
Creatinine WNL >ULN–1.5 × ULN >1.5–3.0 × ULN >3.0–6.0 × ULN >6.0 × ULN 
γ-Glutamyl 
transpeptidase (GGT) 
WNL >ULN–2.5 × ULN >2.5–5.0 × ULN >5.0–20.0 × ULN >20.0 × ULN 
Alkaline Phosphatase 
or 5’–nucleotidase 
WNL >ULN–2.5 × ULN >2.5–5.0 × ULN >5.0–20.0 × ULN >20.0 × ULN 
Transaminases 
(AST/SGOT, 
ALT/SGPT) 
WNL >ULN–2.5 × ULN >2.5–5.0 × ULN >5.0–20.0 × ULN >20.0 × ULN 
Hematuria neg micro only gross, no clots gross + clots requires 
transfusion 
Hypoglycemia     WNL <LLN–55 mg/dL 
<LLN–3.0 mmol/L 
40–<55 mg/dL 
2.2–<3.0 mmol/L 
30–<40 mg/dL 
1.7–<2.2 mmol/L 
<30 mg/dL 
<1.7 mmol/L 
Hyperglycemia    WNL >ULN–160 mg/dL 
>ULN–8.9 mmol/L 
>160–250 mg/dL 
>8.9–13.9 mmol/L 
>250–500 mg/dL 
>13.9–27.8  mmol/L 
>500 mg/dL 
>27.8 mmol/L or 
acidosis 
Hypercalcemia    WNL >ULN–11.5 mg/dL 
>ULN–2.9 mmol/L  
>11.5–12.5 mg/dL 
>2.9–3.1 mmol/L 
>12.5–13.5 mg/dL 
>3.1–3.4 mmol/L 
>13.5 mg/dL 
>3.4 mmol/L 
Hypocalcemia    WNL <LLN–8.0 mg/dL 
<LLN–2.0 mmol/L 
7.0–<8.0 mg/dL 
1.75–<2.0 mmol/L 
6.0–<7.0 mg/dL 
1.5–<1.75 mmol/L 
<6.0 mg/dL 
<1.5 mmol/L 
Hypomagnesemia  WNL <LLN–1.2 mg/dL 
>LLN–0.5 mmol/L 
0.9–<1.2 mg/dL 
0.4–<0.5 mmol/L 
0.7–<0.9 mg/dL 
0.3–<0.4 mmol/L 
<0.7 mg/dL 
<0.3 mmol/L 
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Appendix D Modified Common Terminology Criteria for Adverse Events 
(continued) 
 Grade 
Toxicity 0 1 2 3 4 
LABORATORY FINDINGS (continued) 
Hypertriglyceridemia WNL >ULN–2.5 × ULN >2.5–5.0 × ULN >5.0–10 × ULN >10 × ULN 
Hypercholesterolemia WNL >ULN–300 mg/dL 
>ULN–7.75 mmol/L  
>300–400 mg/dl 
>7.75–10.34 mmol/L
>400-500 mg/dl 
>10.34-12.92 mmol/L 
>500 mg/dl 
>12.92 mmol/L 
Fibrinogen WNL ≥0.75–<1.0 × LLN ≥0.5–<0.75 × LLN ≥0.25–<0.5 × LLN <0.25 × LLN 
Prothrombin time (PT) WNL >ULN–≤1.5 × ULN >1.5–≤2 × ULN >2 × ULN –– 
Partial thromboplastin 
time (PTT) 
WNL >ULN–≤1.5 × ULN >1.5–≤2 × ULN >2 × ULN 
–– 
Amylase  WNL >ULN–.5 × ULN >1.5–2.0 × ULN >2.0–5.0 × ULN >5.0 × ULN 
ALLERGY 
Allergic reaction/ 
hypersensitivity 
(including drug fever) 
none transient rash, drug 
fever <38°C, 
(<100.4°F) 
urticaria drug fever 
≥38°C, (≥100.4°F), 
and/or asymptomatic 
bronchospasm 
symptomatic 
bronchospasm, 
requiring parenteral 
medication(s), with 
or without urticaria; 
allergy-related 
edema/angioedema 
anaphylaxis 
AUDITORY/HEARING 
Inner ear/hearing normal hearing loss on 
audiometry only 
tinnitus or hearing 
loss, not requiring 
hearing aid or 
treatment 
tinnitus or hearing 
loss, correctable with 
hearing aid or 
treatment 
severe unilateral 
or bilateral 
hearing loss 
(deafness), not 
correctable 
CARDIOVASCULAR (ARRHYTHMIA) 
Arrhythmia/ 
dysrhythmia 
none asymptomatic, not 
requiring treatment 
symptomatic, but not 
requiring treatment 
symptomatic and 
requiring treatment 
life-threatening 
(e.g., arrhythmia 
associated with 
CHF, 
hypotension, 
syncope, shock) 
CARDIOVASCULAR (GENERAL) 
Cardiac–ischemia 
/infarction 
none nonspecific T-wave 
flattening or 
changes 
asymptomatic, ST 
and T wave changes 
suggesting ischemia 
angina without 
evidence of 
infarction 
acute myocardial 
infarction 
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Appendix D Modified Common Terminology Criteria for Adverse Events 
(continued) 
 Grade 
Toxicity 0 1 2 3 4 
CARDIOVASCULAR (GENERAL) (continued) 
Cardiac left ventricular 
function 
normal asymptomatic, 
decline of resting 
ejection fraction of 
≥10% but <20% of 
Baseline value; 
shortening fraction 
>24% but <30% 
asymptomatic, but 
resting ejection 
fraction below LLN 
for laboratory of 
decline of resting 
ejection fraction 
>20% of Baseline 
value; <24% 
shortening fraction 
CHF responsive to 
treatment 
severe or 
refractory CHF 
or requiring 
intubation 
Hypertension 
*Note: For pediatric    
patients, use age and 
sex appropriate normal 
values >95th 
percentile ULN. 
none  asymptomatic, 
transient increase by 
>20 mm Hg 
(diastolic) or to 
>150/100* if 
previously WNL; not 
requiring treatment 
recurrent or persistent 
or symptomatic 
increase by >20 mmHg 
(diastolic) or to 
>150/100* if 
previously WNL; not 
requiring treatment 
requiring therapy or 
more intensive 
therapy than 
previously 
hypertensive 
crisis 
Hypotension none  changes, but not 
requiring therapy 
(including transient 
orthostatic 
hypotension) 
requiring brief fluid 
replacement or other 
therapy but not 
hospitalization; no 
physiologic 
consequences 
requiring therapy and 
sustained medical 
attention, but 
resolves without 
persisting 
physiologic 
consequences 
shock 
(associated with 
acidemia and 
impairing vital 
organ function 
due to tissue 
hypoperfusion) 
Pericardial 
effusion/pericarditis 
none asymptomatic 
effusion, not 
requiring treatment 
pericarditis (rub, 
ECG changes, and/or 
chest pain) 
with physiologic 
consequences 
tamponade 
(drainage or 
pericardial 
window 
required) 
CONSTITUTIONAL SYMPTOMS 
Fatigue 
(lethargy, malaise, 
asthenia) 
none increased fatigue 
over Baseline, but 
not altering normal 
activities 
moderate 
(e.g., decrease in 
performance status 
by 1 ECOG level or 
20% Karnofsky or 
Lansky) or causing 
difficulty performing 
some activities 
severe (e.g., decrease 
in performance status 
by >2 ECOG levels 
or 40% Karnofsky or 
Lansky) or loss of 
ability to perform 
some activities 
bedridden or 
disabling 
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Appendix D Modified Common Terminology Criteria for Adverse Events 
(continued) 
 Grade 
Toxicity 0 1 2 3 4 
CONSTITUTIONAL SYMPTOMS (continued) 
Fatigue 
(lethargy, malaise, 
asthenia) 
none increased fatigue 
over Baseline, but 
not altering normal 
activities 
moderate 
(e.g., decrease in 
performance status 
by 1 ECOG level or 
20% Karnofsky or 
Lansky) or causing 
difficulty performing 
some activities 
severe (e.g., decrease 
in performance status 
by >2 ECOG levels 
or 40% Karnofsky or 
Lansky) or loss of 
ability to perform 
some activities 
bedridden or 
disabling 
Fever (in the absence 
of neutropenia, where 
neutropenia is defined 
as AGC <1.0 × 109/L 
Also consider Allergic 
reaction/ 
hypersensitivity 
Note: the temperature 
measurements listed 
above are oral or 
tympanic. 
none 38.0–39.0°C 
(100.4–102.2°F) 
39.1–40.0°C (102.3–
104.0°F) 
>40.0°C (>104.0°F) 
for <24 hrs 
>40.0°C 
(>104.0°F) for 
≥24 hr 
DERMATOLOGY/SKIN 
Alopecia normal mild hair loss pronounced hair loss –– –– 
Phototoxicity/Photose
nsitivity 
Normal painless erythema painful erythema erythema with 
desquamation 
life threatening, 
disabling 
Injection site reaction none pain or itching or 
erythema 
pain or swelling, 
with inflammation or 
phlebitis 
ulceration or necrosis 
that is severe or 
prolonged, or 
requiring surgery  
–– 
Rash/desquamation none or 
no 
change 
macular or popular 
eruption or 
erythema without 
associated 
symptoms 
macular or papular 
eruption or erythema 
with pruritus or other 
associated symptoms 
covering <50% of 
body surface or 
localized 
desquamation or 
other lesions 
covering <50% of 
body surface area 
symptomatic 
generalized 
erythroderma or 
macular, popular or 
vesicular eruption or 
desquamation 
covering >50% of 
body surface area 
generalized 
exfoliative 
dermatitis or 
ulcerating 
dermatitis 
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Appendix D Modified Common Terminology Criteria for Adverse Events 
(continued) 
 Grade 
Toxicity 0 1 2 3 4 
DERMATOLOGY/SKIN (continued) 
Urticaria 
(hives, welts, wheals) 
none requiring no 
medication 
requiring PO or 
topical treatment or 
IV medication or 
corticosteroids for 
<24 hr 
requiring IV 
medication or 
corticosteroids for 
≥24 hr 
–– 
Wound-infections none cellulitis superficial infection infection requiring 
IV antibiotics 
necrotizing 
fasciitis 
GASTROINTESTINAL 
Anorexia none loss of appetite  oral intake 
significantly 
decreased 
requiring IV fluids requiring feeding 
tube or 
parenteral 
nutrition 
Constipation none requiring stool 
softener or dietary 
modification 
requiring laxatives obstipation requiring 
manual evacuation or 
enema 
obstruction or 
toxic megacolon 
Dehydration none dry mucous 
membranes and/or 
diminished skin 
turgor 
requiring IV fluid 
replacement 
brief) 
requiring IV fluid 
replacement 
(sustained) 
physiologic 
consequences 
requiring 
intensive care; 
hemodynamic 
collapse  
Diarrhea 
(patients without 
colostomy) 
none increase of 
<4 stools/day over 
pretreatment 
increase of 4–6 
stools/day or 
nocturnal stools 
increase of ≥7 
stools/day or 
incontinence; or need 
for parenteral support 
for dehydration 
physiologic 
consequences 
requiring 
intensive care; or 
hemodynamic 
collapse 
Nausea none able to eat oral intake 
significantly 
decreased 
no significant intake, 
requiring IV fluids –– 
Stomatitis/pharyngitis 
(oral/pharyngeal 
mucositis) 
none painless ulcers, 
erythema or mild 
soreness in the 
absence of lesions 
painful erythema, 
edema or ulcers but 
can eat or swallow 
painful erythema, 
edema or ulcers 
requiring IV 
hydration 
severe ulceration 
or requires 
parenteral or 
enteral 
nutritional 
support or 
prophylactic 
intubation 
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Appendix D Modified Common Terminology Criteria for Adverse Events 
(continued) 
 Grade 
Toxicity 0 1 2 3 4 
GASTROINTESTINAL (continued) 
Vomiting none 1 episode in 24 hr 
over pretreatment 
2–5 episodes in 24 hr 
over pretreatment 
≥6 episodes in 24 hr 
over pretreatment; or 
need for IV fluids 
requiring 
parenteral 
nutrition; or 
physiologic 
consequences 
requiring 
intensive care; 
hemodynamic 
collapse 
HEMORRHAGE 
Hemorrhage – Other 
(Specify site, 
_________) 
none mild without 
transfusion 
–– 
requiring transfusion catastrophic 
bleeding, 
requiring major 
non-elective 
intervention 
HEPATIC 
Liver 
dysfunction/failure 
(clinical) 
normal 
–– –– 
asterixis encephalopathy 
or coma 
MUSCULOSKELETAL 
Muscle weakness 
(not due to 
neuropathy) 
normal asymptomatic with 
weakness on 
physical 
examination 
symptomatic and 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
symptomatic and 
interfering with 
activities of daily 
living 
bedridden or 
disabling 
NEUROLOGY 
Ataxia 
(incoordination) 
normal asymptomatic but 
abnormal on 
physical 
examination, and 
not interfering with 
function 
mild symptoms 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
moderate symptoms 
interfering with 
activities of daily 
living 
bedridden or 
disabling 
Confusion Normal confusion or 
disorientation or 
attention deficit of 
brief duration; 
resolves 
spontaneously with 
no sequelae 
confusion or 
disorientation or 
attention deficit 
interfering with 
function, but not with 
activities of daily 
living 
confusion or 
delirium interfering 
with activities of 
daily living 
harmful to others 
or self; requiring 
hospitalization 
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Appendix D Modified Common Terminology Criteria for Adverse Events 
(continued) 
 Grade 
Toxicity 0 1 2 3 4 
NEUROLOGY (continued) 
Depressed level of 
consciousness 
normal somnolence or 
sedation not 
interfering with 
function 
somnolence or 
sedation interfering 
with function, but not 
interfering with 
activities of daily 
living 
obtundation or 
stupor; difficult to 
arouse; interfering 
with activities of 
daily living 
coma 
Dizziness/lightheaded
ness 
none not interfering with 
function 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
interfering with 
activities of daily 
living 
bedridden or 
disabling 
Mood alteration – 
anxiety, agitation –
depression 
normal mild mood 
alteration not 
interfering with 
function 
moderate mood 
alteration interfering 
with function, but not 
interfering with 
activities of daily 
living 
severe mood 
alteration interfering 
with activities of 
daily living 
suicidal ideation 
or danger to self 
Neuropathy – 
cerebellar 
none  slight 
incoordination, 
dysdiadokinesis 
intention tremor, 
dysmetria, slurred 
speech, nystagmus 
locomotorataxia cerebellar 
necrosis 
Neuropathy  – motor normal subjective 
weakness, but no 
objective findings 
mild objective 
weakness interfering 
with function, but not 
interfering with 
activities of daily 
living 
objective weakness 
interfering with 
activities of daily 
living 
paralysis 
Neuropathy–sensory normal loss of deep tendon 
reflexes or 
paresthesia 
(including tingling) 
but not interfering 
with function 
objective sensory 
loss or paresthesia 
(including tingling), 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
sensory loss or 
paresthesia 
interfering with 
activities of daily 
living 
permanent 
sensory loss that 
interferes with 
function 
OCULAR/VISUAL 
Ocular/Visual – Other normal mild moderate severe unilateral or 
bilateral loss of 
vision 
(blindness) 
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Appendix D Modified Common Terminology Criteria for Adverse Events 
(continued) 
 Grade 
Toxicity 0 1 2 3 4 
PAIN 
Arthralgia 
(joint pain) 
none mild pain not 
interfering with 
function 
moderate pain:  pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain:  pain or 
analgesics severely 
interfering with 
activities of daily 
living 
disabling 
Headache none mild pain not 
interfering with 
function 
moderate pain: pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain: pain or 
analgesics severely 
interfering with 
activities of daily 
living 
disabling 
Myalgia 
(muscle pain) 
none mild pain not 
interfering with 
function 
moderate pain:  pain 
or analgesics 
interfering with 
function, but not 
interfering with 
activities of daily 
living 
severe pain:  pain or 
analgesics severely 
interfering with 
activities of daily 
living 
disabling 
RENAL 
Renal failure none 
–– –– 
requiring dialysis, 
but reversible 
requiring dialysis 
and irreversible 
Proteinuria 
 
Note: If there is an 
inconsistency between 
absolute value and dip 
stick reading, use the 
absolute value for 
grading. 
normal 
or <0.15  
g/24 
hours 
1 + or 0.15–1.0 
g/24 hours 
2+ to 3+ or 
1.0–3.5 g/24 hr 
4+ or >3.5 g/24 hr nephrotic 
syndrome 
Reference 
Cancer Therapy Evaluation Program. 2003. Common terminology criteria for adverse 
events, version 3.0 (CTCAE). DCTD, NCI, NIH, DHHS: March 31, 2003 
(http://ctep.cancer.gov). Publication date: December 12, 2003. 
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Appendix E Borg Scale 
Borg Scale 
This instrument is to be self-administered by the patient as part of the 6MWT procedure. 
The patient will be given a paper copy of this instrument with the following instructions 
given in writing at the time the instrument is administered: 
“Please rate the current severity of your breathlessness by circling the most appropriate 
number on the following scale.” 
 
0 Nothing at all 
0.5 Very, very slight (just noticeable) 
1 Very slight 
2 Slight (light) 
3 Moderate 
4 Somewhat severe 
5 Severe (heavy) 
6  
7 Very severe 
8  
9  
10 Very, very severe (almost max) 
Reference 
Borg GA 1982. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 
14(5):377–381.  
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Appendix F UCSD Shortness-of-Breath Questionnaire 
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3 LIST OF ABBREVIATIONS & DEFINITIONS OF TERMS 
Acronym/Abbreviation Definition 
AE adverse event 
ALT alanine aminotransferase 
ANCOVA analysis of covariance 
AST aspartate aminotransferase 
ATC Anatomical Therapeutic Chemical 
CYP1A2 cytochrome P450 1A2 
CRF case report form 
d day 
DMC Data Monitoring Committee 
%FVC percent predicted forced vital capacity 
HLGT high-level grouped terms 
HLT high-level terms 
HR hazard ratio 
ITT intent to treat (population) 
IPF idiopathic pulmonary fibrosis 
IXR interactive web or voice response system 
m meter 
MAC Mortality Assessment Committee 
MedDRA Medical Dictionary for Regulatory Activities 
NEC not elsewhere classified 
mL milliliters 
mg milligram 
mg/d milligrams per day 
PFT pulmonary function testing 
SAE serious adverse event 
6MWT 6-minute walk test 
SMQ Standardised MedDRA Queries 
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Acronym/Abbreviation Definition 
SOC System Organ Class 
SSD sum of squared differences 
UCSD SOBQ University of California at San Diego Shortness-of-Breath 
Questionnaire 
ULN upper limit of normal range 
TID three times per day 
WHODRUG World Health Organization Drug Dictionary 
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4 INTRODUCTION 
This statistical analysis plan describes statistical methods and data presentations to be used for 
the summary and analysis of the data from study: 
PIPF-016, “A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the 
Efficacy and safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.”  
Detailed descriptions of the study design and conduct can be found in the protocol.  
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5 STUDY DESIGN 
PIPF-016 is a Phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study 
of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). Approximately 500 patients 
at approximately 140 centers globally will be randomized with equal probability to receive either 
pirfenidone 2403 mg/d or placebo equivalent in divided doses three times per day (TID) with 
food.  
The primary efficacy endpoint is:  
 Change in percent predicted forced vital capacity (%FVC) from Baseline to Week 52. 
The key secondary efficacy outcome variables are as follows: 
 Change in 6-minute walk test (6MWT) distance from Baseline to Week 52 
 Progression-free survival defined as the time to the first occurrence of any of the 
following: (a) death, (b) confirmed ≥10% absolute decline from Baseline in %FVC, 
and (c) confirmed ≥50-meter decline from Baseline in 6MWT distance 
Other secondary efficacy outcome variables are: 
• All-cause mortality 
• Treatment-emergent IPF-related mortality 
• Change from Baseline to Week 52 in dyspnea as measured by the University of 
California at San Diego Shortness-of-Breath Questionnaire (UCSD SOBQ) score 
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6 STUDY OBJECTIVES 
The objectives of the PIPF-016 study are as follows: 
• To confirm the treatment effect of pirfenidone 2403 mg/d compared with placebo on 
change in %FVC in patients with idiopathic pulmonary fibrosis (IPF) 
• To confirm the safety of treatment with pirfenidone 2403 mg/d compared with 
placebo in patients with IPF 
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7 SAMPLE SIZE AND POWER 
This study is designed to provide at least 90% power to detect a treatment difference in 
normalized ranks of change in %FVC at Week 52 of 0.08 with a standard deviation of 0.27. For 
change in 6MWT distance, 250 patients per group will provide approximately 75% power to 
detect a difference in normalized ranks of 0.068 with a standard deviation of 0.285. A sufficient 
sample size was determined to be 500 patients, randomized in a 1:1 ratio of pirfenidone 
2403 mg/d to placebo. 
Parameter estimates for the sample size calculations are based on the experience in Studies 
PIPF-004 and PIPF-006. These calculations were generated using nQuery Advisor 5.0 software. 
In this one-year study of pirfenidone to reduce decline in lung function, mortality is included as a 
secondary endpoint to provide supportive evidence of benefit, but the study has not been 
powered to show a significant mortality benefit. A sample size of 250 patients per group 
provides only 10% power with an alpha of 0.05 to detect a hazard ratio (HR) of 0.77 in all-cause 
mortality, the effect size observed in the pooled analyses of PIPF-004 and PIPF-006. 
Accordingly, the mortality analyses will be conducted on both the PIPF-016 dataset and on the 
pooled dataset that also includes PIPF-004 and PIPF-006. Furthermore, pooling data from this 
study with those from the two previous studies, PIPF-004 and PIPF-006, provides less than 20% 
power to detect a hazard ratio of 0.77 at an alpha of 0.05. 
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8 RANDOMIZATION 
After completing the informed consent process, eligible patients will be enrolled in the study. A 
patient number will be assigned by an interactive web or voice response system (IXR). Eligible 
patients will be randomly allocated in a ratio of 1:1 to receive either pirfenidone 2403 mg/d or 
placebo. The randomization will be permuted block randomization without stratification by site 
or any demographic or Baseline characteristic. 
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9 ANALYSIS POPULATIONS 
The intent-to-treat (ITT) population used for all efficacy analyses will include all patients who 
signed informed consent and were randomized to study treatment. The safety population will 
include all patients who signed informed consent and received any amount of study drug. 
Patients will be analyzed according to the treatment arm to which they are randomized, 
regardless of treatment actually received. Patients who receive the incorrect study drug will be 
classified as protocol deviations. 
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10 PATIENT DEMOGRAPHICS AND BASELINE CHARACTERISTICS 
Descriptive statistics will be used to summarize demographic and Baseline patient 
characteristics. Continuous variables (e.g., age) will be summarized with the number, mean, 
median, standard deviation, minimum, and maximum. Treatment group differences between 
placebo and pirfenidone 2403-mg/d will be evaluated using a two-sided t-test. Categorical 
variables (e.g., sex) will be summarized with patient counts and percentages. Treatment group 
differences between placebo and pirfenidone 2403 mg/d will be evaluated using the Chi-squared 
test for dichotomous or nonordinal data or the Cochran-Mantel-Haenszel test (with modridit 
scores) for ordinal data. Baseline data will be defined as the last observation before 
randomization except for efficacy variables, which will be defined as specified in Section 12.4. 
Data collected on study Day 1 is assumed to be collected before randomization and dosing. 
Patient Baseline medical conditions (comorbidities) reported in the Medical History Case Report 
Form (CRF) will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). 
Patient comorbidities at Baseline will be summarized by treatment group for all treated patients 
in two tables. The first table will summarize all comorbidities reported on the CRF. The second 
will summarize only comorbidities ongoing on the randomization date. 
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11 PRIOR AND CONCOMITANT MEDICATIONS 
All prior and concomitant medications collected will be coded to the World Health Organization 
Drug Dictionary (WHODRUG). All coding will be reviewed by the study medical monitor. All 
tabulations of use of prior and concomitant medications will be summarized by the 2nd level 
Anatomical Therapeutic Chemical (ATC) grouping and the Preferred Name in the classification 
system of the WHODRUG, unless indicated otherwise. 
11.1 Prior Medications 
Prior medications taken after informed consent is signed and before randomization, will be 
summarized by treatment group. In addition, prior medications taken between 28 days (inclusive) 
before Screening and the date of randomization will be summarized by treatment group. 
11.2 Concomitant Medications 
Concomitant medications are medications other than study drug that a patient reports taking 
between the first dose and up to 28 days after the last dose of study drug. These include 
medications that are taken before the first dose of study drug and continue to be taken during 
study treatment. Concomitant medications will be summarized by treatment group. In addition 
any medications taken more than 28 days after last dose will be summarized by treatment group. 
11.2.1 Concomitant Use of Selected Medications 
The use of cytochrome P450 1A2 (CYP1A2) inhibitors, listed in Table 11-1, will be summarized 
to facilitate assessment of potential signals in subsequent analyses of safety. These concomitant 
medications were chosen because their pathway of hepatic metabolism may be common to that 
of pirfenidone. These medications are classified by the pharmacologic/therapeutic subgroup (2nd 
level), as well as certain specified subgroup ATC codes of the WHODRUG.  
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Table 11-1 Selected Concomitant Medications Classified  
by WHO Drug Dictionary ATC Codes 
ATC Code CYP 1A2 Inhibitors Medication 
A02BA01 Cimetidine 
C01BB02 Mexiletine 
C01BD01 Amiodarone 
D05AD02 Methoxsalen 
J01MA02 Ciprofloxacin 
J01MA04 Enoxacin 
N06AB08 Fluvoxamine 
G03A Hormonal contraceptives for systemic use 
R01BA01 Phenylpropanolamine 
P02CA02 Tiabendazole 
A02BA01 Cimetidine 
 
The summary of CYP1A2 inhibitors will be displayed by study treatment group for all patients 
who receive study drug.  
11.2.2 Prohibited Use of Medications  
The concomitant use of certain medications is prohibited because of their potential to affect the 
safety or efficacy of pirfenidone. The prohibited use of medications while on study treatment 
will be tabulated.  
Use of systemic corticosteroids for protocol-defined acute IPF exacerbation is permitted up to 
21 consecutive days, but prohibited if used for 21 or more consecutive days. Use of systemic 
corticosteroids is prohibited for any IPF indication other than acute exacerbation and is permitted 
for all other indications. 
Prohibited medications, classified by the WHODRUG ATC codes if applicable, are listed in 
Table 11-2. Additional medications may be included as prohibited if a review of concomitant 
medication reveals other prohibited medication use, for example, investigational medications not 
anticipated. 
The summary of the concomitant use of these prohibited or restricted medications during study 
treatment will be displayed by study treatment group for all treated patients. 
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Table 11-2 Prohibited Medications Classified by WHO Drug Dictionary ATC Codes 
ATC Code Usea Medications 
  Antithrombotic Agents 
B01AA03 II Warfarin 
B01AB II Heparin group 
B01AC11 I Iloprost 
  Antihypertensives 
C02KX01 I Bosentan 
C02KX02 I Ambrisentan 
  Agents Acting on the Renin-Angiotensin System 
C09A II ACE inhibitors, plain 
  Lipid Modifying Agents 
C10AA II HMG CoA reductase inhibitors 
  Urologicals 
G04BE03 II Sildenafil 
G04BE08 II Tadalafil 
G04BE09 II Vardenafil 
H02  III Corticosteroids for Systemic Use 
  Antineoplastic Agents 
L01AA01 I Cyclophosphamide 
L01XE I Protein kinase inhibitors 
L01XX28 I Imatinib 
  Immunostimulants 
L03AB I Interferons 
L03AC I Interleukins 
L03AX I Other cytokines and immunomodulators 
  Immunosuppressive Agents  
L04AA01 I Cyclosporin 
L04AA06 I Mycophenolic acid 
L04AA11 I Etanercept 
L04AA12 I Infliximab 
L04AA17 I Adalimumab  
L04AD I Calcineurin Inhibitors 
L04AX01 I Azathioprine 
L04AX03 I Methotrexate 
  Anti-inflammatory and Antirheumatic Products 
M01CC01 I Penicillamine 
  Antigout Preparations  
M04AC01 II Colchicine 
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Table 11-2 Prohibited Medications in PIPF-016 Classified by WHO Drug Dictionary 
ATC Codes (continued)  
ATC Code Usea Medications 
  Psychoanaleptics  
N06AB08 I Fluvoxamine 
  Drugs for Obstructive Airway Diseases 
R03DC II Leukotriene-receptor antagonists 
   Cough and Cold Preparations  
R05CB01 I Acetylcysteine 
  Investigational Agents 
 I Tetrathiomolybdate 
 I BIBF 1120 (tyrosine kinase inhibitor) 
a   I: prohibited under all circumstances; II: prohibited if used for IPF; III: prohibited under certain circumstances 
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12 STATISTICAL METHODS 
12.1 Hypothesis Testing 
The null hypothesis for the primary outcome is that the absolute change in percent predicted 
FVC from Baseline to Week 52 is the same in the pirfenidone the 2403 mg/d treatment group 
and the placebo treatment group.  
Similarly, in all other hypothesis tests of secondary and exploratory outcomes, the null 
hypothesis is that there is no treatment difference between the pirfenidone 2403 mg/d treatment 
group and the placebo treatment group.  
All tests will be conducted against a two-sided alternative at the α = 0.05 significance level with 
the following exceptions. The primary efficacy analysis will be tested at an alpha level of 
0.0498; adjusting for the two anticipated interim mortality analyses. If the primary endpoint is 
significant at p = 0.0498, then the two key secondary endpoints will be analyzed using 
Hochberg’s procedure for two tests of significance, using 0.050 if both are <=0.050 and 0.025 if 
one test is >0.050 (Hochberg 1988). 
12.2 Patient Disposition, Compliance, and Exposure 
12.2.1 Patient Disposition 
The number and percent of randomized patients who receive and who do not receive a dose of 
study drug will be summarized by treatment group. The number and percent of randomized 
patients who do not complete the study and who permanently discontinue treatment, along with 
the reasons for discontinuation, will be summarized by treatment group. 
A Kaplan-Meier plot of the time from randomization to withdrawal from study by treatment 
group will be presented. Patients on the study at the time of study termination (patients who did 
not withdraw early from the study) will be treated as censored at their last study visit or date 
entered into the rollover study. 
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A Kaplan-Meier plot of the time from randomization to permanent discontinuation of study 
treatment by treatment group will be presented. Patients on study treatment at the time of study 
termination (patients who did not permanently discontinue from study treatment) will be treated 
as censored at the time of last dose. 
Graphs will also be presented showing the number of patients on study and on treatment by time. 
These graphs will be plotted both by day and by assessment window to indicate how many 
patients were potentially available to be evaluated at each assessment time. 
12.2.2 Patient Compliance with Study Drug Regimen 
Compliance with dosing will be calculated as a percentage as 100 times the total number of 
capsules taken from first dose until Week 52B divided by the total number of capsules prescribed 
from first dose until Week 52B. Prescribed dose will be according to investigator prescription, 
allowing for dose modification, and not the randomized target dose. Patients who discontinue 
study treatment before 52 weeks for reasons other than lung transplantation or death will be 
considered to be 0% compliant for the number of days from discontinuing study treatment until 
Week 52. For patients who discontinue study treatment before 52 weeks for lung transplantation 
or who die while on treatment before 52 weeks, compliance will be calculated based on the 
compliance from the date of first dose to the date of discontinuation of treatment or death. 
The calculation for compliance is the numerator divided by denominator multiplied by 100. 
The numerator is: 
The sum of  
(stop date − start date + 1)  number of capsules/day taken 
The denominator is: 
 The sum of  
(stop date − start date + 1)  number of capsules/day prescribed 
Where the summation is from the first dose on the Study Treatment Dosing CRF page up to 
Week 52B, death, or lung transplant. This ratio is then multiplied by 100. 
If the patient discontinues for any reason other than death or lung transplantation before 
Week 52, then the compliance estimate will be calculated as: 
                                                                                             
                           
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In addition compliance while on treatment will be calculated as 100 times the actual number of 
capsules taken from the first dose to the last dose on the Study Treatment Dosing CRF page 
divided by the prescribed number of capsules until study treatment discontinuation. 
12.2.3 Duration of Exposure to Study Drug 
The total duration of exposure is defined as the time interval between the first dose and the last 
dose, inclusive, of study drug based on the patient study drug dosing information. 
Total duration (weeks) of exposure to study drug in the ITT population will be summarized by 
descriptive statistics (i.e., N, mean, standard deviation, median, minimum, and maximum). Total 
duration of exposure will also be summarized by number and percent of patients exposed for 
specific periods of time, including >0 to less than 3 months, 3 to less than 6 months, 6 to less 
than 9 months, 9 to less than 12 months, greater than or equal to 12 months. A month is defined 
as the number of days from first until last exposure to study drug times 12 divided by 365.25. 
12.3 Protocol Deviations 
All protocol deviations will be identified and categorized before database lock. Example 
categories include the following: 
• Inclusion/Exclusion criteria violation 
• Informed consent error (e.g., consent signed after study procedures performed) 
• Study drug dosing errors (e.g., patients did not take prescribed dose of study drug) 
• Concomitant medications (e.g., took prohibited concomitant medication) 
• Safety assessment (e.g., safety assessments not done) 
• Efficacy assessment (e.g., efficacy assessments not done) 
 
Other instances where study procedures were not performed according to protocol may also be 
classified as protocol deviations. 
Protocol deviations will be summarized by category with patient counts and percentages. At each 
level of summation, patients will be counted only once. Deviations will be listed for individual 
patients by group. Patients granted protocol exceptions will also be listed along with their 
exceptions. 
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12.4 Efficacy Analyses 
12.4.1 Analysis Model 
The data for the change from Baseline outcomes are not expected to be normally distributed. 
Therefore, data will be analyzed using a rank analysis of covariance (ANCOVA) model with a 
standardized rank change from Baseline as the outcome and standardized rank Baseline value as 
a covariate. Ties will be assigned the mean of the corresponding ranks. Standardized ranks 
correspond to modified ridits in the SAS® system and are obtained as ranks for all patients 
(regardless of treatment) divided by the sample size plus one. The treatment effect will be tested 
using the Mantel-Haenszel mean score chi-square test of the residuals. These analyses will be 
performed as described in section 7.7, pages 174-177 of Stokes et al. (2000). Refer to 
Section 14.1 (Handling of Missing Efficacy Data) regarding imputation of missing data. When 
the data are ranked, patients with missing data due to death will be ranked worse than those who 
remain alive. Patients who die will be ranked according to the number of days from 
randomization until death, with the shortest time until death as the worst rank (Lachin 1999; 
Finkelstein and Schoenfeld 1999).  
12.4.2 Primary Efficacy Analysis 
The primary efficacy analysis is a fixed effect rank ANCOVA of the change from Baseline to 
Week 52 in absolute change in % FVC between the 2403 mg/day pirfenidone and placebo 
groups in the ITT population. Ranked Baseline %FVC will be included as a covariate. The 
primary efficacy analysis will be tested at an alpha level of 0.0498; adjusting for the two 
anticipated interim mortality analyses. 
All FVC values will be evaluated and selected by a central reader considering ATS criteria for 
acceptability and repeatability. Baseline %FVC will be defined as the mean of the FVC 
measurements obtained at Screening and Day 1 visits; if either is missing, the non-missing value 
will be used. Week 52 %FVC will be defined as the mean of the FVC measurements obtained as 
part of the Week 52 visit; if either is missing, the non-missing value will be used. If both values 
are missing, the data will be imputed as specified in Section 14.  
The magnitude of the treatment effect of pirfenidone will be presented as the distribution 
(number and percentage) of patients across the following categories of change from Baseline: 
• Decline of ≥10% or death before the Week 52 visit 
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• Decline of <10% to >0% 
• Stability or improvement of ≥0% 
Also, an ogive plot of the change from Baseline to Week 52 will be provided. 
Supportive analyses of the primary efficacy outcome will include the following: 
1. A repeated measures mixed linear model for rank change from Baseline in %FVC will be 
presented, using ranks calculated for change to Weeks 13, 26, 39, and 52. The mixed 
model will include fixed effects for treatment; covariates for Baseline %FVC, and a 
repeated effect of assessment week, unstructured covariance structure, and patient as the 
subject factor. Treatment effect will be tested at each visit (with a treatment by visit 
interaction term) and overall. Patients who die will be ranked worse than all other 
recorded data at the corresponding 13 week visit following the death and then within this 
group will be ranked by time until death. 
2. Change from Baseline to Weeks 13, 26, 39, and 52 in FVC volume. This analysis will use 
the same analysis methods as the primary efficacy analysis, ranking the relative change in 
volume. The relative change is defined for each 13-week visit as (visit FVC volume-
Baseline FVC volume)/Baseline FVC volume. The magnitude of the treatment effect of 
pirfenidone will be presented as the distribution (number and percentage) of patients 
across the following categories of change from Baseline:  
• Relative decline of ≥10% or death before the corresponding 13-week visit 
• Relative decline of <10% to >0% 
• Stability or improvement of ≥0% 
3. Landmark analyses of change from Baseline in %FVC to Weeks 13, 26, and 39. These 
will use the same analysis methods and summary of treatment effect as the primary 
efficacy analysis. 
4. A sensitivity analysis will use the last observation carried forward for imputing Week 52 
%FVC missing for reasons other than death. Missing due to death will be imputed as 
specified in Section 14. 
12.4.3 Secondary Efficacy Analyses  
12.4.3.1 Key Secondary Endpoints 
Two key secondary endpoints are change in 6MWT distance from Baseline to Week 52 and 
progression-free survival. The effect upon the overall type I error introduced by testing two 
secondary endpoints will be controlled as follows:  if the primary endpoint is significant at 
p = 0.0498, then the two key secondary endpoints will be analyzed using Hochberg’s procedure 
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for two tests of significance, using 0.050 if both are ≤0.050 and 0.025 if one test is >0.050 
(Hochberg 1988).  
12.4.3.1.1 Change from Baseline to Week 52 in Distance Walked in the 6MWT 
Change in 6MWT distance from Baseline to Week 52 is a key secondary endpoint. Baseline 
6MWT distance will be the average of the measurements recorded at the Screening and 
Day 1 visits. The 6MWT distance at Week 52 will be defined as the average of the 6MWT 
distance recorded on two separate days at Week 52. Data will be analyzed using a rank 
ANCOVA model similar to that outlined in Section 12.4.1 including ranking patients who 
die worst according to time until death.  
If a patient does not complete the 6MWT for any reason, or walks for less than 6 minutes, the 
actual distance walked will be used as if the test were completed. If a patient walks for more 
than 6 minutes, 6MWT distance will be estimated as: 
                                                                      
Completely missing walk distance will be imputed as specified in Section 14.1  
The magnitude of the treatment effect of pirfenidone will be presented as the distribution 
(number and percentage) of patients across the following categories of change from Baseline: 
• Decline of ≥50 meters (m) or death before the corresponding 13-week visit 
• Decline of <50 m to >0 m 
• Stability or improvement of ≥0 m  
These analyses also will be performed at Weeks, 13, 26, and 39. 
12.4.3.1.2 Progression-Free Survival 
Progression-free survival is a key secondary endpoint and is defined as the time to the first 
occurrence of any of the following events: 
• Death 
• Confirmed ≥10% absolute decline from Baseline in %FVC  
• Confirmed ≥50-meter decline from Baseline in 6MWT distance  
In the case of %FVC and 6MWT distance, the decline must be confirmed at two consecutive 
visits at least 6 weeks apart. If the first decline is at Week 52A, it can be confirmed in less 
than 6 weeks at Week 52B. In all cases, the first of the two visits will be used as the 
timepoint for the calculation of the time to event. Progression-free survival will be compared 
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between the pirfenidone 2403 mg/d and placebo groups using the product limit method log-
rank test (Kalbfleisch and Prentice 1980). A proportional hazards model with only treatment 
in the model will be used to estimate the hazard ratio, ties will be handled with the 
approximate likelihood method of Efron (1977). Kaplan-Meier estimates will be used to 
summarize progression-free survival time. 
Patients who survive without progression will be censored at Week 52B or if the patient 
discontinued early at the time of their last available %FVC or 6MWT distance assessment. 
Patients who die before progression will be counted as a death event unless the death is after 
Week 52B or more than 182 days after the last available %FVC or 6MWT distance 
assessment or more than 364 days after randomization. If the death is not counted as an 
event, the patient will be censored at the time of their last available %FVC or 6MWT 
distance assessment. 
The following summaries will be tabulated by treatment group for the analysis: the number 
of patients included in the analysis (as event or as censored), the number of patients with an 
event, the number of patients with a 10% absolute decline in %FVC, the number of patients 
with a 50 m decline in 6MWT distance, the number of patients who die, the number of 
patients censored, the distribution of survival times without disease progression, and the 
survival probabilities for each 13-week period from Baseline to the Week 52. Descriptively, 
the number of patients who have more than one outcome will be presented by all outcomes 
that occurred. 
12.4.3.2 Other Secondary Endpoints 
12.4.3.2.1 Change from Baseline to Week 52 in Dyspnea (UCSD SOBQ Score)  
Change in dyspnea, as measured by UCSD SOBQ score from Baseline to Week 52 is a 
secondary endpoint and will be analyzed using the same methods described in Section 12.4.1. 
The Baseline UCSD SOBQ score will be the average of the measurements recorded at the 
Screening and Day 1 visits. The UCSD SOBQ score at Week 52 will be defined as the 
average of the UCSD SOBQ score recorded on two separate days at Week 52. To maintain 
the validity of the result from UCSD SOBQ, patients who answer at least 18 out of 24 items 
(75%) will be defined as non-missing for this analysis. The aggregated score will be 
calculated for each patient by summing the scores from all items in the UCSD SOBQ. In the 
event that one or more items in the UCSD SOBQ at a visit are unanswered, the mean score 
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from answered items (sum of scores/number of answered items) for a visit will be multiplied 
by number of total items to calculate the aggregated score. This is equivalent to: 
                 
                                                                                   
Missing data will be imputed as specified in Section 14.1.  
The magnitude of the treatment effect of pirfenidone will be presented as the distribution 
(number and percentage) of patients across the following categories of change from Baseline: 
• Increase of ≥20 or death before the corresponding 13-week visit 
• Increase of <20 to >0 
• Stability or Decrease of ≥0 
These analyses also will be performed at Weeks, 13, 26, and 39. 
12.4.3.2.2 Mortality 
The two mortality endpoints are all-cause mortality and treatment-emergent IPF-related 
mortality. Patients who discontinue study treatment before Week 52 will be followed for vital 
status through Week 52. All-cause mortality will include events occurring in this extended 
period. Supportive endpoints are IPF-related mortality and treatment-emergent all-cause 
mortality. Treatment-emergent mortality is defined as deaths that occur between 
randomization and the earlier of the Week 52B visit or 28 days (inclusive) after the last dose 
of blinded study treatment. Relationship of cause of death to IPF will be assessed by the 
Mortality Assessment Committee (MAC). 
Mortality will be compared between the pirfenidone 2403 mg/d and placebo groups using the 
product limit method log-rank test (Kalbfleisch and Prentice 1980); the pooled analysis will 
be stratified by study. A proportional hazards model with only treatment in the model for the 
study analysis and treatment and study in the model for the pooled analysis will be used to 
estimate the hazard ratio, ties will be handled with the approximate likelihood method of 
Efron (1977). Kaplan-Meier estimates will be used to summarize each survival time analysis. 
Patients who are alive and complete the study will be censored at the Week 52B visit. Most 
patients who complete Week 52B are expected to roll over into an open-label study. Patients 
who discontinue regular study visits will be censored at the earliest of (a) Study Day 364, 
(b) the last available contact date (including contact after discontinuation of regular study 
visits), or (c) date of lung transplantation. 
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The following summaries will be tabulated by treatment group for the analysis: the total 
number of patients included in the analysis (as event or as censored), the number of deaths, 
the number of censored patients, the appropriate quantiles to summarize survival time, the 
magnitude of treatment effect estimated by HR, and survival probabilities for each 13-week 
period from Baseline to Week 52.  
Mortality data from this study also will be pooled with the data from Studies PIPF-004 and 
PIPF-006. For the pooled analysis, the PIPF-004 and PIPF-006 results will be censored at 
Week 52 if an event has not occurred earlier in order to allow the three studies to contribute 
comparable follow-up time to the pooled analysis. There was no MAC for studies PIPF-004 
and PIPF-006; therefore, the assessment of relationship of cause of death to IPF by the 
investigator will be used. 
12.5 Safety Analyses 
12.5.1 Adverse Events 
All adverse events (AEs) will be mapped to MedDRA. Treatment-emergent AEs and serious 
adverse events (SAEs) will be summarized by the preferred terms within each system organ 
class. An event will be considered treatment-emergent if the onset date is on or after the first 
dose and within 28 days after the last dose of study treatment. 
The following summary tables for AEs and SAEs according to the MedDRA system organ class 
(SOC) and preferred term will be presented: 
• Treatment-emergent AEs 
• Treatment-emergent SAEs 
• Treatment-emergent treatment-related AEs 
• Treatment-emergent treatment-related SAEs 
• AEs leading to early discontinuation of study treatment 
• AEs resulting in withdrawal from study 
• Treatment-emergent AEs with Grade 3 (severe) or 4 (life-threatening) severity 
If any adverse event is missing the assessment of relationship to study drug, it will be included in 
the summary tables as a “probably related” event. Likewise, if any adverse event is missing the 
assessment of severity, it will be included in the summary tables as a “severe” (i.e., modified 
Common Terminology Criteria for Adverse Events Grade 3) event. 
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12.5.2 Death 
All reported deaths will be analyzed. All-cause and IPF-related deaths as assessed by the MAC 
will be summarized by treatment group. Crude mortality rates will be computed as the total 
number of deaths divided by the total number of patients exposed in each treatment group. In 
addition, IPF-related mortality (i.e., IPF-related versus non–IPF-related) will also be 
summarized.  
The cause of death as assessed by the MAC and as reported by the investigator will be coded 
using MedDRA. The cause of death as assessed by the MAC and as reported by the investigator 
will be summarized using the MedDRA coded terms by treatment group and by preferred terms 
within each system organ class. 
12.5.3 Clinical Laboratory Evaluations 
Clinical central laboratory data (hematology and chemistry) obtained at Baseline and each 
measurement timepoint will be summarized by treatment group in the following ways: 
1 Descriptive statistics (hematology and chemistry only) (mean, median, standard 
deviation, and range) at each measurement timepoint and for the change from 
Baseline in the measurements at each post-Baseline visit. If there are multiple 
assessments within a visit window, the closest assessment to the target visit date 
within the visit window will be summarized. If the assessments are equidistant from 
the target visit date, the later assessment will be used. 
2 Shift tables will be provided by toxicity levels for assessments with modified 
Common Terminology Criteria for Adverse Events and for the other assessments will 
be provided by normal ranges for the frequencies of patients below, within, and above 
the normal ranges for the most out-of-range value as compared with Baseline. If a 
patient has both high and low out-of-range values the patient result will be 
summarized according to the value that is furthest from the respective limit. 
3 The incidence and percentage of patients with measurements by the most out-of-
range value toxicity levels (Grade 3 and 4) using the modified Common Terminology 
Criteria for Adverse Events, Version 3.  
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12.5.4 Special Assessments of Potential Hepatotoxicity 
12.5.4.1 Modified Hy’s Rule 
Using the modified Hy’s rule by Bjornsson and Olsson (Bjornsson and Olsson 2005), the 
incidence of patients with ALT or AST values greater than 3 times the upper limit of normal 
(ULN) and total bilirubin greater than 2 times the ULN (based on the same blood draw of ALT, 
AST, and total bilirubin while on study drug) will be used to assess the potential for study drug-
induced liver toxicity.  
12.5.4.2 Specific Liver-Related Laboratory Outcomes 
Table 12-1 lists the specific liver-related laboratory outcomes that will be assessed.  
Table 12-1 Liver-Related Laboratory Outcomes 
Liver Function Test Range of Test Values 
AST 3  to 4.99  ULN 
 5  to 9.99  ULN 
 10  to 19.99 ULN 
 ≥20  ULN 
ALT 3  to 4.99  ULN 
 5  to 9.99  ULN 
 10  to 19.99 ULN 
 ≥20  ULN 
AST or ALT 3  to 4.99  ULN 
 5  to 9.99  ULN 
 10  to 19.99 ULN 
 ≥20  ULN 
Total bilirubin  >ULN 
 >1.5  ULN 
 >2  ULN 
AST or ALT plus total bilirubin > 3 ULN plus >1.5  ULN 
AST or ALT plus total bilirubin > 3 ULN plus >2  ULN 
Alkaline phosphatase >1.5  ULN 
ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal 
 
Crude incidence rates of events will be computed as the number of events divided by the total 
number of patients exposed to study drug by treatment group. Adjusted incidence rates of events 
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will be defined as the number of events divided by the total number of patient-years of exposure 
for each treatment group. 
In addition, the worst liver-related laboratory results will be summarized (with the categories of 
test values specified in Table 12-1) using crude incidence rates of patients. Crude incidence rates 
of patients will be computed as the number of patients with the liver function test values of 
interest divided by the total number of patients who received study drug in a treatment group. 
The summary and plot of time from first study dose to the elevation of AST or ALT 
>5 x ULN will be analyzed using Kaplan-Meier estimates.  A scatterplot of the post-Baseline 
maximum value of total bilirubin versus the maximum value of AST or ALT will be generated. 
12.5.5 Vital Signs 
Vital signs will be summarized by treatment group and by visit with descriptive statistics (mean, 
median, standard deviation, and range) for the actual values and change from Baseline. 
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13 CHANGES FROM PROTOCOL-SPECIFIED ANALYSES 
13.1 Categorical Analysis of Change from Baseline in Dyspnea (UCSD SOBQ Score) 
The clinical study protocol (dated 16 March 2011, Section 5.4.2.3.1) defined the cutpoints for the 
categorical analysis of change from Baseline in UCSD SOBQ. One of the thresholds used to 
present the magnitude of the treatment effect on SOBQ was changed from 25 to 20 based on new 
findings from external data sources suggesting a more clinically relevant threshold. The primary 
analysis of this endpoint, rank ANCOVA, was not changed. 
13.2 Analysis of FVC volume 
The clinical study protocol (dated 16 March 2011, section 5.4.2.1) describes a supportive 
analysis of FVC as the change from Baseline to Week 52 in FVC volume (in mL). Based on new 
findings from external sources, the analysis of FVC volume will be based on relative change (%) 
rather than actual volume (mL). A categorical analysis of relative change from Baseline has been 
added. 
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14 MISSING DATA 
14.1 Missing Efficacy Data 
14.1.1 Missing efficacy assessment due to death 
In the rank ANCOVA model, patients who die will be ranked worst according to time until death 
if the death occurs before or on the nominal study day for each visit as defined in the protocol.  
14.1.2 Missing efficacy assessment for reasons other than death 
Efficacy assessments missing due to reasons other than death (e.g., missing visits, early 
withdrawal from the study, including missing values due to lung transplantations) will be 
imputed by a procedure referred to as the sum of squared differences (SSD) outlined as follows: 
Step 1:  For each post-Baseline missing value to be imputed at a visit (Visit X) for a 
particular patient (Patient A), a set of all patients without any missing values for visits 
from Baseline up to Visit X as Patient A will be selected. 
Step 2:  For the patients in this set, the SSDs between each patient selected in Step 1 and 
Patient A will be calculated across all non-missing values from Baseline up to the visit 
prior to Visit X. 
Step 3:  The 3 patients with the smallest SSDs will be identified and the average of their 
non-missing value at Visit X will be used to impute the missing value for Patient A at 
that visit. The number of smallest SSDs to calculate the average can be less than 3 due to 
availability of patients defined in Step 1 or more than 3 based on tied SSDs.  
Missing individual item-level scores of the SOBQ will be imputed as described in 
Section 12.4.3.3.  
Any randomized patients in the ITT population who do not receive any study drug and do not 
provide any post-Baseline data for the rank analyses will be assigned a modified ridit of 0.5 to 
reflect that they were tied with all other patients.  
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14.2 Imputation of Incomplete Adverse Event Onset Dates 
To facilitate the summarization of treatment-emergent adverse events, those with incomplete or 
missing onset dates will have the onset dates imputed. For conservative purposes, it is assumed 
that all reported adverse events are treatment-emergent, unless proven otherwise. For treatment-
emergent adverse events, all incomplete or missing onset dates will be imputed to the earliest 
date possible (using any reliable portions of the onset date that are available) after the first dose 
of study drug. If it is not possible (i.e., given the completed portions of the adverse event onset 
date and the known first dose date) that the event started after the first dose of study treatment, 
then the adverse event will be considered non-treatment-emergent and the onset date will be left 
as an incomplete date. 
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15 OTHER CONSIDERATIONS 
15.1 Visit Windows 
For summary and analysis of clinical laboratory, efficacy, and safety evaluations, the end of one 
interval and beginning of the next interval for any two visits is the midpoint between the two 
nominal visits. 
The analysis windows for laboratory, physical examination, and vital sign data are presented in 
Table 15-1, and those for %FVC, 6MWT distance, and UCSD SOBQ measurements in 
Table 15-2. In the event of multiple values for an assessment within an analysis window, the 
value closest to the scheduled visit date will be used for analyses. If two values tie as closest to 
the time point (for example, one value is before and the other value is after the time point), then 
the later value will be selected as the analysis value.  
An exception to this is the Week 52 pulmonary function testing (PFT), for which a second set of 
PFT will be performed. For the Week 52 PFT, the two assessments closest to the Week 52 Visit 
within the Week 52 Visit window are to be assigned as the first and second day Week 52 
assessments. 
The definition for the study days included in each study window is defined as below: 
Study Day prior to randomization = Visit Date – Date of Randomization 
Study Day on or after randomization = Visit Date – Date of Randomization + 1 
 
Safety assessments will be based on date of first dose rather than date of randomization. 
Treatment Day prior to first dose = Visit Date – Date of first dose 
Treatment Day on or after first dose = Visit Date – Date of first dose + 1 
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Table 15-1 Analysis Windows for Hematology, Chemistry, Physical 
Examinations, and Vital Signs 
Scheduled Visit Target Study Day Window (Days) 
Screening Closest Assessment Before 
Baseline 
-85 to -2 
Randomization 1 -1 to 1 
Week 2 15 2 to 21 
Week 4 29 22 to 42 
Week 8 57 43 to 74 
Week 13 92 75 to 102 
Week 16 113 103 to 126 
Week 20 141 127 to 161 
Week 26 183 162 to 228 
Week 39 274 229 to 319 
Week 52 365 320 to 393 
Note: The follow-up visit is not included in scheduled visit windows. 
 
Table 15-2 Analysis Window for %FVC, 6MWT Distance, and UCSD SOBQ 
Measurements 
Scheduled Visit Target Study Day Window (Days) 
Screening Closest Assessment Before 
Baseline 
-85 to -2 
Randomization 1 -1 to 1 
Week 13 92 2 to 136 
Week 26 183 137 to 227 
Week 39 274 228 to 318 
Week 52 365 319 to 393 
Note: The follow-up visit is not included in scheduled visit windows. 
InterMune, Inc.  Statistical Analysis Plan PIPF-016 
Pirfenidone  12 March 2012 
CONFIDENTIAL AND PROPRIETARY Page 34 
16 REFERENCES 
Bjornsson E, Olsson R. 2005. Outcome and prognostic markers in severe drug-induced liver 
disease. Hepatology 42:481–489. 
Efron B. 1977. The efficiency of Cox's likelihood function for censored data. Journal of the 
American Statistical Association 72:557–565. 
Finkelstein DM and Schoenfeld DA. 1999. Combining mortality and longitudinal measures in 
clinical trials. Statistics in Medicine 18:1341–1354. 
Hochberg Y. 1988. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 
75,4: 800–802. 
Kalbfleisch JD and Prentice RL. 1980. The Statistical Analysis of Failure Time Data, New York: 
John Wiley & Sons, Inc. 
Lachin MJ. 1999. Worst-Rank Score Analysis with Informatively Missing Observations in 
Clinical Trials. Controlled Clinical Trials 20:408–422. 
SAS Institute. 2008. SAS® System for Windows, Version 9.2, Cary, NC: SAS Institute, Inc. 
Stokes ME, Davis CS, Koch GG. 2000. Categorical Data Analysis Using the SAS System, Cary, 
NC: SAS Institute, Inc. Section 7.7, pages 174–177. 
InterMune, Inc.  Statistical Analysis Plan PIPF-016 
Pirfenidone  12 March 2012 
CONFIDENTIAL AND PROPRIETARY Page 35 
17 LIST OF END OF TEXT TABLES AND FIGURES 
Name Title 
Table 14.1-1 Number of Patients by Investigator: All Randomized Patients (ITT) 
Table 14.1-2 Summary of Patient Disposition: All Patients (Washout or Screened) 
Table 14.1-3 Time to Event Analysis of Permanent Discontinuation of Study Treatment: 
All Randomized Patients (ITT) 
Table 14.1-4 Time to Event Analysis of Early Withdrawal from Study: All Randomized 
Patients (ITT) 
Table 14.1-5 Demographic Profile: All Randomized Patients (ITT) 
Table 14.1-6 Other Baseline Characteristics: All Randomized Patients (ITT) 
Table 14.1-7 Medical History : All Randomized Patients (ITT) 
Table 14.1-8 Medical History by Decreasing Frequency: All Randomized Patients (ITT) 
Table 14.1-9 Medical History Ongoing at Baseline: All Randomized Patients (ITT) 
Table 14.1-10 Prior Medications - Within Protocol Window: All Randomized Patients 
(ITT) 
Table 14.1-11 Prior Medications - Within Protocol Window by Decreasing Frequency: All 
Randomized Patients (ITT) 
Table 14.1-12 Prior Medications - All Reported: All Randomized Patients (ITT) 
Table 14.1-13 Concomitant Medication Use: All Randomized Patients (ITT) 
Table 14.1-14 Concomitant Medication Use by Decreasing Frequency: All Randomized 
Patients (ITT) 
Table 14.1-15 Medication Use for Pulmonary Indications after Discontinuation of Study 
Treatment 
Table 14.1-16 Concomitant Use of Selected CYP1A2 Inhibitors: All Randomized Patients 
(ITT) 
Table 14.1-17  Prohibited Use of Medications: All Randomized Patients (ITT) 
Table 14.1-18 Supplemental Oxygen or Prescription Change: All Randomized Patients 
(ITT) 
Table 14.1-19 Study Treatment Compliance: All Randomized Patients (ITT) 
Table 14.1-20 Duration on Study Treatment: All Randomized Patients (ITT): All Treated 
Patients (safety) 
Table 14.1-21 Study Treatment Overdose: All Treated Patients (safety) 
Table 14.1-22 Protocol Deviations: All Randomized Patients (ITT) 
Table 14.1-23 Six Minute Walk Test O2 Use: All Randomized Patients (ITT) 
Table 14.1-24 Six Minute Walk Test Reasons Walk Duration Not Completed: All 
Randomized Patients (ITT) 
Table 14.2.1-1 Percent Predicted Forced Vital Capacity:  All Randomized Patients (ITT) 
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Name Title 
Table 14.2.1-2 Forced Vital Capacity Volume:  All Randomized Patients (ITT) 
Table 14.2.1-3 Forced Vital Capacity 5% Categories: All Randomized Patients (ITT) 
Table 14.2.2-1 Distance Walked (Meters) in 6-Minute Walk Test:  All Randomized Patients 
(ITT) 
Table 14.2.2-2 Time to Event Analysis of Progression-Free Survival: All Randomized 
Patients (ITT) 
Table 14.2.2-3 Total Score of UCSD Shortness of Breath Questionnaire:  All Randomized 
Patients (ITT) 
Table 14.2.2-4 Time to Event Analysis of All Cause Mortality: All Randomized Patients 
(ITT) 
Table 14.2.2-5 Time to Event Analysis of Treatment-Emergent IPF-related Mortality: All 
Randomized Patients (ITT) 
Table 14.2.2-6 Time to Event Analysis of IPF-related Mortality: All Randomized Patients 
(ITT) 
Table 14.2.2-7 Time to Event Analysis of Treatment-Emergent All Cause Mortality: All 
Randomized Patients (ITT) 
Table 14.2.2-8 Time to Event Analysis of All Cause Mortality: All Randomized Patients 
Studies PIPF-004, PIPF-006, PIPF-016 
Table 14.2.2-9 Time to Event Analysis of Treatment-Emergent IPF-related Mortality: All 
Randomized Patients Studies PIPF-004, PIPF-006, PIPF-016 
Table 14.2.2-10 Time to Event Analysis of IPF-related Mortality: All Randomized Patients 
Studies PIPF-004, PIPF-006, PIPF-016 
Table 14.2.2-11 Time to Event Analysis of Treatment-Emergent All Cause Mortality: All 
Randomized Patients Studies PIPF-004, PIPF-006, PIPF-016 
Table 14.3.1-1 Overview of Treatment-Emergent Adverse Events and Deaths: All Treated 
Patients (Safety) 
Table 14.3.1-2 Summary of Treatment-Emergent Adverse Events Showing Events and 
Patients with Events:  All Treated Patients (Safety) 
Table 14.3.1-3 Summary of Treatment-Emergent Adverse Events by Decreasing Frequency: 
All Treated Patients (Safety) 
Table 14.3.1-4 Summary of Treatment-Emergent Treatment-Related Adverse Events: All 
Treated Patients (Safety) 
Table 14.3.1-5 All Treatment-Emergent Adverse Events by Highest Relationship to Study 
Treatment:  All Treated Patients (Safety) 
Table 14.3.1-6 All Treatment-Emergent Adverse Events by Maximum Severity: All Treated 
Patients (Safety) 
Table 14.3.1-7 Treatment-Emergent Adverse Events that are Severe or Life-Threatening: All 
Treated Patients (Safety) 
Table 14.3.2-1 All Treatment-Emergent Serious Adverse Events Showing Events and 
Patients with Events: All Treated Patients (Safety) 
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Name Title 
Table 14.3.2-2 All Treatment-Emergent Serious Adverse Events by Decreasing Frequency: 
All Treated Patients (Safety) 
Table 14.3.2-3 All Treatment-Emergent Treatment-Related Serious Adverse Events: All 
Treated Patients (Safety) 
Table 14.3.2-4 All Treatment-Emergent Serious Adverse Events by Highest Relationship to 
Study Treatment: All Treated Patients (Safety) 
Table 14.3.2-5 All Treatment-Emergent Serious Adverse Events by Maximum Severity: All 
Treated Patients (Safety) 
Table 14.3.2-6 Treatment-Emergent Adverse Events Resulting in Study Treatment 
Discontinuation: All Treated Patients (Safety) 
Table 14.3.2-7 Treatment-Emergent Adverse Events Resulting in Study Treatment Decrease 
or Interruption: All Treated Patients (Safety) 
Table 14.3.2-8 Adverse Events Resulting in Withdrawal from the Study: All Treated 
Patients (Safety) 
Table 14.3.2-9 Incidence of Death: All Treated Patients (Safety) 
Table 14.3.2-10 Mortality Assessment Committee Cause of Death: All Treated Patients 
(Safety) 
Table 14.3.2-11 Investigator Assessment of Cause of Death: All Treated Patients (Safety) 
Table 14.3.2-12 Incidence of Lung Transplantation: All Treated Patients (Safety) 
Table 14.3.4-1 Laboratory Assessments for Blood Chemistry by Scheduled Visit: All 
Treated Patients (Safety) 
Table 14.3.4-2 Laboratory Assessments for Hematology by Scheduled Visit: All Treated 
Patients (Safety) 
Table 14.3.4-3 Serum Chemistry Shift Table: All Treated Patients (Safety) 
Table 14.3.4-4 Hematology Shift Table: All Treated Patients (Safety) 
Table 14.3.4-5 Grade 3/4 Serum Chemistry Toxicity: All Treated Patients (Safety) 
Table 14.3.4-6 Grade 3/4 Hematology Toxicity: All Treated Patients (Safety) 
Table 14.3.5-1 Specific Liver-Related Laboratory Outcomes 
Table 14.3.5-2 Time to Event of Elevation of AST or ALT (> 5 X ULN) 
Table 14.3.5-3 Worst Liver-Related Laboratory Outcomes 
Table 14.3.4-7 Vital Signs by Scheduled Visit: All Treated Patients (Safety) 
Figure 14.1-1 
 
Kaplan-Meier Plot of the Time to Early Withdrawal From Study: All 
Randomized Patients (ITT) 
Figure 14.1-2 Kaplan-Meier Plot of the Time to Permanent Discontinuation From Study 
Treatment: All Treated Patients (Safety) 
Figure 14.1-3 Number of Patients on Study by Time: All Randomized Patients (ITT) 
Figure 14.1-4 Number of Patients on Study Treatment by Time: All Treated Patients 
(Safety) 
Figure 14.2.1-1 Ogive Plot of Change from Baseline to Week 52 in Percent Predicted Forced 
Vital Capacity: All Randomized Patients (ITT) 
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Name Title 
Figure 14.2.1-2 Plot of Percent Predicted Forced Vital Capacity Based on Mixed Linear 
Model (With Imputation): All Randomized Patients (ITT) 
Figure 14.2.2-1 Ogive Plot of Change from Baseline to Week 52 in the Distance Walked 
(Meters) in 6-Minute Walk Test: All Randomized Patients (ITT) 
Figure 14.2.2-2 Kaplan-Meier Plot of IPF Progression-Free Survival: All Randomized 
Patients (ITT) 
Figure 14.2.2-3 Ogive Plot of Change from Baseline to Week 52 in UCSD SOBQ Total 
Score: All Randomized Patients (ITT) 
Figure 14.2.2-4 Kaplan-Meier Plot of All Cause Mortality: All Randomized Patients (ITT) 
Figure 14.2.2-5 Kaplan-Meier Plot of Treatment-Emergent IPF-related Mortality: All 
Randomized Patients (ITT) 
Figure 14.2.2-6 Kaplan-Meier Plot of IPF-related Mortality: All Randomized Patients (ITT) 
Figure 14.2.2-7 Kaplan-Meier Plot of Treatment-Emergent All Cause Mortality: All 
Randomized Patients (ITT) 
Figure 14.2.2-8 Kaplan-Meier Plot of All Cause Mortality: All Randomized Patients Studies 
PIPF-004, PIPF-006, PIPF-016 
Figure 14.2.2-9 Kaplan-Meier Plot of Treatment-Emergent IPF-related Mortality: All 
Randomized Patients Studies PIPF-004, PIPF-006, PIPF-016 
Figure 14.2.2-10 Kaplan-Meier Plot of IPF-related Mortality: All Randomized Patients 
Studies PIPF-004, PIPF-006, PIPF-016 
Figure 14.2.2-11 Kaplan-Meier Plot of Treatment-Emergent All Randomized Patients Studies 
PIPF-004, PIPF-006, PIPF-016 
Figure 14.3-1 Kaplan-Meier Plot of Time to AST or ALT > 5 x ULN 
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AMENDMENT 1: CHANGES TO 
STATISTICAL ANALYSIS PLAN PIPF-016 
 
Summary of Changes 
In this amendment, 16 changes have been made to this Statistical Analysis plan: 
1. Updated contact information 
Affected text:  
TITLE PAGE 
2. Clarified text on Demographic and Baseline Characteristics  
Affected text:  
Section 10 Patient Demographics and Baseline Characteristics 
3. Changed end date for Prior Medications 
Affected text:  
Section 11.1 Prior Medications 
4. Clarified text on Concomitant Medications 
Affected text:  
Section 11.2 Concomitant Medications 
5. Modified selected CYP1A2 inhibitors 
Affected text:  
Section 11.2.1 Concomitant Use of Selected Medications 
6. Modified text on Compliance to simplify and removing programing specific wording 
Affected text:  
Section 12.2.2 Patient Compliance with Study Drug Regimen 
7. Changed units from Month to Week for the Duration of Exposure summary 
Affected text:  
Section 12.2.3 Duration of Exposure to Study Drug 
8. Clarified the text on Primary Efficacy Analysis and modified the allocation of 0% 
change within the categorical summaries of %FVC and FVC volume 
Affected text:  
Section 12.3.2 Primary Efficacy Analysis 
9. Modified the model and the allocation of 0 meters change within the categorical 
summary of 6MWT Distance 
Affected text:  
Section 12.3.3.1.1 Change from Baseline to Week 52 in Distance Walked in the 6MWT 
10. Fixed censoring rule for Progression-Free Survival Analysis 
Affected text:  
Section 12.3.3.1.2 Progression Free Survival 
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11. Modified the allocation of 0 points change within the categorical summary of the 
UCSD SOBQ score 
Affected text: 
Section 12.3.3.2.1 Change from Baseline to Week 52 in Dyspnea (UCSD SOBQ Score) 
12. Clarified text on Mortality Analysis 
Affected text:  
Section 12.3.3.2.2 Mortality 
13. Added Analyses for Adverse Events 
Affected text:  
Section 12.4.1 Adverse Events 
14. Clarified Analyses for Death 
Affected text:  
Section 12.4.2 Death 
15. Updated Special Assessments of Potential Hepatotoxicity  
Affected text:  
Section 12.4.4 Special Assessments of Potential Hepatotoxicity 
16. Added Appendix A 
Affected text: 
Appendix A 
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Specific Changes in Amendment 1 of SAP PIPF-016 
Specific changes of substance to the SAP are listed below. Excerpts of the original text are 
followed by excerpts of the revised text with changes highlighted in bold. Minor administrative 
changes to enhance readability, to correct minor grammatical issues, or to clarify methods are 
excluded. 
1 Updated contact information 
 Change and 
Rationale: 
Update information for the SAP Sponsor’s Medical Officer and Statisticians 
 Section: TITLE PAGE 
 Original 
Text: 
Williamson Bradford, MD, PhD 
Senior Vice President, Clinical Science and Biometrics 
and 
Spencer Hudson, PhD 
Vice President, Biometrics 
 Revised Text: Robert Fishman, MD  
Senior Vice President, Clinical Development 
and 
Zhengning Lin, PhD 
Vice President, Biometrics 
2 Clarified text on Demographic and Baseline Characteristics 
 Change and 
Rationale: 
Text was modified and added to remove ambiguity and clarify methods 
 Section: Section 10 Patient Demographics and Baseline Characteristics 
 Original 
Text: 
Treatment group differences between placebo and pirfenidone 2403 mg/d will be 
evaluated using the Chi-squared test for dichotomous nonordinal data or the 
Cochran-Mantel-Haenszel test (with modridit scores) for ordinal data. Baseline 
data will be defined as the last observation before randomization except for 
efficacy variables, which will be defined as specified in Section 12.3. Data 
collected on study Day 1 is assumed to be collected before randomization and 
dosing. 
 Revised Text: Treatment group differences between placebo and pirfenidone 2403 mg/d will be 
evaluated using the chi-squared test for dichotomous or non-ordinal data or the 
extended Mantel-Haenszel test (with modified ridit row mean scores) for 
ordinal data (see Chapter 4, Stokes et al 2000)…Baseline data collected on Study 
Day 1 is assumed to be collected before randomization and dosing. 
Baseline FVC and DLco measurements were performed according to 
standardized guidelines (Miller et al 2005; Macintyre 2005). As described in 
Appendix A, percent predicted FVC and percent predicted DLco were 
calculated using the formulae of Crapo et al. (1981), TLCO measurements 
were converted to DLCO to determine eligibility using the formula of 
PIPF-016 Statistical Analysis Plan 
InterMune │ Confidential & Proprietary │ Page 5 of 44 
MacIntyre et al (2005), and all DLCO measurements were adjusted for the 
patient’s hemoglobin level using the formula of Cotes et al (1979). 
3 Changed end date for Prior Medications 
 Change and 
Rationale: 
The end of prior medication period was changed from Randomization date to 
First dose date to be consistent with concomitant medication interval and because 
medication use is primarily a safety concern. 
 Section: Section 11.1 Prior Medications 
 Original 
Text: 
Prior medications taken after informed consent is signed and before 
randomization, will be summarized by treatment group. In addition, prior 
medications taken between 28 days (inclusive) before Screening and the date of 
randomization will be summarized by treatment group. 
 Revised Text: Prior medications taken after informed consent is signed and before the first 
dose of study drug will be summarized by treatment group. In addition, prior 
medications taken within the protocol window (between 28 days (inclusive) 
before Screening and the date of first study drug dose) will be summarized by 
treatment group. 
4 Clarified text on Concomitant Medications 
 Change and 
Rationale: 
Modified summary of concomitant medication to only include period concurrent 
with study drug and clarified additional summary of medications with a 
pulmonary indication. The concomitant medication period was modified to be 
more specific about which medications have the most potential to have safety 
interactions with pirfenidone dosing. 
 Section: Section 11.2 Concomitant Medications 
 Original 
Text: 
Concomitant medications are medications other than study drug that a patient 
reports taking between the first dose and up to 28 days after the last dose of study 
drug. These include medications that are taken before the first dose of study drug 
and continue to be taken during study treatment. Concomitant medications will 
be summarized by treatment group. In addition any medications taken more 
than 28 days after last dose will be summarized by treatment group 
 Revised Text: Concomitant medications are medications other than study drug that a patient 
reports taking between the first dose and last dose of study drug. These include 
medications that are taken before the first dose of study drug and continue to be 
taken during study treatment. Concomitant medications will be summarized by 
treatment group. 
All concomitant medications were to be collected until 28 days (inclusive) 
after the last dose of study treatment; thereafter, for patients who 
discontinued study treatment early, only concomitant medications used for 
pulmonary indications were collected, until the last study visit. Medications 
with a pulmonary indication taken after the last study drug dose will be 
summarized by treatment group. 
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5 Modified selected CYP1A2 inhibitors 
 Change and 
Rationale: 
Cimetidine was removed from selected CYP1A2 list. Propafenone and Zileuton 
were added after an updated literature review  
 Section: Section 11.2.1 Table 1 Selected Concomitant Medications Classified by 
WHO Drug Dictionary ATC Codes 
 Original 
Text: Cimetidine 
 Revised Text: Propafenone, Zileuton 
6 Modified text on Compliance to simplify and remove programming specific wording 
 Change and 
Rationale: 
Removed text that consisted primarily of the specifications for programming the 
compliance calculations because details of these calculations will be provided in 
the computational methods. 
 Section: Section 12.2.2 Patient Compliance with Study Drug Regimen 
 Original 
Text: 
The calculation for compliance is the numerator divided by denominator 
multiplied by 100. 
The numerator is: 
The sum of  
(stop date − start date + 1) × number of capsules/day taken 
The denominator is: 
The sum of  
(stop date − start date + 1) × number of capsules/day prescribed 
Where the summation is from the first dose on the Study Treatment Dosing 
CRF page up to Week 52B, death, or lung transplant. This ratio is then 
multiplied by 100. 
If the patient discontinues for any reason other than death or lung 
transplantation before Week 52, then the compliance estimate will be 
calculated as: 
(compliance for the period to the date of discontinuation ×  
number of days on study treatment) / (52 weeks × 7 days per week) 
In addition compliance while on treatment will be calculated as 100 times 
the actual number of capsules taken from the first dose to the last dose on 
the Study Treatment Dosing CRF page divided by the prescribed number of 
capsules until study treatment discontinuation. 
 Revised Text: These calculations are based on the study treatment dosing CRF, which is 
completed based on patient diary entries, discussion with each patient, and 
review of the number of capsules returned. 
7 Changed units from Month to Week for the Duration of Exposure summary 
 Change and 
Rationale: 
Changed units from “Month” to “Week” for the Duration of Exposure summary 
to be consistent with the rest of the report. 
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 Section: Section 12.2.3 Duration of Exposure to Study Drug 
 Original 
Text: 
Total duration of exposure will also be summarized by number and percent of 
patients exposed for specific periods of time, including >0 to less than 3 months, 
3 to less than 6 months, 6 to less than 9 months, 9 to less than 12 months, 
greater than or equal to 12 months. A month is defined as the number of 
days from first until last exposure to study drug times 12 divided by 365.25. 
 Revised Text: Total duration of exposure will also be summarized by number and percent of 
patients exposed for specific periods of time, including >0 to less than 13 weeks, 
13 to less than 26 weeks, 26 to less than 39 weeks, 39 to less than 52 weeks, 
and greater than or equal to 52 weeks. 
8 Clarifed the text on Primary Efficacy Analysis and modified the allocation of 0% change 
within the categorical summaries of %FVC and FVC volume 
 Change and 
Rationale: 
Clarified the handling of multiple baseline assessments. Changed the allocation 
of 0% change from the “Stability or Improvement” category to the “Decline of 
<10%” category to be consistent with the previous PIPF-004 and PIPF-006 
studies and changed “Stability or Improvement” to “No Decline.” Reordered 
supportive analyses for clarity. Specified that baseline %FVC will be ranked to 
remove ambiguity. 
 Section: Section 12.3.2 Primary Efficacy Analysis 
 Original 
Text: 
Week 52 %FVC will be defined as the mean of the FVC measurements obtained 
as part of the Week 52 visit; if either is missing, the non-missing value will be 
used. If both values are missing, the data will be imputed as specified in Section 
14. 
The magnitude of the treatment effect of pirfenidone will be presented as the 
distribution (number and percentage) of patients across the following categories 
of change from Baseline: 
• Decline of ≥10% or death before the Week 52 visit 
• Decline of <10% to >0% 
• Stability or improvement of ≥0% 
Also, an ogive plot of the change from Baseline to Week 52 will be provided. 
Supportive analyses of the primary efficacy outcome will include the following: 
1. A repeated measures mixed linear model for rank change from Baseline 
in %FVC will be presented, using ranks calculated for change to Weeks 
13, 26, 39, and 52. The mixed model will include fixed effects for 
treatment; covariates for Baseline %FVC, and a repeated effect of 
assessment week, unstructured covariance structure, and patient as the 
subject factor. Treatment effect will be tested at each visit (with a 
treatment by visit interaction term) and overall. Patients who die will be 
ranked worse than all other recorded data at the corresponding 13 week 
visit following the death and then within this group will be ranked by 
time until death. 
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2. Change from Baseline to Weeks 13, 26, 39, and 52 in FVC volume. This 
analysis will use the same analysis methods as the primary efficacy 
analysis, ranking the relative change in volume. The relative change is 
defined for each 13-week visit as (visit FVC volume-Baseline FVC 
volume)/Baseline FVC volume. The magnitude of the treatment effect of 
pirfenidone will be presented as the distribution (number and percentage) 
of patients across the following categories of change from Baseline: 
• Relative decline of ≥10% or death before the corresponding 13-
week visit 
• Relative decline of <10% to >0% 
• Stability or improvement of ≥0% 
Landmark analyses of change from Baseline in %FVC to Weeks 13, 26, and 39. 
These will use the same analysis methods and summary of treatment effect as the 
primary efficacy analysis 
 Revised Text: If there are more than two assessment days prior to randomization the two 
dates closest to randomization will be used. Week 52 %FVC will be defined as 
the mean of the FVC measurements obtained as part of the Week 52 visit; if 
either is missing, the non-missing value will be used. If both values are missing, 
the data will be imputed as specified in Section 14. 
The magnitude of the treatment effect of pirfenidone will be presented as the 
distribution (number and percentage) of patients across the following categories 
of change from Baseline to Week 52: 
• Decline of ≥10% or death 
• Decline of <10% to ≥0% 
• No Decline (%FVC change >0%) 
Also, an ogive plot of the change from Baseline to Week 52 will be provided. 
Supportive analyses of the primary efficacy outcome will include the following: 
1. Landmark analyses of change from Baseline in %FVC to Weeks 13, 
26, and 39. These will use the same analysis methods and summary 
of treatment effect as the primary efficacy analysis. 
2. A repeated measures mixed linear model for rank change from Baseline 
in %FVC will be presented, using ranks calculated for change to Weeks 
13, 26, 39, and 52. The mixed model will include fixed effects for 
treatment; covariates for Ranked Baseline %FVC, and a repeated effect 
of assessment week, unstructured covariance structure, and patient as the 
subject factor. Treatment effect will be tested at each visit (with a 
treatment by visit interaction term) and overall. Patients who die will be 
ranked worse than all other recorded data at the corresponding 13 week 
visit following the death and then within this group will be ranked by 
time until death. 
3. Change from Baseline to Weeks 13, 26, 39, and 52 in FVC volume. This 
analysis will use the same analysis methods as the primary efficacy 
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analysis, ranking the relative change in volume. The relative change is 
defined for each 13-week visit as (visit FVC volume-Baseline FVC 
volume)/Baseline FVC volume. The magnitude of the treatment effect of 
pirfenidone will be presented as the distribution (number and percentage) 
of patients across the following categories of change from Baseline: 
• Relative decline of ≥10% or death 
• Relative decline of <10% to 0% 
• No Decline (FVC volume change >0) 
9 Modified the model and the allocation of 0 meters change within the categorical summary of 
6MWT Distance 
 Change and 
Rationale: 
Ranked Baseline DLco was added to the analysis model for testing the treatment 
effect on the 6MWT distance because publications indicate a strong association 
between DLco and disease progression and this association was also observed in 
the PIPF-004 and PIPF-006 studies. Adding DLco to the analysis model for 
6MWT should increase the statistical power for detecting a treatment difference 
for this key secondary endpoint which has relatively low statistical power due to 
large data variation. 
Changed the allocation of 0 meters from the “Stability or Improvement” category 
to the “Decline of <50 m” category to be consistent with the allocation of 0% 
change for %FVC, the primary efficacy variable, and changed “Stability or 
Improvement” to “No Decline.” 
 Section: Section 12.3.3.1.1 Change from Baseline to Week 52 in Distance Walked in 
the 6MWT 
 Original 
Text: 
Data will be analyzed using a rank ANCOVA model similar to that outlined in 
Section 12.3.1 including ranking patients who die worst according to time until 
death. 
Later in this section 
The magnitude of the treatment effect of pirfenidone will be presented as the 
distribution (number and percentage) of patients across the following categories 
of change from Baseline: 
• Decline of ≥50 meters (m) or death before the corresponding 13-
week visit 
• Decline of <50 m to >0 m 
• Stability or Improvement of ≥0 m 
 Revised Text: Data will be analyzed using a rank ANCOVA model, with ranked Baseline 
6MWT distance and ranked Baseline DLco as covariates. As outlined in 
Section 12.3.1, patients who die will be ranked worst, according to time until 
death. 
Later in this section 
The magnitude of the treatment effect of pirfenidone will be presented as the 
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distribution (number and percentage) of patients across the following categories 
of change from Baseline: 
• Decline of ≥50 meters (m) or death 
• Decline of <50 m to 0 m 
• No Decline (6MWT distance change >0 m) 
10 Fixed censoring rule for Progression-Free Survival Analysis 
 Change and 
Rationale: 
Added Lung Transplant to list defining Deaths that will not be counted for 
Progression for consistency with Survival analyses. 
 Section: Section 12.3.3.1.2 Progression-Free Survival 
 Original 
Text: 
Patients who die before progression will be counted as a death event unless the 
death is after Week 52B or more than 182 days after the last available %FVC or 
6MWT distance assessment or more than 364 days after randomization. 
 Revised Text: Patients who die before progression will be counted as a death event unless the 
death is after the Week 52 visit or more than 182 days after the last available 
%FVC or 6MWT distance assessment or more than 364 days after randomization 
(ie, Study Day 365) or after Lung Transplantation. 
 
11 Modified the allocation of 0 points change within the categorical summary of the UCSD 
SOBQ score 
 Change and 
Rationale: 
Changed the allocation of 0 points change from the “Stability or Decrease” 
category to the “Increase of <20” category to be consistent with the allocation of 
0% for %FVC, the primary efficacy variable, and changed “Increase of” and 
“Stability or Decrease” to “Worsening of” and “No Worsening,” respectively. 
 Section: Section 12.3.3.2.1 Change from Baseline to Week 52 in Dyspnea (UCSD 
SOBQ Score) 
 Original 
Text: 
The magnitude of the treatment effect of pirfenidone will be presented as the 
distribution (number and percentage) of patients across the following categories 
of change from Baseline: 
• Increase of ≥20 or death before the corresponding 13-week visit 
• Increase of <20 to >0 
• Stability or Decrease of ≥0 
 Revised Text: Missing UCSD SOBQ scores will be imputed as specified in Section 14.1. 
The magnitude of the treatment effect of pirfenidone will be presented as the 
distribution (number and percentage) of patients across the following categories 
of change from Baseline: 
• Worsening of UCSD SOBQ score ≥20 points or death  
• Worsening of UCSD SOBQ score <20 to 0 points 
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• No Worsening (UCSD SOBQ score change <0 points). 
12 Clarify text on Mortality Analysis 
 Change and 
Rationale: 
Definition of IPF-related mortality for the efficacy analysis was specified and 
censoring and model specifications were clarified. Study Day 364 was changed 
to Study Day 365 to remove inconsistency with Section 12.3.3.1.2 where the 
term “more than 364 days after randomization” (which is Study Day 365) is used. 
 Section: Section 12.3.3.2.2 Mortality 
 Original 
Text: 
The two mortality endpoints are all-cause mortality and treatment-emergent IPF-
related mortality. Patients who discontinue study treatment before Week 52 will 
be followed for vital status through Week 52. All-cause mortality will include 
events occurring in this extended period. Supportive endpoints are IPF-related 
mortality and treatment-emergent all-cause mortality. Treatment-emergent 
mortality is defined as deaths that occur between randomization and the 
earlier of the Week 52B visit or 28 days (inclusive) after the last dose of 
blinded study treatment. Relationship of cause of death to IPF will be assessed 
by the Mortality Assessment Committee (MAC). 
Mortality will be compared between the pirfenidone 2403 mg/d and placebo 
groups using the product limit method log-rank test (Kalbfleisch and Prentice 
1980); the pooled analysis will be stratified by study. A proportional hazards 
model with only treatment in the model for the study analysis and treatment 
and study in the model for the pooled analysis will be used to estimate the 
hazard ratio, ties will be handled with the approximate likelihood method of 
Efron (1977). Kaplan-Meier estimates will be used to summarize each survival 
time analysis. Patients who are alive and complete the study will be censored at 
the Week 52B visit. Most patients who complete Week 52B are expected to roll 
over into an open-label study. Patients who discontinue regular study visits will 
be censored at the earliest of (a) Study Day 364, (b) the last available contact date 
(including contact after discontinuation of regular study visits), or (c) date of lung 
transplantation. 
The following summaries will be tabulated by treatment group for the analysis: 
the total number of patients included in the analysis (as event or as censored), the 
number of deaths, the number of censored patients, the appropriate quantiles to 
summarize survival time, the magnitude of treatment effect estimated by HR, and 
survival probabilities for each 13-week period from Baseline to Week 52. 
Mortality data from this study also will be pooled with the data from Studies 
PIPF-004 and PIPF-006. For the pooled analysis, the PIPF-004 and PIPF-006 
results will be censored at Week 52 if an event has not occurred earlier in order 
to allow the three studies to contribute comparable follow-up time to the pooled 
analysis. There was no MAC for studies PIPF-004 and PIPF-006; therefore, the 
assessment of relationship of cause of death to IPF by the investigator will be 
used. 
 Revised Text: The two mortality secondary endpoints are all-cause mortality and treatment-
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emergent IPF-related mortality. Patients who discontinue study treatment before 
Week 52 will be followed for vital status through Week 52, and all-cause 
mortality will include events occurring in this extended period. Treatment-
emergent mortality is defined as deaths that occur between randomization and the 
earlier of the Week 52 visit or for patients that discontinue study treatment 
early, 28 days (inclusive) after the last dose of study treatment. Relationship of 
cause of death to IPF will be assessed by the Mortality Assessment Committee 
(MAC) and classified into one of four categories: 1) death directly caused by 
IPF; 2) IPF indirectly contributed to death; 3) IPF has not contributed to 
death; and 4) unknown contribution of IPF to death. IPF-related mortality 
will be defined based on the MAC classification of death as “directly caused 
by IPF”. Supportive mortality endpoints are IPF-related mortality and 
treatment-emergent all-cause mortality. 
Mortality will be compared between the pirfenidone 2403 mg/d and placebo 
groups using the product limit method log-rank test (Kalbfleisch and Prentice 
1980). A proportional hazards model with only treatment in the model will be 
used to estimate the hazard ratio; ties will be handled with the approximate 
likelihood method of Efron (1977). Kaplan-Meier estimates will be used to 
summarize each survival time analysis. Patients who are alive and have a Week 
52 visit will be censored at that Week 52 visit. Most patients who complete 
Week 52 are expected to roll over into an open-label extension study. Patients 
who discontinue regular study visits, including not completing the Week 52 
visit, will be censored at the earliest of (a) Study Day 365, (b) the last available 
contact/known to be alive date (including contact after discontinuation of regular 
study visits), or (c) date of lung transplantation. Deaths that occur after 
censoring will not be counted as events for these survival analyses of 
mortality. For IPF-related mortality, patients will be censored following the 
same rules as for all-cause mortality except that patients with non IPF-
related death will be censored at the date of death if they are not censored 
earlier. 
Treatment emergent mortality and Treatment emergent IPF-related 
mortality will be handled with the same methods as mortality and IPF-
related mortality, respectively, with the exception that Treatment emergent 
deaths are those that occur after the first dose of study treatment and within 
28 days of the last dose of study treatment. 
The following summaries will be tabulated by treatment group for the analysis: 
the total number of patients included in the analysis (as event or as censored), the 
number of deaths, the number of censored patients, the appropriate quantiles to 
summarize survival time, the magnitude of treatment effect estimated by the 
hazard ratio, and survival probabilities for each 13-week period from Baseline 
to Week 52. 
Mortality data from Study PIPF-016 also will be pooled with data from the 
pirfenidone 2403 mg/d and placebo groups from Studies PIPF-004 and PIPF-
006. For the pooled analysis, the PIPF-004 and PIPF-006 results will be censored 
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at Study Day 365 if an event has not occurred earlier in order to allow the three 
studies to contribute comparable follow-up times to the pooled analysis. There 
was no MAC for studies PIPF-004 and PIPF-006; therefore, the assessment of 
relationship of cause of death to IPF by the investigator will be used. Mortality 
will be compared between the pirfenidone 2403 mg/d and placebo groups 
using the product limit method log-rank test, stratified by study and 
geographic region (USA and rest of world (ROW)). A proportional hazards 
model with treatment, study and geographic region (USA and ROW) in the 
model will be used to estimate the hazard ratio; ties will be handled with the 
approximate likelihood method of Efron (1977). 
13 Added Analyses for Adverse Events 
 Change and 
Rationale: 
Additional summaries of adverse events were specified for completeness. 
 Section: Section 12.4.1 Adverse Events 
 Original 
Text: 
• Treatment-emergent AEs 
• Treatment-emergent SAEs 
• Treatment-emergent treatment-related AEs 
• Treatment-emergent treatment-related SAEs 
• AEs leading to early discontinuation of study treatment 
• AEs resulting in withdrawal from study 
• Treatment-emergent AEs with Grade 3 (severe) or 4 (life-threatening) 
severity 
 Revised Text: • Treatment-emergent AEs 
• Treatment-emergent SAEs 
• Treatment-emergent treatment-related AEs 
• Treatment-emergent treatment-related SAEs 
• AEs leading to early discontinuation of study treatment 
• SAEs leading to early discontinuation of study treatment 
• AEs leading to study treatment decrease or interruption 
• SAEs leading to study treatment decrease or interruption 
• AEs resulting in withdrawal from study 
• SAEs resulting in withdrawal from study 
• Treatment-emergent AEs with Grade 3 (severe) or 4 (life-threatening) 
severity 
• Treatment-emergent SAEs with Grade 3 (severe) or 4 (life-threatening) 
severity 
14 Clarified Analyses for Death 
 Change and The summary was changed to be based on Treatment emergent deaths to reflect 
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Rationale: the safety focus of the tables. MAC scoring of the IPF-relatedness of the deaths 
was added. 
 Section: Section 12.4.2 Death 
 Original 
Text: 
All reported deaths will be analyzed. All-cause and IPF-related deaths as 
assessed by the MAC will be summarized by treatment group. Crude mortality 
rates will be computed as the total number of deaths divided by the total number 
of patients exposed in each treatment group. In addition, IPF-related mortality 
(i.e., IPF-related versus non–IPF-related) will also be summarized. 
 Revised Text: All reported deaths will be analyzed. Treatment emergent All-cause and 
Treatment emergent IPF-related deaths as assessed by the MAC will be 
summarized by treatment group. Mortality rates will be computed as the total 
number of deaths divided by the total number of patients exposed in each 
treatment group. In addition, the IPF-relatedness of each death according to 
the assessment of the MAC (as described in Section 12.3.3.2.2) will be 
summarized. 
15 Updated Special Assessments of Potential Hepatotoxicity 
 Change and 
Rationale: 
Summary of Potential Hepatotoxicity was expanded to aid in the assessment of 
potential liver effects. 
 Section: Section 12.4.4 Special Assessments of Potential Hepatotoxicity 
 Original 
Text: 
12.5.4.1 Modified Hy’s Rule 
Using the modified Hy’s rule by Bjornsson and Olsson (Bjornsson and Olsson 
2005), the incidence of patients with ALT or AST values greater than 3 times the 
upper limit of normal (ULN) and total bilirubin greater than 2 times the ULN 
(based on the same blood draw of ALT, AST, and total bilirubin while on study 
drug) will be used to assess the potential for study drug-induced liver toxicity. 
Later in this section 
The summary and plot of time from first study dose to the elevation of AST or 
ALT >5 x ULN will be analyzed using Kaplan-Meier estimates. A scatterplot of 
the post-Baseline maximum value of total bilirubin versus the maximum value of 
AST or ALT will be generated. 
 Revised Text: 12.4.4.1 Assessment of Potential Liver Toxicity 
The incidence of patients with ALT or AST values greater than 3 times the upper 
limit of normal (ULN) and total bilirubin greater than 2 times the ULN (based on 
the same blood draw of ALT, AST, and total bilirubin while on study drug) will 
be used to assess the potential for study drug-induced liver toxicity. 
Later in this section 
The summary and plot of time from first dose of study drug to the elevation of 
AST or ALT >5 × ULN will be analyzed using Kaplan-Meier estimates. 
Scatterplots, (ie, evaluation of drug-induced serious hepatotoxicity; eDISH), 
of the post-Baseline maximum value of total bilirubin versus the maximum value 
of AST, ALT and AST, or ALT will be generated. 
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16 Added Appendix A 
 Change and 
Rationale: 
Added Appendix A to specify the calculations of percent predicted FVC and 
percent predicted Hgb-corrected DLCO 
 Section: Appendix A Computational Formulas For Physiological Endpoints 
 Original 
Text: There was no appendix 
 Revised Text: (Entire Appendix A is added and is not reproduced here.) 
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16 Added Appendix A 
 Change and 
Rationale: 
Added Appendix A to specify the calculations of percent predicted FVC and 
percent predicted Hgb-corrected DLCO 
 Section: Appendix A Computational Formulas For Physiological Endpoints 
 Original 
Text: There was no appendix 
 Revised Text: (Entire Appendix A is added and is not reproduced here.) 
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3. LIST OF ABBREVIATIONS and DEFINITIONS OF TERMS 
Acronym/Abbreviation Definition 
6MWT 6-minute walk test 
%FVC percent predicted forced vital capacity 
AE adverse event 
ALT alanine aminotransferase 
ANCOVA analysis of covariance 
AST aspartate aminotransferase 
ATC Anatomical Therapeutic Chemical 
ATS American Thoracic Society 
CYP1A2 cytochrome P450 1A2 
CRF case report form 
d day 
DLCO carbon monoxide diffusing capacity 
DMC Data Monitoring Committee 
eDISH evaluation of drug-induced serious hepatotoxicity 
FVC forced vital capacity 
HLGT high-level grouped terms 
HLT high-level terms 
HR hazard ratio 
ITT Intent-to-treat (population) 
IPF idiopathic pulmonary fibrosis 
IXR interactive web or voice response system 
m meter 
MAC Mortality Assessment Committee 
MedDRA Medical Dictionary for Regulatory Activities 
mL milliliter 
mg milligram 
mg/d milligrams per day 
PFT pulmonary function testing 
ROW rest of world 
SAE serious adverse event 
SMQ Standardised MedDRA Queries 
SOC System Organ Class 
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Acronym/Abbreviation Definition 
SSD sum of squared differences 
TID three times per day 
UCSD SOBQ University of California at San Diego Shortness-of-Breath Questionnaire 
ULN upper limit of normal range 
WHODRUG World Health Organization Drug Dictionary 
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4. INTRODUCTION 
This statistical analysis plan describes statistical methods and data presentations to be used for 
the summary and analysis of the data from study: 
PIPF-016, “A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy 
and safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis” 
Detailed descriptions of the study design and conduct can be found in the protocol. 
5. STUDY DESIGN 
PIPF-016 is a Phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study 
of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). Approximately 500 patients 
at approximately 140 centers globally will be randomized with equal probability to receive either 
pirfenidone 2403 mg/d or placebo equivalent in divided doses three times per day (TID) with 
food. Study treatment is to stop for each patient 52 weeks after randomization. Patients 
discontinuing study treatment prior to that time are to remain on the study and continue to have 
full study assessments performed up to and including the Week 52 visit. 
The primary efficacy endpoint is: 
• Change in percent predicted forced vital capacity (%FVC) from Baseline to Week 52. 
The key secondary efficacy outcome variables are: 
• Change in 6-minute walk test (6MWT) distance from Baseline to Week 52 
• Progression-free survival, defined as the time to the first occurrence of any of the 
following: (a) death, (b) confirmed ≥10% absolute decline from Baseline in %FVC, 
and (c) confirmed ≥50-meter decline from Baseline in 6MWT distance 
Other secondary efficacy outcome variables are: 
• All-cause mortality 
• Treatment-emergent IPF-related mortality 
• Change from Baseline to Week 52 in dyspnea as measured by the University of 
California at San Diego Shortness-of-Breath Questionnaire (UCSD SOBQ) score 
6. STUDY OBJECTIVES 
The objectives of Study PIPF-016 are as follows: 
• To confirm the treatment effect of pirfenidone 2403 mg/d compared with placebo on 
change in %FVC in patients with idiopathic pulmonary fibrosis (IPF) 
• To confirm the safety of treatment with pirfenidone 2403 mg/d compared with 
placebo in patients with IPF 
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7. SAMPLE SIZE AND POWER 
This study is designed to provide at least 90% power to detect a treatment difference in 
normalized ranks of change in %FVC at Week 52 of 0.08 with a standard deviation of 0.27. For 
change in 6MWT distance, 250 patients per group will provide approximately 75% power to 
detect a difference in normalized ranks of 0.068 with a standard deviation of 0.285. A sufficient 
sample size was determined to be 500 patients, randomized in a 1:1 ratio of pirfenidone 
2403 mg/d to placebo. 
Parameter estimates for the sample size calculations are based on the experience in Studies 
PIPF-004 and PIPF-006. These calculations were generated using nQuery Advisor 5.0 software. 
In this 52-week study of pirfenidone to reduce decline in lung function, mortality is included as a 
secondary endpoint to provide supportive evidence of benefit, but the study has not been 
powered to show a significant mortality benefit. A sample size of 250 patients per group 
provides only 10% power with an alpha of 0.05 to detect a hazard ratio (HR) of 0.77 in all-cause 
mortality, the effect size observed in the pooled analyses of PIPF-004 and PIPF-006. 
Accordingly, the mortality analyses will be conducted on both the PIPF-016 dataset and on the 
pooled dataset that includes PIPF-004 and PIPF-006. Even so, pooling data from this study with 
those from the two previous studies provides less than 20% power to detect an HR of 0.77 at an 
alpha of 0.05. 
8. RANDOMIZATION 
After completing the informed consent process, eligible patients will be enrolled in the study. A 
patient number will be assigned by an interactive web or voice response system (IXR). Eligible 
patients will be randomly allocated in a ratio of 1:1 to receive either pirfenidone 2403 mg/d or 
placebo. The randomization will be permuted block randomization without stratification by site 
or any demographic or Baseline characteristic. 
9. ANALYSIS POPULATIONS 
The intent-to-treat (ITT) population, used for all efficacy analyses, will include all patients who 
signed informed consent and were randomized to study treatment. The safety population will 
include all patients who signed informed consent and received any amount of study drug. 
Patients will be analyzed according to the treatment arm to which they are randomized, 
regardless of treatment actually received. Receipt of the incorrect study drug will be classified as 
a protocol deviation. 
10. PATIENT DEMOGRAPHICS AND BASELINE 
CHARACTERISTICS 
Descriptive statistics will be used to summarize demographic and Baseline patient 
characteristics. Continuous variables (eg, age) will be summarized with number, mean, median, 
standard deviation, minimum, and maximum. Treatment group differences between placebo and 
pirfenidone 2403 mg/d will be evaluated using a two-sided t-test. Categorical variables (eg, sex) 
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will be summarized with number and percentage. Treatment group differences between placebo 
and pirfenidone 2403 mg/d will be evaluated using the chi-squared test for dichotomous or non-
ordinal data or the extended Mantel-Haenszel test (with modified ridit row mean scores) for 
ordinal data (see Chapter 4, Stokes et al 2000). Baseline data will be defined as the last 
observation before randomization except for efficacy variables, which will be defined as 
specified in Section 12.3; Baseline data collected on Study Day 1 is assumed to be collected 
before randomization and dosing. 
Baseline FVC and DLco measurements were performed according to standardized guidelines 
(Miller et al 2005; Macintyre 2005). As described in Appendix A, percent predicted FVC and 
percent predicted DLco were calculated using the formulae of Crapo et al. (1981), TLCO 
measurements were converted to DLCO to determine eligibility using the formula of MacIntyre et 
al (2005), and all DLCO measurements were adjusted for the patient’s hemoglobin level using the 
formula of Cotes et al (1979). 
Baseline medical conditions (comorbidities) reported in the Medical History Case Report Form 
(CRF) will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and 
summarized by treatment group for all treated patients in two tables. The first table will 
summarize all comorbidities reported on the CRF. The second will summarize only 
comorbidities that were ongoing on the date of randomization. 
11. PRIOR AND CONCOMITANT MEDICATIONS 
All prior and concomitant medications collected will be coded to the World Health Organization 
Drug Dictionary (WHODRUG). All coding will be reviewed by the study medical monitor. All 
tabulations of use of prior and concomitant medications will be summarized by the 2nd level 
Anatomical Therapeutic Chemical (ATC) grouping and the Preferred Name in the classification 
system of the WHODRUG, unless indicated otherwise. 
11.1. Prior Medications 
Prior medications, taken after informed consent is signed, and before the first dose of study drug, 
will be summarized by treatment group. In addition, prior medications taken within the protocol 
window (between 28 days (inclusive) before Screening and the date of first study drug dose) will 
be summarized by treatment group. 
11.2. Concomitant Medications 
Concomitant medications are medications other than study drug that a patient reports taking 
between the first dose and last dose of study drug. These include medications that are taken 
before the first dose of study drug and continue to be taken during study treatment. Concomitant 
medications will be summarized by treatment group. 
All concomitant medications were to be collected until 28 days (inclusive) after the last dose of 
study treatment; thereafter, for patients who discontinued study treatment early, only 
concomitant medications used for pulmonary indications were collected, until the last study visit. 
Medications with a pulmonary indication taken after the last study drug dose will be summarized 
by treatment group. 
PIPF-016 Statistical Analysis Plan 
InterMune │ Confidential & Proprietary │ Page 23 of 44 
11.2.1. Concomitant Use of Selected Medications 
The use of specific cytochrome P450 1A2 (CYP1A2) inhibitors, listed in Table 1, will be 
summarized to facilitate assessment of potential signals in subsequent analyses of safety. These 
concomitant medications were chosen because their pathway of hepatic metabolism may be 
common to that of pirfenidone. These medications are classified by pharmacologic/therapeutic 
subgroup (2nd level), as well as certain specified subgroup ATC codes of the WHODRUG. 
 
Table 1: Selected Concomitant Medications Classified by 
WHO Drug Dictionary ATC Codes 
ATC Code1 CYP 1A2 Inhibitor 
C01BB02 Mexiletine 
C01BD01 Amiodarone 
C01BC03 Propafenone 
D05AD02 Methoxsalen 
J01MA02 Ciprofloxacin 
J01MA04 Enoxacin 
N06AB08 Fluvoxamine 
G03A Hormonal contraceptives for systemic use 
R01BA01 Phenylpropanolamine 
P02CA02 Tiabendazole 
 Zileuton 
1 ATC code is listed if available 
 
The summary of CYP1A2 inhibitors will be displayed by study treatment group for all patients 
who receive study drug. 
11.2.2. Prohibited Use of Medications 
The concomitant use of certain medications is prohibited because of their potential to affect the 
safety or efficacy of pirfenidone. The prohibited use of medications while on study treatment 
will be tabulated. 
Use of systemic corticosteroids for protocol-defined acute IPF exacerbation is permitted up to 
21 consecutive days, but prohibited if used for 21 or more consecutive days. Use of systemic 
corticosteroids is prohibited for any IPF indication other than acute exacerbation but is permitted 
for all other indications. 
Prohibited medications, classified by the WHODRUG ATC codes if applicable, are listed in 
Table 2. Additional medications may be included as prohibited if a review of concomitant 
medication reveals other prohibited medication use, for example, investigational medications not 
anticipated. 
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The summary of the concomitant use of these prohibited or restricted medications during study 
treatment will be displayed by study treatment group for all treated patients. 
 
Table 2: Prohibited Medications Classified by WHO Drug Dictionary ATC Codes 
ATC Codea Useb Medication 
  Antithrombotic Agents 
B01AA03 II Warfarin 
B01AB II Heparin group 
B01AC11 I Iloprost 
  Antihypertensives 
C02KX01 I Bosentan 
C02KX02 I Ambrisentan 
  Agents Acting on the Renin-Angiotensin System 
C09A II ACE inhibitors, plain 
  Lipid Modifying Agents 
C10AA II HMG CoA reductase inhibitors 
  Urologicals 
G04BE03 II Sildenafil 
G04BE08 II Tadalafil 
G04BE09 II Vardenafil 
H02 III Corticosteroids for Systemic Use 
  Antineoplastic Agents 
L01AA01 I Cyclophosphamide 
L01XE I Protein kinase inhibitors 
L01XX28 I Imatinib 
  Immunostimulants 
L03AB I Interferons 
L03AC I Interleukins 
L03AX I Other cytokines and immunomodulators 
  Immunosuppressive Agents 
L04AA01 I Cyclosporin 
L04AA06 I Mycophenolic acid 
L04AA11 I Etanercept 
L04AA12 I Infliximab 
L04AA17 I Adalimumab  
L04AD I Calcineurin Inhibitors 
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Table 2: Prohibited Medications Classified by WHO Drug Dictionary ATC Codes 
(Continued) 
ATC Codea Useb Medication 
  Immunosuppressive Agents, con’t. 
L04AX01 I Azathioprine 
L04AX03 I Methotrexate 
  Anti-inflammatory and Antirheumatic Products 
M01CC01 I Penicillamine 
  Antigout Preparations 
M04AC01 II Colchicine 
  Psychoanaleptics 
N06AB08 I Fluvoxamine 
  Drugs for Obstructive Airway Diseases 
R03DC II Leukotriene-receptor antagonists 
  Cough and Cold Preparations 
R05CB01 I Acetylcysteine 
  Investigational Agents 
 I Tetrathiomolybdate 
 I Nintedanib (BIBF 1120 tyrosine kinase inhibitor) 
a ATC code is listed if available. 
b I: prohibited under all circumstances; II: prohibited if used for IPF; III: prohibited under certain circumstances. 
 
12. STATISTICAL METHODS 
12.1. Hypothesis Testing 
The null hypothesis for the primary outcome is that the absolute change in %FVC from Baseline 
to Week 52 is the same in the pirfenidone the 2403 mg/d treatment group and the placebo 
treatment group. 
Similarly, in all other hypothesis tests of secondary and exploratory outcomes, the null 
hypothesis is that there is no treatment difference between the pirfenidone 2403 mg/d treatment 
group and the placebo group. 
All tests will be conducted against a two-sided alternative at the α=0.05 significance level, with 
the following exceptions. The primary efficacy analysis will be tested at an alpha level of 0.0498, 
adjusting for the two anticipated interim mortality analyses. If the primary endpoint is significant 
at p=0.0498, then the two key secondary endpoints will be analyzed using Hochberg’s procedure 
for two tests of significance, using α=0.050 if both calculated p-values are ≤0.050 and α=0.025 if 
either calculated p-value is >0.050 (Hochberg 1988). 
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12.2. Patient Disposition, Compliance, and Exposure 
12.2.1. Patient Disposition 
The number and percent of randomized patients who receive and who do not receive a dose of 
study drug will be summarized by treatment group. The number and percent of randomized 
patients who do not complete the study and randomized patients who permanently discontinue 
treatment, along with the reasons for discontinuation, will be summarized by treatment group. 
These are two separate summaries because patients may discontinue treatment but continue 
regular study assessments. 
A Kaplan-Meier plot of the time from randomization to withdrawal from study by treatment 
group will be presented. Patients on the study at the time of study termination (patients who did 
not withdraw early from the study) will be censored at their last study visit or date entered into 
the rollover study. 
A Kaplan-Meier plot of the time from randomization to early discontinuation of study treatment 
by treatment group will be presented. Patients who did not discontinue early from study 
treatment will be censored at the time of last dose. 
Graphs will also be presented showing the number of patients on study and on treatment by time. 
These graphs will be plotted both by day and by assessment window to indicate how many 
patients were potentially available to be evaluated at each assessment time. 
12.2.2. Patient Compliance with Study Drug Regimen 
Compliance with dosing will be calculated as a percentage: 100 times the total number of 
capsules taken from first dose until the Week 52 visit divided by the total number of capsules 
prescribed from first dose until the Week 52 visit. Prescribed dose will be according to 
investigator prescription, allowing for dose modification, rather than the randomized target dose. 
Patients who discontinue study treatment before 52 weeks for reasons other than lung 
transplantation or death will be considered to be 0% compliant for the number of days from 
discontinuing study treatment until Week 52. For patients who discontinue study treatment 
before 52 weeks for lung transplantation or who die while on treatment before 52 weeks, 
compliance will be calculated based on the compliance from the date of first dose to the date of 
discontinuation of treatment or death. These calculations are based on the study treatment dosing 
CRF, which is completed based on patient diary entries, discussion with each patient, and review 
of the number of capsules returned. 
12.2.3. Duration of Exposure to Study Drug 
The total duration of exposure is defined as the time interval between the first dose and the last 
dose, inclusive, of study drug based on the patient study drug dosing information. 
Total duration (weeks) of exposure to study drug in the ITT population will be summarized by 
descriptive statistics (ie, total number, mean, standard deviation, median, minimum, and 
maximum). Total duration of exposure will also be summarized by number and percent of 
patients exposed for specific periods of time, including >0 to less than 13 weeks, 13 to less than 
26 weeks, 26 to less than 39 weeks, 39 to less than 52 weeks, and greater than or equal to 52 
weeks. 
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12.2.4. Protocol Deviations 
All protocol deviations will be identified and categorized before database lock, except for the 
taking of wrong study drug which can only be identified after unblinding. Examples of 
categories include the following: 
• Inclusion/exclusion criteria violation 
• Informed consent error (eg, consent signed after study procedures performed) 
• Study drug dosing errors (eg, patients did not take prescribed dose of study drug) 
• Concomitant medications (eg, took prohibited concomitant medication) 
• Safety assessment (eg, safety assessments not done) 
• Efficacy assessment (eg, efficacy assessments not done) 
Other instances where study procedures were not performed according to protocol may also be 
classified as protocol deviations. 
Protocol deviations will be summarized by category with patient counts and percentages. At each 
level of summation, patients will be counted only once. Deviations will be listed for individual 
patients by group. Patients who were granted protocol exceptions will also be listed along with 
their exceptions. 
12.3. Efficacy Analyses 
12.3.1. Analysis Model 
Data for the change from Baseline outcomes are not expected to be normally distributed. 
Therefore, data will be analyzed using a rank analysis of covariance (ANCOVA) model with 
standardized rank change from Baseline as the outcome and standardized rank Baseline value as 
a covariate. Ties will be assigned the mean of the corresponding ranks. Standardized ranks 
correspond to modified ridits in the SAS® system (SAS 2008) and are obtained as ranks for all 
patients (regardless of treatment) divided by the sample size plus one. The treatment effect will 
be tested using the Mantel-Haenszel mean score chi-square test of the residuals. These analyses 
will be performed as described in Section 7.7, pages 174-177 of Stokes et al (2000). Methods for 
imputation of missing data are described in Section 14.1. When the data are ranked, patients with 
missing data due to death will be ranked worse than those who remain alive. Patients who die 
will be ranked according to the number of days from randomization until death, with the shortest 
time until death as the worst rank (Lachin 1999; Finkelstein and Schoenfeld 1999). 
12.3.2. Primary Efficacy Analysis 
The primary efficacy analysis is a fixed effect rank ANCOVA of the change from Baseline to 
Week 52 in absolute change in %FVC between the pirfenidone 2403 mg/day and placebo groups 
in the ITT population. Ranked Baseline %FVC will be included as a covariate. The primary 
efficacy analysis will be tested at an alpha level of 0.0498, adjusting for the two anticipated 
interim mortality analyses. 
All FVC values will be evaluated and selected by a central reader considering American 
Thoracic Society (ATS) criteria for acceptability and repeatability (Miller et al 2005). Baseline 
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%FVC will be defined as the mean of the FVC measurements obtained at Screening and Day 1 
visits; if either is missing, the non-missing value will be used. If there are more than two 
assessment days prior to randomization the two dates closest to randomization will be used. 
Week 52 %FVC will be defined as the mean of the FVC measurements obtained as part of the 
Week 52 visits; if either is missing, the non-missing value will be used. If both values are 
missing, the data will be imputed as specified in Section 14. 
The magnitude of the treatment effect of pirfenidone will be presented as the distribution 
(number and percentage) of patients across the following categories of change from Baseline to 
Week 52: 
• Decline of ≥10% or death 
• Decline of <10% to 0% 
• No Decline (%FVC change >0%) 
Also, an ogive plot of the change from Baseline to Week 52 will be provided. 
Supportive analyses of the primary efficacy outcome will include the following: 
1. Landmark analyses of change from Baseline in %FVC to Weeks 13, 26, and 39. These 
will use the same analysis methods and summary of treatment effect as the primary 
efficacy analysis. 
2. A repeated measures mixed linear model for rank change from Baseline in %FVC will be 
presented, using ranks calculated for change to Weeks 13, 26, 39, and 52. The mixed 
model will include fixed effects for treatment, ranked Baseline %FVC as a covariate, and 
a repeated effect of assessment week, unstructured covariance structure, and patient as 
the subject factor. Treatment effect will be tested at each visit (with a treatment by visit 
interaction term) and overall. Patients who die will be ranked worse than all other 
recorded data at the corresponding 13 week visit following the death and then within this 
group will be ranked by time until death. 
3. Change from Baseline to Weeks 13, 26, 39, and 52 in FVC volume. This analysis will use 
the same analytical methods as the primary efficacy analysis, ranking the relative change 
in volume. The relative change is defined for each 13-week visit as (visit FVC volume - 
Baseline FVC volume)/Baseline FVC volume. The magnitude of the treatment effect of 
pirfenidone will be presented as the distribution (number and percentage) of patients 
across the following categories of change from Baseline: 
• Relative decline of ≥10% or death 
• Relative decline of <10% to 0% 
• No Decline (FVC volume change >0) 
4. A sensitivity analysis will use the last observation carried forward for imputing Week 52 
%FVC values that are missing for reasons other than death. Missing %FVC values due to 
death will be imputed as specified in Section 14. 
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12.3.3. Secondary Efficacy Analyses 
12.3.3.1. Key Secondary Endpoints 
Two key secondary endpoints are change in 6MWT distance from Baseline to Week 52 and 
progression-free survival. The effect upon the overall type I error introduced by testing two 
secondary endpoints will be controlled as follows: if the primary endpoint is significant at 
p=0.0498, then the two key secondary endpoints will be analyzed using Hochberg’s procedure 
for two tests of significance, using α=0.050 if both calculated p-values are ≤0.050 and α=0.025 if 
either calculated p-value is >0.050 (Hochberg 1988). 
12.3.3.1.1. Change from Baseline to Week 52 in Distance Walked in 6MWT 
Change in 6MWT distance from Baseline to Week 52 is a key secondary endpoint. Baseline 
6MWT distance will be the average of the measurements recorded at the Screening and Day 1 
visits. The 6MWT distance at Week 52 will be defined as the average of the 6MWT distance 
recorded on two separate days at Week 52. Data will be analyzed using a rank ANCOVA model, 
with ranked Baseline 6MWT distance and ranked Baseline DLco as covariates. As outlined in 
Section 12.3.1, patients who die will be ranked worst, according to time until death. 
If a patient starts the walk test but does not complete it for any reason, or walks for less than 6 
minutes, the actual distance walked will be used as if the test were completed. If a patient walks 
for more than 6 minutes, 6MWT distance will be estimated as: 
(6 × actual distance walked) / (actual duration of walk test) 
Completely missing walk distance will be imputed as specified in Section 14.1. 
The magnitude of the treatment effect of pirfenidone will be presented as the distribution 
(number and percentage) of patients across the following categories of change from Baseline: 
• Decline of ≥50 meters (m) or death 
• Decline of <50 m to 0 m 
• No Decline (6MWT distance change >0 m) 
These analyses also will be performed at Weeks, 13, 26, and 39. 
12.3.3.1.2. Progression-Free Survival 
Progression-free survival is a key secondary endpoint and is defined as the time to the first 
occurrence of any of the following events: 
• Death 
• Confirmed ≥10% absolute decline from Baseline in %FVC 
• Confirmed ≥50-meter decline from Baseline in 6MWT distance 
The decline in either %FVC or 6MWT distance must be confirmed at two consecutive 
assessments at least 6 weeks apart. If the first decline is at Week 52A, it can be confirmed in less 
than 6 weeks at Week 52B. In all cases, the first of the two visits will be used as the time point 
for the calculation of the time to event. Progression-free survival will be compared between the 
pirfenidone 2403 mg/d and placebo groups using the product limit method log-rank test 
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(Kalbfleisch and Prentice 1980). A proportional hazards model with only treatment in the model 
will be used to estimate the hazard ratio. Ties will be handled with the approximate likelihood 
method of Efron (1977). Kaplan-Meier estimates will be used to summarize progression-free 
survival time. 
Patients who survive without progression will be censored at the Week 52 visit or if the patient 
discontinued early, at the time of their last available %FVC or 6MWT distance assessment. 
Patients who die before progression will be counted as a death event unless the death is after the 
Week 52 visit or more than 182 days after the last available %FVC or 6MWT distance 
assessment or more than 364 days after randomization (ie, Study Day 365) or after Lung 
Transplantation. If the death is not counted as an event, the patient will be censored at the time of 
their last available %FVC and/or 6MWT distance assessment, whichever is the latest. 
The following summaries will be tabulated by treatment group for the analysis: the number of 
patients included in the analysis (as event or as censored), the number of patients with an event, 
the number of patients with a 10% absolute decline or more in %FVC, the number of patients 
with a 50 m decline or more in 6MWT distance, the number of patients who die, the number of 
patients censored, the distribution of survival times without disease progression, and the survival 
probabilities for each 13-week period from Baseline to the Week 52. Descriptively, the number 
of patients who have more than one outcome will be presented by all outcomes that occurred. 
12.3.3.2. Other Secondary Endpoints 
12.3.3.2.1. Change from Baseline to Week 52 in Dyspnea (UCSD SOBQ Score) 
Change in dyspnea, as measured by UCSD SOBQ score from Baseline to Week 52, is a 
secondary endpoint and will be analyzed using the same methods described in Section12.4.1. 
The Baseline UCSD SOBQ score will be the average of the measurements recorded at the 
Screening and Day 1 visits. The UCSD SOBQ score at Week 52 will be defined as the average 
of the UCSD SOBQ score recorded on two separate days at Week 52. To maintain the validity of 
the result from UCSD SOBQ, patients who answer at least 18 out of 24 items (75%) will be 
defined as non-missing for this analysis. The aggregated score will be calculated for each patient 
by summing the scores from all items in the UCSD SOBQ. In the event that one or more items in 
the UCSD SOBQ at a given assessment are unanswered, the mean score from answered items 
(sum of scores/number of answered items) will be multiplied by the number of total items to 
calculate the aggregated score. This is equivalent to: Aggregated Score = sum of answered item scores ×  total number of itemsnumber of answered items  
Missing UCSD SOBQ scores will be imputed as specified in Section 14.1. 
The magnitude of the treatment effect of pirfenidone will be presented as the distribution 
(number and percentage) of patients across the following categories of change from Baseline: 
• Worsening of UCSD SOBQ score ≥20 points or death 
• Worsening of UCSD SOBQ score <20 to 0 points 
• No Worsening (UCSD SOBQ score change <0 points) 
These analyses also will be performed at Weeks, 13, 26, and 39. 
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12.3.3.2.2. Mortality 
The two mortality secondary endpoints are all-cause mortality and treatment-emergent IPF-
related mortality. Patients who discontinue study treatment before Week 52 will be followed for 
vital status through Week 52, and all-cause mortality will include events occurring in this 
extended period. Relationship of cause of death to IPF will be assessed by the Mortality 
Assessment Committee (MAC) and classified into one of four categories: 1) death directly 
caused by IPF; 2) IPF indirectly contributed to death; 3) IPF has not contributed to death; and 
4) unknown contribution of IPF to death. IPF-related mortality will be defined based on the 
MAC classification of death as “directly caused by IPF”. Supportive mortality endpoints are 
IPF-related mortality and treatment-emergent all-cause mortality. 
Mortality will be compared between the pirfenidone 2403 mg/d and placebo groups using the 
product limit method log-rank test (Kalbfleisch and Prentice 1980). A proportional hazards 
model with only treatment in the model will be used to estimate the hazard ratio; ties will be 
handled with the approximate likelihood method of Efron (1977). Kaplan-Meier estimates will 
be used to summarize each survival time analysis. Patients who are alive and have a Week 52 
visit will be censored at that Week 52 visit. Most patients who complete Week 52 are expected to 
roll over into an open-label extension study. Patients who discontinue regular study visits, 
including not completing the Week 52 visit, will be censored at the earliest of (a) Study Day 365, 
(b) the last available contact/known to be alive date (including contact after discontinuation of 
regular study visits), or (c) date of lung transplantation. Deaths that occur after censoring will not 
be counted as events for these survival analyses of mortality. For IPF-related mortality, patients 
will be censored following the same rules as for all-cause mortality except that patients with non 
IPF-related death will be censored at the date of death if they are not censored earlier. 
Treatment emergent mortality and Treatment emergent IPF-related mortality will be handled 
with the same methods as All-Cause mortality and IPF-related mortality, respectively, with the 
exception that Treatment emergent deaths are those that occur after the first dose of study 
treatment and within 28 days of the last dose of study treatment. 
The following summaries will be tabulated by treatment group for the analysis: the total number 
of patients included in the analysis (as event or as censored), the number of deaths, the number 
of censored patients, the appropriate quantiles to summarize survival time, the magnitude of 
treatment effect estimated by the hazard ratio, and survival probabilities for each 13-week period 
from Baseline to Week 52. 
Mortality data from Study PIPF-016 also will be pooled with data from the pirfenidone 
2403 mg/d and placebo groups from Studies PIPF-004 and PIPF-006. For the pooled analysis, 
the PIPF-004 and PIPF-006 results will be censored at Study Day 365 if an event has not 
occurred earlier in order to allow the three studies to contribute comparable follow-up times to 
the pooled analysis. There was no MAC for studies PIPF-004 and PIPF-006; therefore, the 
assessment of relationship of cause of death to IPF by the investigator will be used. Mortality 
will be compared between the pirfenidone 2403 mg/d and placebo groups using the product limit 
method log-rank test, stratified by study and geographic region (USA and rest of world (ROW)). 
A proportional hazards model with treatment, study and geographic region (USA and ROW) in 
the model will be used to estimate the hazard ratio; ties will be handled with the approximate 
likelihood method of Efron (1977). 
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12.4. Safety Analyses 
12.4.1. Adverse Events 
All adverse events (AEs) will be mapped to MedDRA. Treatment-emergent AEs and serious 
adverse events (SAEs) will be summarized by preferred terms within each system organ class. 
An event will be considered treatment-emergent if the onset date is on or after the first dose and 
within 28 days after the last dose of study treatment. 
The following summary tables for AEs and SAEs according to the MedDRA system organ class 
(SOC) and preferred term will be presented: 
• Treatment-emergent AEs 
• Treatment-emergent SAEs 
• Treatment-emergent treatment-related AEs 
• Treatment-emergent treatment-related SAEs 
• AEs leading to early discontinuation of study treatment 
• SAEs leading to early discontinuation of study treatment 
• AEs leading to study treatment decrease or interruption 
• SAEs leading to study treatment decrease or interruption 
• AEs resulting in withdrawal from study 
• SAEs resulting in withdrawal from study 
• Treatment-emergent AEs with Grade 3 (severe) or 4 (life-threatening) severity 
• Treatment-emergent SAEs with Grade 3 (severe) or 4 (life-threatening) severity 
If any adverse event is missing the assessment of relationship to study drug, it will be included in 
the summary tables as a “probably related” event. Likewise, if any adverse event is missing the 
assessment of severity, it will be included in the summary tables as a “severe” (ie, modified 
Common Terminology Criteria for Adverse Events Grade 3) event. 
12.4.2. Death 
All reported deaths will be analyzed. Treatment-emergent deaths due to any cause and treatment-
emergent IPF-related deaths (as assessed by the MAC) will be summarized by treatment group. 
Mortality rates will be computed as the total number of deaths divided by the total number of 
patients exposed in each treatment group. In addition, the IPF-relatedness of each death 
according to the assessment of the MAC (as described in Section 12.3.3.2.2) will be summarized. 
The cause of death as assessed by the MAC and as reported by the investigator will be coded 
using MedDRA and summarized using MedDRA-coded terms by treatment group and by 
preferred term within each system organ class. 
12.4.3. Clinical Laboratory Evaluations 
Clinical central laboratory data (hematology and chemistry) obtained at Baseline and at each 
measurement time point will be summarized by treatment group in the following ways: 
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1. Descriptive statistics (hematology and chemistry only): mean, median, standard 
deviation, and range at each measurement time point and for the change from Baseline in 
the measurement at each post-Baseline visit. If there are multiple assessments within a 
visit window, the assessment closest to the target visit date within the visit window will 
be summarized. If the assessments are equidistant from the target visit date, the later 
assessment will be used. 
2. Shift tables will be provided by toxicity level for assessments using the modified 
Common Terminology Criteria for Adverse Events (Version 3). For other assessments, 
shift tables will be provided by the frequencies of patients below, within, and above the 
normal range for the most out-of-range value as compared with Baseline. If a patient has 
both high and low out-of-range values, the result will be summarized according to the 
value that is furthest from the respective limit. 
3. The incidence and percentage of patients with measurements by the most out-of-range 
toxicity level (Grade 3 and 4) using the modified Common Terminology Criteria for 
Adverse Events (Version 3) will also be provided. 
12.4.4. Special Assessments of Potential Hepatotoxicity 
12.4.4.1. Assessment of Potential Liver Toxicity 
The incidence of patients with ALT or AST values greater than 3 times the upper limit of normal 
(ULN) and total bilirubin greater than 2 times the ULN (based on the same blood draw of ALT, 
AST, and total bilirubin while on study drug) will be used to assess the potential for study drug-
induced liver toxicity. 
12.4.4.2. Specific Liver-Related Laboratory Outcomes 
Table 3 lists the specific liver-related laboratory outcomes that will be assessed. 
 
Table 3: Liver-Related Laboratory Outcomes 
Liver Test Range of Test Values 
AST 3 to 4.99 × ULN 
5 to 9.99 × ULN 
10 to 19.99 ×ULN 
≥20 × ULN 
ALT 3 to 4.99 × ULN 
5 to 9.99 × ULN 
10 to 19.99 ×ULN 
≥20 × ULN 
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Table 3: Liver-Related Laboratory Outcomes (Continued) 
Liver Test Range of Test Values 
AST or ALT 3 to 4.99 × ULN 
5 to 9.99 × ULN 
10 to 19.99 ×ULN 
≥20 × ULN 
Total bilirubin  >ULN 
>1.5 × ULN 
>2 × ULN 
AST or ALT plus total bilirubin 
AST or ALT plus total bilirubin 
>3× ULN plus >1.5 × ULN 
>3× ULN plus >2 × ULN 
Alkaline phosphatase >1.5 × ULN 
ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal 
 
Crude incidence rates of events will be computed as the number of events divided by the total 
number of patients exposed to study drug by treatment group. Adjusted incidence rates of events 
will be defined as the number of events divided by the total number of patient-years of exposure 
for each treatment group. 
In addition, the worst liver-related laboratory results will be summarized (with the categories of 
test values specified in Table 3) using crude incidence rates of patients. Crude incidence rates of 
patients will be computed as the number of patients with the liver test value of interest divided 
by the total number of patients who received study drug in a treatment group. 
The summary and plot of time from first dose of study drug to the elevation of AST or ALT 
>5 × upper limit of normal (ULN) will be analyzed using Kaplan-Meier estimates. Scatterplots 
(ie, evaluation of drug-induced serious hepatotoxicity; eDISH) of the post-Baseline maximum 
value of total bilirubin versus the maximum value of AST, ALT and AST, or ALT will be 
generated. 
12.4.5. Vital Signs 
Vital signs will be summarized by treatment group and by visit using descriptive statistics (mean, 
median, standard deviation, range) for the actual values and change from Baseline. 
13. CHANGES FROM PROTOCOL-SPECIFIED ANALYSES 
13.1. Categorical Analysis of Change from Baseline in Dyspnea (UCSD 
SOBQ Score) 
The clinical study protocol (dated 16 March 2011, Section 5.4.2.3.1) defined cut points for the 
categorical analysis of change from Baseline in UCSD SOBQ. One of the thresholds used to 
present the magnitude of the treatment effect on UCSD SOBQ was changed from 25 to 20 
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(Section 12.3.3.2.1). The primary analysis method of this endpoint, rank ANCOVA, was not 
changed. 
13.2. Analysis of FVC volume 
The clinical study protocol (dated 16 March 2011, see Section 5.4.2.1) described a supportive 
analysis of FVC as the change from Baseline to Week 52 in FVC volume (in mL). The analysis 
of FVC volume will be based on relative change (%) from Baseline rather than actual volume 
(mL), using a categorical analysis (Section 12.3.2). 
14. MISSING DATA 
14.1. Missing Efficacy Data 
14.1.1. Missing Efficacy Assessment due to Death 
In the rank ANCOVA model, patients who die will be ranked worst according to time until death 
if the death occurs before or on the nominal study day for each visit, as defined in the protocol. 
14.1.2. Missing Efficacy Assessment for Reasons Other Than Death 
Efficacy assessments missing due to reasons other than death (eg, missing visits, early 
withdrawal from the study, or missing values due to lung transplantation) will be imputed by a 
procedure referred to as the sum of squared differences (SSD), outlined as follows: 
Step 1: For each post-Baseline missing value to be imputed at a visit (Visit X) for a 
particular patient (Patient A), a set of all patients without any missing values for visits from 
Baseline up to Visit X will be selected. 
Step 2: For the patients in this set, the SSDs between each patient selected in Step 1 and 
Patient A will be calculated across all non-missing values from Baseline up to the visit prior 
to Visit X. 
Step 3: The 3 patients with the smallest SSDs will be identified and the average of their non-
missing value at Visit X will be used to impute the missing value for Patient A at that visit. 
The number of smallest SSDs to calculate the average can be less than 3 due to availability of 
patients defined in Step 1 or more than 3 based on tied SSDs. 
Missing individual item-level scores of the UCSD SOBQ will be addressed algorithmically, as 
described in Section 12.4.3. 
Any randomized patients in the ITT population who do not receive any study drug and do not 
provide any post-Baseline data for the rank analyses will be assigned a modified ridit of 0.5 to 
reflect that they were tied with all other patients. 
14.2. Imputation of Incomplete Adverse Event Onset Dates 
To facilitate the summarization of treatment-emergent adverse events, those with incomplete or 
missing onset dates will have the onset dates imputed. For conservative purposes, it is assumed 
that all reported adverse events are treatment-emergent, unless proven otherwise. For treatment-
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emergent adverse events, all incomplete or missing onset dates will be imputed to the earliest 
date possible (using any reliable portions of the onset date that are available) after the first dose 
of study drug. If it is not possible (ie, given the completed portions of the adverse event onset 
date and the known first dose date) that the event started after the first dose of study treatment, 
then the adverse event will be considered non-treatment-emergent and the onset date will be left 
as an incomplete date. 
15. OTHER CONSIDERATIONS 
15.1. Visit Windows 
For the analysis and summary of clinical laboratory, efficacy, and safety data, the end of one 
interval and beginning of the next interval for any two visits is the midpoint between the two 
nominal visits. 
The analysis windows for laboratory, physical examination, and vital sign data are presented in 
Table 4, and those for %FVC, 6MWT distance, and UCSD SOBQ measurements in Table 5. In 
the event of multiple values for an assessment within an analysis window, the value closest to the 
scheduled visit date will be used for analyses. If two values tie as closest to the time point (for 
example, one value is before and the other value is after the time point), then the later value will 
be selected as the analysis value. 
An exception to this is the Week 52 pulmonary function testing (PFT), for which a second set of 
PFT will be performed. For the Week 52 PFT, the two assessments closest to the Week 52 Visit 
target study day within the Week 52 Visit window are to be assigned as the first and second day 
Week 52 assessments. 
The definition for the study days included in each study window is defined as below: 
Study Day prior to randomization=Visit Date – Date of Randomization 
Study Day on or after randomization=Visit Date – Date of Randomization + 1 
Safety assessments will be based on date of first dose rather than date of randomization: 
Treatment Day prior to first dose=Visit Date – Date of First Dose 
Treatment Day on or after first dose=Visit Date – Date of First Dose + 1 
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Table 4: Analysis Windows for Hematology, Chemistry, Physical Examinations, 
and Vital Signs 
Scheduled Visit Target Study Day Window (Days) 
Screening Closest assessment before Baseline -85 to -2 (If a Baseline value is available on Day 1,  
Day −1 value will be used for Screening) 
Baseline 1 -1 to 1 
Week 2 15 2 to 21 
Week 4 29 22 to 42 
Week 8 57 43 to 74 
Week 13 92 75 to 102 
Week 16 113 103 to 126 
Week 20 141 127 to 161 
Week 26 183 162 to 228 
Week 39 274 229 to 319 
Week 52 365 320 to 393 
Note: The follow-up visit is not included in scheduled visit windows. 
 
 
Table 5: Analysis Window for %FVC, 6MWT Distance, and UCSD SOBQ 
Measurements 
Scheduled Visit Target Study Day Window (Days) 
Screening Closest assessment before Baseline -85 to -2 (If a Baseline value is available on Day 1, 
Day −1 value will be used for Screening) 
Baseline 1 -1 to 1 
Week 13 92 2 to 136 
Week 26 183 137 to 227 
Week 39 274 228 to 318 
Week 52 365 319 to 393 
Note: The follow-up visit is not included in scheduled visit windows. 
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17. LIST OF END-OF-TEXT TABLES AND FIGURES 
Table Title 
Table 14.1-1 Number of Patients by Investigator All Randomized Patients (ITT) 
Table 14.1-2 Summary of Patient Disposition All Randomized Patients (ITT) 
Table 14.1-3 Time to Event Analysis of Early Discontinuation of Study Treatment All Randomized 
Patients (ITT) 
Table 14.1-4 Time to Event Analysis of Early Withdrawal from Study All Randomized Patients (ITT) 
Table 14.1-5 Demographic Profile All Randomized Patients (ITT) 
Table 14.1-6 Other Baseline Characteristics All Randomized Patients (ITT) 
Table 14.1-7 Medical History All Randomized Patients (ITT) 
Table 14.1-8 Medical History by Decreasing Frequency All Randomized Patients (ITT) 
Table 14.1-9 Medical History Ongoing at Baseline All Randomized Patients (ITT) 
Table 14.1-10 Prior Medications -Within Protocol Window All Randomized Patients (ITT) 
Table 14.1-11 Prior Medications -Within Protocol Window by Decreasing Frequency All Randomized 
Patients (ITT) 
Table 14.1-12 Prior Medications - All Reported All Randomized Patients (ITT) 
Table 14.1-13 Concomitant Medication Use All Randomized Patients (ITT) 
Table 14.1-14 Concomitant Medication Use by Decreasing Frequency All Randomized Patients (ITT) 
Table 14.1-15 Medication Use for Pulmonary Indications after Discontinuation of Study Treatment All 
Randomized Patients (ITT) 
Table 14.1-16 Concomitant Use of Selected CYP1A2 Inhibitors All Randomized Patients (ITT) 
Table 14.1-17 Prohibited Use of Medications All Randomized Patients (ITT) 
Table 14.1-18 Change in Supplemental Oxygen Use All Randomized Patients (ITT) 
Table 14.1-19 Study Treatment Compliance All Randomized Patients (ITT) 
Table 14.1-20 Extent of Exposure to Study Drug All Treated Patients (Safety) 
Table 14.1-21 Overall Exposure to Pirfenidone According to Total Duration and Mean Daily Dose - All 
Treated Patients (Safety) 
Table 14.1-22 Dose Reduction and Interruption of Study Drug - All Treated Patients (Safety) 
Table 14.1-23 Study Treatment Overdose All Treated Patients (Safety) 
Table 14.1-24 Protocol Deviations All Randomized Patients (ITT) 
Table 14.1-25 Six Minute Walk Test O2 Use All Randomized Patients (ITT) 
Table 14.2.1-1 Analysis of Percent Predicted Forced Vital Capacity (With Imputation)) All Randomized 
Patients (ITT) 
Table 14.2.1-2 Percent Predicted Forced Vital Capacity With Ranked Repeated Measures (With 
Imputation) All Randomized Patients (ITT) 
Table 14.2.1-3 Analysis of Percent Predicted Forced Vital Capacity (with LOCF Imputation) All 
Randomized Patients (ITT) 
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Table Title 
Table 14.2.1-4 Analysis of Forced Vital Capacity Volume (With Imputation) All Randomized Patients 
(ITT) 
Table 14.2.1-5 Forced Vital Capacity 5% Categories (With Imputation) All Randomized Patients (ITT) 
Table 14.2.2-1 Analysis of Distance Walked (Meters) in 6-Minute Walk Test (With Imputation) All 
Randomized Patients (ITT) 
Table 14.2.2-2 Time to Event Analysis of Progression-Free Survival All Randomized Patients (ITT) 
Table 14.2.2-3 Analysis of Total Score of UCSD Shortness of Breath Questionnaire (With Imputation) All 
Randomized Patients (ITT) 
Table 14.2.2-4 Time to Event Analysis of All Cause Mortality All Randomized Patients (ITT) 
Table 14.2.2-5 Time to Event Analysis of Treatment-Emergent IPF-related Mortality - All Randomized 
Patients (ITT) 
Table 14.2.2-6 Time to Event Analysis of IPF-related Mortality All Randomized Patients (ITT)  
Table 14.2.2-7 Time to Event Analysis of Treatment-Emergent All Cause Mortality All Randomized 
Patients (ITT) 
Table 14.2.2-8 Time to Event Analysis of All Cause Mortality All Randomized Patients Studies PIPF-004, 
PIPF-006, PIPF-016 
Table 14.2.2-9 Time to Event Analysis of Treatment-Emergent IPF-related Mortality All Randomized 
Patients Studies PIPF-004, PIPF-006, PIPF-016 
Table 14.2.2-10 Time to Event Analysis of IPF-related Mortality All Randomized Patients Studies PIPF-
004, PIPF-006, PIPF-016 
Table 14.2.2-11 Time to Event Analysis of Treatment-Emergent All Cause Mortality All Randomized 
Patients Studies PIPF-004, PIPF-006, PIPF-016 
Table 14.3.1-1 Overview of Treatment-Emergent Adverse Events and Deaths All Treated Patients (Safety) 
Table 14.3.1-2 Summary of Treatment-Emergent Adverse Events as Events and Patients with Events All 
Treated Patients (Safety) 
Table 14.3.1-3 Summary of Treatment-Emergent Adverse Events by Decreasing Frequency All Treated 
Patients (Safety) 
Table 14.3.1-4 Summary of Treatment-Emergent Treatment-Related Adverse Events All Treated Patients 
(Safety) 
Table 14.3.1-5 All Treatment-Emergent Adverse Events by Highest Relationship to Study Treatment All 
Treated Patients (Safety) 
Table 14.3.1-6 All Treatment-Emergent Adverse Events by Maximum Severity All Treated Patients 
(Safety) 
Table 14.3.1-7 Treatment-Emergent Adverse Events that are Severe or Life-Threatening All Treated 
Patients (Safety) 
Table 14.3.2-1 Summary of Treatment-Emergent Serious Adverse Events as Events and Patients with 
Events All Treated Patients (Safety) 
Table 14.3.2-2 All Treatment-Emergent Serious Adverse Events by Decreasing Frequency All Treated 
Patients (Safety) 
Table 14.3.2-3 All Treatment-Emergent Treatment-Related Serious Adverse Events All Treated Patients 
(Safety) 
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Table Title 
Table 14.3.2-4 All Treatment-Emergent Serious Adverse Events by Highest Relationship to Study 
Treatment All Treated Patients (Safety) 
Table 14.3.2-5 All Treatment-Emergent Serious Adverse Events by Maximum Severity All Treated 
Patients (Safety) 
Table 14.3.2-6 Treatment-Emergent Serious Adverse Events that are Severe or Life-Threatening All 
Treated Patients (Safety) 
Table 14.3.2-7 Treatment-Emergent Adverse Events Resulting in Study Treatment Discontinuation All 
Treated Patients (Safety) 
Table 14.3.2-8 Treatment-Emergent Adverse Events Resulting in Study Treatment Decrease or 
Interruption All Treated Patients (Safety) 
Table 14.3.2-9 Treatment-Emergent Serious Adverse Events Resulting in Study Treatment 
Discontinuation All Treated Patients (Safety) 
Table 14.3.2-10 Treatment-Emergent Serious Adverse Events Resulting in Study Treatment Decrease or 
Interruption All Treated Patients (Safety) 
Table 14.3.2-11 Adverse Events Resulting in Withdrawal from Study All Treated Patients (Safety) 
Table 14.3.2-12 Serious Adverse Events Resulting in Withdrawal from Study All Treated Patients (Safety) 
Table 14.3.2-13 Incidence of Death All Treated Patients (Safety) 
Table 14.3.2-14 Mortality Assessment Committee Cause of Treatment Emergent Death All Treated Patients 
(Safety) 
Table 14.3.2-15 Investigator Assessment of Cause of Treatment Emergent Death All Treated Patients 
(Safety) 
Table 14.3.2-16 Incidence of Lung Transplantation All Treated Patients (Safety) 
Table 14.3.4-1 Laboratory Assessments for Blood Chemistry by Scheduled Visit All Treated Patients 
(Safety) 
Table 14.3.4-2 Laboratory Assessments for Hematology by Scheduled Visit All Treated Patients (Safety) 
Table 14.3.4-3 Serum Chemistry Shift Table All Treated Patients (Safety) 
Table 14.3.4-4 Hematology Shift Table All Treated Patients (Safety) 
Table 14.3.4-5 Grade 3/4 Serum Chemistry Toxicity All Treated Patients (Safety) 
Table 14.3.4-6 Grade 3/4 Hematology Toxicity All Treated Patients (Safety) 
Table 14.3.5-1 Specific Liver-Related Laboratory Outcomes All Treated Patients (Safety) 
Table 14.3.5-2 Time to Event of Elevation of AST or ALT (> 5 x ULN) All Treated Patients (Safety) 
Table 14.3.5-3 Worst Specific Liver-Related Laboratory Outcome All Treated Patients (Safety) 
Table 14.3.6-1 Vital Signs by Scheduled Visit All Treated Patients (Safety) 
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Figure Title 
Figure 14.1-2 Kaplan-Meier Plot of the Time to Early Discontinuation From Study Treatment All Treated 
Patients (Safety) 
Figure 14.1-3 Number of Patients on Study by Time All Randomized Patients (ITT) 
Figure 14.1-4 Number of Patients on Study Treatment by Time All Treated Patients (Safety) 
Figure 14.2.1-1 Ogive Plot of Change from Baseline to Week 52 in Percent Predicted Forced Vital 
Capacity All Randomized Patients (ITT) 
Figure 14.2.2-1 Ogive Plot of Change from Baseline to Week 52 in the Distance Walked (Meters) in 6-
Minute Walk Test All Randomized Patients (ITT) 
Figure 14.2.2-2 Kaplan-Meier Plot of Progression-Free Survival All Randomized Patients (ITT) 
Figure 14.2.2-3 Ogive Plot of Change from Baseline to Week 52 in UCSD SOBQ Total Score: All 
Randomized Patients (ITT) 
Figure 14.2.2-4 Kaplan-Meier Plot of All Cause Mortality All Randomized Patients (ITT) 
Figure 14.2.2-5 Kaplan-Meier Plot of Treatment-Emergent IPF-related Mortality All Randomized Patients 
(ITT) 
Figure 14.2.2-6 Kaplan-Meier Plot of All Cause Mortality All Randomized Patients Studies PIPF-004, 
PIPF-006, PIPF-016 
Figure 14.2.2-7 Kaplan-Meier Plot of Treatment-Emergent IPF-related Mortality All Randomized Patients 
Studies PIPF-004, PIPF-006, PIPF-016 
Figure 14.2.2-8 Kaplan-Meier Plot of Time to AST or ALT > 5 x ULN 
Figure 14.3.1-1 eDISH Plot of Maximum Post-Baseline Total Bilirubin vs. Maximum Post-Baseline ALT 
in PIPF-016 Study 
Figure 14.3.1-2 eDISH Plot of Maximum Post-Baseline Total Bilirubin vs. Maximum Post-Baseline AST 
in PIPF-016 Study 
Figure 14.3.1-3 eDISH Plot of Maximum Post-Baseline Total Bilirubin vs. Maximum Post-Baseline AST 
or ALT in PIPF-016 Study 
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APPENDIX A. COMPUTATIONAL FORMULAS FOR PHYSIOLOGICAL 
ENDPOINTS 
A.1 Percent Predicted FVC 
Percent predicted FVC is calculated as follows, according to the formulae of Hankinson et al. 
(1999): 
100 × (maximum FVC value in liters reported on the CRF/predicted FVC) 
The formulas for computing predicted FVC are as follows: 
Predicted FVC for men 
Caucasian-American 
0.00018642 × height (cm)2 + 0.00064 × age (yr) – 0.000269 × age (yr)2 – 0.1933 
African-American 
0.00016643 × height (cm)2 – 0.01821 × age (yr) – 0 × age (yr)2 – 0.1517 
Mexican-American 
0.00017823 × height (cm)2 – 0.00891 × age (yr) – 0.000182 × age (yr)2 + 0.2376 
Predicted FVC for women 
Caucasian-American 
0.00014815 × height (cm)2 + 0.01870 × age (yr) – 0.000382 × age (yr)2 – 0.3560 
African-American 
0.00013606 × height (cm)2 + 0.00536 × age (yr) – 0.000265 × age (yr)2 – 0.3039 
Mexican-American 
0.00014246 × height (cm)2 + 0.00307 × age (yr) – 0.000237 × age (yr)2 + 0.1210 
 
The following table assigns the formula to use based on the race/ethnicity categories collected on 
the Demographics CRF: 
Race per Demographics CRF Formula to Use from Above 
American Indian Caucasian-American 
Asian Caucasian-American * 0.88 
Black African-American 
Native Hawaiian or Pacific Islander African-American 
White Caucasian-American if non-Hispanic ethnicity 
Mexican-American if Hispanic ethnicity 
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Age is defined as the truncated integer age at randomization. The predicted FVC value remains 
unchanged for the entire study. 
 
A.2 Percent Predicted DLCO 
Baseline DLCO is defined as the mean of the two numerically closest acceptable of the values 
reported on the CRF at a visit. If the three values have two pairs that are the same difference 
from the central value, then the mean of the three values will be used. 
If a value is reported as TLCO it will be converted to DLCO using the following formula from 
MacIntyre et al. (2005): 
DLCO=TLCO × 2.987 (TLCO in mmol/min/kPa) 
Percent predicted FVC is calculated as follows, according to the formulae of Crapo and Morris 
(1981): 
100 × (Hgb-corrected DLCO value (in mL/min/mmHg)/predicted DLCO) 
The formulas for computing predicted DLCO are as follows: 
Predicted DLCO for men 
0.410 × height (cm) − 0.210 × age (yr) − 26.31 
Predicted DLCO for women 
0.282 × height (cm) − 0.157 × age (yr) − 10.89 
Age is defined as the truncated integer age at randomization. For Asian, Black, and Native 
Hawaiian or Pacific Islander race groups multiply the predicted value by 0.88, ethnicity should 
be ignored. 
All analyses of DLCO are corrected for the patient’s hemoglobin (Hgb) value, using one of the 
following formulas from Cotes (1979): 
Hgb-corrected DLCO for men: 
DLCO × (10.22 + Hgb)/(1.7 × Hgb) 
Hgb-corrected DLCO for women: 
DLCO × (9.38 + Hgb)/(1.7 × Hgb) 
where Hgb indicates the value of hemoglobin, in g/dL. If the Hgb value is reported in g/L, then 
the Hgb value is divided by 10. If the Hgb value is reported in mmol/L, then the Hgb value is 
divided by 0.6206. 
Use the hemoglobin value available on the same day if possible; otherwise, use the closest 
hemoglobin value before or after the actual DLCO/TLCO assessment date. If the two values are 
equidistant, use the value before the actual DLCO/TLCO assessment. If a central and a local value 
are available on the same day, use the central laboratory value in preference to the value from the 
local laboratory. 
